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Neuroinflammation is considered to be an important underlying process in the 
pathology of major depressive disorder (MDD) within a subpopulation of patients. MDD 
is associated with increased levels of proinflammatory cytokines in the blood, and 
cytokine-based treatments can induce depression. In mice, the induction of systemic 
inflammation with lipopolysaccharide (LPS) can induce depressive-like behaviours that 
are associated with symptoms of MDD. Microglia mediate the neuroinflammatory 
response within the brain and have a critical role in inflammation-induced depressive-
like behaviours. Microglia within the brain exist in low O2 conditions (~5 %), though 
experimentation in vitro is typically carried out in high O2 conditions (20 %). The NLRP3 
inflammasome is a molecular complex central to the production of the proinflammatory 
cytokine IL-1β and the propagation of the inflammatory response. NLRP3 
inflammasome activity has been implicated in chronic stress and inflammation-based 
models of depressive-like behaviours in mice.  
The aims of this thesis were to study LPS-induced depressive-like behaviour in 
C57BL/6J mice, the role of NLRP3 in the behavioural output and the influence of 
oxygen (O2) availability on NLRP3 inflammasome activity in microglia cell cultures. 
Acute LPS induced depressive-like behaviours were observed in hedonia-based tasks 
but not in the forced swim test (FST). However, acute LPS induces a brief period of 
inflammation that does not address the sustained nature of depression. A FST 
depressive-like behaviour was observed in a novel 3-day increasing dose LPS model 
of sustained inflammation, whilst circumventing the development of LPS tolerance. The 
LPS-induced sickness was partially dependent upon NLRP3, though the resulting 
depressive-like behaviour was not. NLRP3 inflammasome signalling in microglia was 
studied in 5 % O2 conditions to replicate the hypoxic environment within the brain. 
Primary microglia isolated from mixed glial cultures by mild trypsinisation exhibited 
functional NLRP3 inflammasome expression and activity. When exposed to 5 % O2 (24 
hours), NLRP3 inflammasome activity and adenosine triphosphate (ATP)-induced cell 
death was attenuated, whilst the production of other proinflammatory cytokines were 
unaffected. These data demonstrate the O2 sensitivity of NLRP3 inflammasome 
signalling in microglia.  
This thesis demonstrates a novel model of sustained inflammation and that 
inhibiting NLRP3 signalling may provide a target for attenuating neuroinflammation and 
the resulting behavioural changes. The importance of understanding the influence of 
O2 in microglia function and neuroinflammation was highlighted by the sensitivity of 
NLRP3 inflammasome activity to low O2.  
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AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA analysis of variance 
ASC apoptosis speck-like protein containing a CARD 
ATP adenosine triphosphate 
Aβ amyloid-β 
BBB blood-brain barrier 
BDNF brain-derived neurotrophic factor 
BMDM bone marrow-derived macrophage 
CARD caspase activation and recruitment domain 
CD constant dose 
CNS central nervous system 
COX-2 cyclooxygenase-2 
CRF corticotropin-releasing factor 
CRP C-reactive protien 
CSF cerebrospinal fluid 
DAMP danger-associated molecular patterns 
DCFDA 2’,7’ –dichlorofluorescin diacetate 
FST forced swim test 
FUST female urine sniffing test 
GR glucocorticoid receptor 
GSDMD gasdermin D 
h hours 
H2O2 hydrogen peroxide 












LDH lactate dehydrogenase 
LPS lipopolysaccharide 
LRR leucine-rich repeat 
MAOI monoamine oxidase inhibitor 
MAPK mitogen-activated protein kinase 
MDD major depressive disorder 
mRNA messenger ribonucleic acid 
MyD88 myeloid differentiation primary response 88 
NBD nucleotide binding domain 
NF-κB Nuclear factor-κB 
NLR NOD-like receptor 
NLRP3 NOD-, LRR- and pyrin domain-containing 3 
NMDA N-methyl-D-aspartate receptor 
NO nitric oxide 
NOS nitric oxide synthase 
NOX NADPH oxidase 
NSAID non-steroidal anti-inflammatory drug 
O2- superoxide radical 
OFT open field test 
OH hydroxyl radical 
PAMP pathogen-associated molecular pattern 
PGE2 prostaglandin E2 
PHD prolyl hydroxylases  
PI3K  phosphoinositide 3-kinase 
poly(I:C) polyinosinic:polycytidylic acid 
ROS reactive oxygen species 
s.c. subcutaneous 
SEM standard error of the mean 
SNRI serotonin-noradrenaline reuptake inhibitor 
SOD superoxide dismutase 
SPT sucrose preference test 





TLR4 toll-like receptor 4 
TNF-α tumour necrosis factor-α 
TST tail suspension test 
TXNIP thioredoxin-interacting protein 
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1.1 An overview of major depressive disorder (MDD) 
1.1.1 Symptoms of depression 
Major depressive disorder (MDD) is a mental illness that has been documented 
in people as early as Ancient Greece, with Hippocrates description of “melancholic 
affection” (Nestler et al., 2002). The current Diagnostic and Statistical Manual of Mental 
Disorders (DSM-5) criteria for MDD requires the presence of at least 5 of 9 listed 
symptoms, including persistent low mood, a reduced sensation of pleasure or interest, 
suicidal thoughts, feelings of low self-worth, loss of energy, reduced ability to 
concentrate and changes in sleep, weight or activity (American Psychiatric Association, 
2013). Whilst a diagnosis of depression does not require all symptoms to be present, 
patients must have experienced symptoms everyday for at least two weeks. The 
disorder is not only detrimental to the well-being of the affected individual and people 
close to the individual, but depression as a whole also has a negative effect on society 
and the economy due to the resulting reduction in productivity and increased 
healthcare costs. 
 
1.1.2 Prevalence and economic burden of depression 
Depression reportedly affects 350 million people worldwide and over the course 
of a lifetime, the prevalence of depression is considered to lie between 10-20 % 
(Kessler et al., 2003a; Lépine and Briley, 2011). Women are almost twice as likely to 
be diagnosed with depression than men, with depression affecting 5 % of males and 9 
% of females in a given 12-month period in the United States (Kessler et al., 2003b; 
Kessler et al., 2005; Lohoff, 2010). Furthermore, as age increases, the prevalence of 
depression increases (Blazer, 2003). In 2010, the economic cost of depression was 
estimated to be €19.2 billion in the UK and $210.5 billion United States (Fineberg et al., 
2013; Greenberg et al., 2015). These figures incorporate the direct medical costs 
incurred as well as indirect costs, such as lost productivity in the workplace, which 
accounted for almost 50 %. In 2010, depression accounted for 2.5 % of worldwide 
disability adjusted life years (DALYs), which represent the average number of years of 
life an individual will lose due to an illness, and 8.2 % of years spent living with 
disability (Ferrari et al., 2013). The World Health Organization predicts depression will 
become the second biggest cause of DALYs (5.7 % of the worldwide total) by the year 
2030 (Mathers and Loncar, 2006). Furthermore, depression is a risk factor for a 
number of other disorders, such as acute coronary syndrome (Litchman et al., 2014). 
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The consensus is that depression is a growing global health problem that requires 
effective intervention to reduce its individual and economic burden on the global 
population (Moussavi et al., 2007; Ferrari et al., 2013; Lopez et al., 2006; Murray and 
Lopez, 1997). 
 
1.1.3 Pathophysiology and treatment of depression 
The treatment of depression changed in the mid-20th century with the 
development of a number of antidepressant drugs targeting the neurotransmission of 
monoamines. These monoamines include serotonin, noradrenaline and dopamine 
(Delgado, 2000). The new drugs were primarily tricyclic antidepressants (TCAs), which 
inhibit the reuptake of monoamines, and monoamine oxidase inhibitors (MAOIs), which 
inhibit the metabolism of monoamines. By inhibiting the metabolism or uptake of 
monoamines from the synaptic cleft, higher levels of synaptic neurotransmitter are 
available to stimulate their post-synaptic receptors (Delgado, 2000). However, TCAs 
and MAOIs have a number of adverse effects. Along with sedation, dry mouth and 
constipation, TCAs can also cause cardiac abnormalities, and MAOIs, which are very 
rarely used today, can have potentially dangerous interactions with tyramine rich foods 
(Gray and Stahl, 2012; Harrigan and Brady, 1999). The presence of these side effects 
prompted the development of more selective drugs. As a result, selective monoamine 
reuptake inhibitors were developed for serotonin (SSRIs), noradrenaline (NRIs) and/or 
dopamine (DRIs). There are also drugs that inhibit the uptake of multiple monoamines, 
such as serotonin-noradrenaline reuptake inhibitors (SNRIs). The ability of these drugs 
to treat depression led to the most prominent theory of depression, based upon the 
concept of reduced monoamine neurotransmission (Heninger et al. 1996). Today, the 
first line treatment for MDD are SSRIs, with sertraline and citalopram considered the 
safest option due to low interaction potentials (National Collaborating Centre for Mental 
Health UK, 2010). 
Whilst generally well-tolerated, current mainstream antidepressants still exhibit 
some adverse effects, such as include sexual dysfunction (Gregorian et al., 2002) and 
nausea (Beasley et al., 2000). The antidepressant activity of these drugs has a delayed 
onset of several weeks, during which the rate of suicidal behaviours can increase 
(Vázquez et al., 2015; Rosen et al., 1999; Jick et al., 2004). Furthermore, the rate of 
remission for antidepressant intervention is between 35 – 50 % (Cleare et al., 2015). 
For example, the SSRI citalopram is reported to have a remission rate of only one third 
(Trivedi et al., 2006). This low rate of success leads to patients having to often change 
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their course of antidepressants in order to find a tolerable and effective treatment. 
Subsequent treatment courses have an even lower success rates (Rush et al., 2006a). 
The cumulative remission rate following a maximum of four treatment courses was 67 
%, and patients that did not respond to initial treatment were more likely to relapse 
(Rush et al., 2006a). Treatment-resistant depression is a term applied to cases in 
which multiple courses of treatment fail to improve the symptoms of MDD and is seen 
in up to 50 % of depressed patients (Fava, 2013). Treatments that enhance 
monoamine signalling do not treat the underlying cause of depression but simply 
attempt to treat a physiological symptom of depression. Understanding the various 
mechanisms by which depression develops in different subpopulations of depression 
can help elucidate and address the underlying causes. 
Alternatives to the monoamine hypothesis for depression are being explored, 
such as glutamate signalling and the hypothalamic-pituitary-adrenal (HPA) axis. 
Ketamine is a non-competitive antagonist for the N-methyl-D-aspartate (NMDA) 
receptor for glutamate and has been shown to exhibit antidepressant activity in 
humans and in animal models (Berman et al., 2000; Fond et al., 2014; Browne et al., 
2013). The effects of ketamine on mood are rapid, with a reduction in depressive 
symptoms reported 2 h after administration, and can last at least one week, even in 
treatment-resistant depression (Zarate et al., 2006). Such findings have led to 
intranasal administration of ketamine as an alternative treatment for depression, which 
can significantly improve depressive symptoms after 24 h (Lapidus et al., 2014). The 
primary role of the HPA axis is to respond to stress and induce the production of 
glucocorticoids. Depressed patients often exhibit high levels of cortisol in their blood 
(Butler and Besser, 1968). The increase in cortisol is thought to be a result of a faulty 
inhibitory feedback loop via the glucocorticoid receptor (GR) that regulates HPA axis 
activity. Impaired GR function results in the high levels of cortisol observed in 
depressed patients and can contribute to the physiological and behavioural changes in 
depression (Pariante and Lightman, 2008). Whilst a range of CRF antagonists have 
been tested in clinical trials in humans, none have been successful in phase III trials 
(Zorilla and Koob, 2010; Koob and Zorilla, 2012). Other potential targets for 
intervention include adult hippocampal neurogenesis (Sahay et al., 2007), which is 
enhanced following antidepressant intervention (Malberg et al., 2000; Perera et al., 
2007), and kappa opioid receptor antagonism (Lutz et al., 2013), which can induce 
antidepressant-like behaviours in rodents (Mague et al., 2003). 
Though some of the components underlying the pathophysiology of depression 
have been elucidated, the etiology of the disorder is still unclear. The roles of 
psychological stress, genetics, hormones, neurogenesis, neuroplasticity and 
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inflammation have each been shown to influence distinct cellular processes implicated 
in the development of depression and depressive symptoms, and are thought to feed 
into each other (Hasler, 2010; Pittenger and Duman, 2008). 
 
1.2 Linking depression and inflammation 
Over recent decades, our understanding of the interactions between the immune 
system, the brain and behaviour has grown and the role of inflammation in depression 
has become a popular topic of research. The concept of the immune system 
contributing to depression in a subpopulation of patients is supported by pre-clinical 
and clinical evidence. 
 
1.2.1 Elevation of cytokine levels in depression 
Cytokines are signalling proteins that are produced and released by immune 
cells in response to stimulation, whether by an exogenous or endogenous signal. Their 
function is critical in the innate immune system and act by either propagating or 
inhibiting the inflammatory response. Proinflammatory cytokines, including interleukin 
(IL)-6, IL-1β and tumour necrosis factor (TNF)-α, have a wide range of functions and 
play a key role in regulating both innate and adaptive immunity, with functions such as 
attracting and activating other immune cells, stimulating differentiation and inhibiting or 
inducing apoptosis (Hopkins, 2003; Scheller et al., 2011; Bradley, 2008).  
The elevation of circulating proinflammatory cytokines in the blood in 
depressed, but otherwise healthy, individuals is a marker of inflammation (Dowlati et 
al., 2010). This phenomenon has been repeatedly observed and systematically 
reviewed in a number of meta-analyses (Table 1.1.). These studies had slightly 
different inclusion criteria and target proteins but all reported elevations in certain 
inflammatory cytokines. Three meta-analyses included studies assessing people with 
an MDD diagnosis (Dowlati et al., 2010; Howren et al., 2009; Liu et al., 2012), one 
assessed depressive symptoms (Hiles et al., 2012a), and one studied suicidal patients 
(Black and Miller, 2015), all compared to healthy controls. All five meta-analyses 
reported a significant positive association of circulating IL-6 with depression, whilst 
positive associations were also reported for TNF-α, IL-1β, C-reactive protein (CRP), IL-
1 receptor antagonist (IL-1ra), soluble IL-2 receptor (sIL-2R), as well as the anti-
inflammatory cytokine IL-10. CRP is an acute phase protein produced by the liver in 
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response to inflammation. The elevation in IL-1ra is associated with elevations in IL-1β 
as an endogenous negative regulator. sIL-2R is the soluble receptor for IL-2, which is 
necessary for its inflammatory actions. In addition to blood samples, one meta-analysis 
also examined post-mortem brain tissue of suicide victims and reported a significant 
increase in IL-6 and IL-1β compared to healthy controls (Black and Miller, 2015). In 
depressed patients, circulating monocytes in the blood have been shown to exhibit an 
enhanced proinflammatory phenotype following stimulation that is positively associated 
with the severity of depressive symptoms (Suarez et al., 2004).  
IL-6 is the only cytokine to be consistently reported to associate with 
depression, and this association is supported in animal studies that will be discussed 
later. IL-6 expression can be induced via the transcription factor nuclear factor (NF)-κB 
and can exert proinflammatory effects through the activation of Janus kinase/signal 
transducer and activator of transcription (JAK/STAT) and the mitogen activated protein 
kinase (MAPK) signalling, both culminating in transcription and the production of 
cytokines (Hodes et al., 2016). 
Two further meta-analyses have been carried out reviewing the effect of 
antidepressant treatment on cytokine levels in the blood (Hannestrad et al., 2011; Hiles 
et al., 2012b). The first review assessed serum levels of IL-6, IL-1β and TNF-α before 
and after antidepressant treatment (Hannestad et al., 2011). It was found that overall 
antidepressant treatment reduced depressive symptoms as well as serum levels of IL-6 
and IL-1β, whilst SSRI treatment in particular reduced serum levels of IL-6 and TNF-α. 
The second review assessed serum IL-6, CRP and IL-10 levels before and after 
treatment and found that pharmacological intervention significantly reduced IL-6 and 
CRP levels, and did not affect the anti-inflammatory cytokine IL-10 (Hiles et al., 2012b). 
The findings of these two reviews support the theory that abnormalities in cytokine 
levels are linked to depressive behaviour, though variability exists amongst treatment 
groups. Classes of antidepressants other than SSRIs did not significantly reduce 
cytokine levels whilst still reducing depressive symptoms (Hannestad et al., 2011). 
Although this finding indicates not all antidepressant treatments result in reduced 
cytokine levels, it could still be argued that antidepressants attenuate the negative 









al., Hiles et al., Liu et al.,  
Black & 
Miller, 
2009 2010 2012a 2012 2015 
IL-6 ↑ ↑ ↑ ↑ ↑ 
IL-1β ↑ - 	   - ↑ 
IL-10  - - - ↑ 
TNF-α 	   ↑ 	   ↑ - 
IL-4  -  -  
IL-2 	   - 	   -  
IFN-y  -  -  
IL-8 	   - 	   -  
CRP ↑    ↑ 
IL-1ra ↑ 	   	   	   	  
sIL-2R    ↑  
Table 1-1. A summary of meta-analysis findings linking serum 
cytokine levels with depression.  
Significant positive associations (↑) or no significant associations (-) are shown for 
inflammatory markers that were assessed. 
 
1.2.2 Cytokine-induced depression 
To understand the direct effect of cytokines on mood, cytokine-based 
treatments and depressive symptoms can be monitored. This can be done with 
patients receiving interferon (IFN)-α treatments for diseases including hepatitis C and 
some cancers. IFN-α is proinflammatory cytokine that has anti-viral properties as well 
as efficacy against tumours (Capuron and Miller, 2004). IFN-α has the capacity to 
induce the expression of other cytokines and has been shown to significantly increase 
the levels of IL-6 and monocyte chemoattractant protein-1 (MCP-1) in the 
cerebrospinal fluid (CSF) of hepatitis C patients (Raison et al., 2009). The development 
of depressive symptoms occurs in up to 50 % of hepatitis C and cancer patients 
receiving IFN-α treatment and often results in the withdrawal from treatment 
(Musselman et al., 2001; Capuron et al., 2002; Capuron et al., 2003). Following 
termination of treatment, depressive behaviours return to baseline, indicating the 
effects of IFN-α are transient and reversible (Huckans et al., 2015). One of the studies 
detailing increased depressive symptoms following IFN-α and IL-2 treatment showed 
that the severity of symptoms correlated with a decrease in serum levels of the 
essential amino acid tryptophan, the precursor to serotonin (Capuron et al., 2002). 
These findings show that cytokine-induced depression interacts with the monoamine 
system and can alter serotonergic synthesis and neurotransmission. It was also 
reported that IFN-α-induced depressive symptoms correlated with an increase in 
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adrenocorticotrophic hormone (ACTH) and cortisol, indicating the activation of the HPA 
axis (Capuron et al., 2003). Furthermore, pre-treatment with the SSRI paroxetine 
before IFN-α treatment in malignant melanoma patients provided significant protection 
from the development of depression, with only 11 % of patients reporting depressive 
symptoms compared to 45 % of placebo-treated patients (Musselman et al., 2001). 
Similarly, one study showed that paroxetine treatment during IFN-α-induced 
depression resulted in significant reduction in depressive symptoms and allowed 11 out 
of 14 hepatitis C patients that had developed depression to complete their course of 
treatment (Kraus et al., 2002). These findings indicate the administration of IFN-α can 
induce depression that is pathologically similar to idiopathic depression and responds 
to existing pharmacological interventions. Taken together with the raised levels of 
cytokines seen in depressed patients, it is likely that the elevation in cytokines is, at 
least in part, contributing to the development of depression. 
 
1.2.3 Anti-inflammatory drugs in depression 
The effect of anti-inflammatory drugs on depression and depressive symptoms 
has been studied and reviewed in a recent meta-analysis (Köhler et al., 2014). It was 
found that anti-inflammatory intervention with both non-steroidal anti-inflammatory 
drugs (NSAIDs), such as celecoxib, and cytokine inhibitors (primarily TNF-α inhibitors 
such as infliximab and etanercept) reduce depressive symptoms when compared with 
a placebo. Furthermore, treatment with cytokine inhibitors or NSAIDs did not result in 
increases in infections or increases in adverse gastrointestinal or cardiovascular 
effects, demonstrating a low risk of serious adverse effects. Anti-inflammatory 
treatment has also been shown to enhance the antidepressant activity of SSRIs 
(Mendlewicz et al., 2006; Akhondzadeh et al., 2009).  
Cyclooxygenase (COX) is an enzyme that contributes to the inflammatory 
process via the synthesis of prostaglandins (PGs), including PGE2 (Sugimoto and 
Narumiya, 2006). PGE2 elevations have been reported in depressed patients and can 
induce the expression of cytokines such as IL-6 (Ohishi et al., 1988; Hinson et al., 
1996). COX-2 is expressed within the brain and cerebral blood vessels and has been 
shown to be induced by inflammatory insults and cytokines, indicating it can propagate 
the inflammatory process within the brain (Madrigal et al., 2003; Skelly et al., 2013). In 
clinical trials, the inhibition of COX-2 with NSAIDs, such as celecoxib and 
acetylsalicylic acid, alongside SSRI treatments have been shown to improve 
depressive symptoms greater than antidepressant treatment alone (Akhondzadeh et 
 24 
al., 2009; Müller et al., 2006; Mendlewicz et al., 2006). In addition, these findings have 
been supported in preclinical experiments that show reduced depressive-like behaviour 
in mice treated with anti-inflammatory drugs such as celecoxib and minocycline 
(Brunello et al., 2006; Henry et al., 2008; Guo et al., 2009). Similarly, cytokine 
inhibitors, such as TNF-α antagonist infliximab, have been shown to significantly 
improve depressive symptoms in MDD patients exhibiting elevated levels of TNF-α 
(Raison et al., 2013). This finding is supported by preclinical experiments that show 
TNF-α inhibition reverses TNF-α-induced depressive behaviour in mice (Kaster et al., 
2012). Together, these findings indicate that inhibiting aspects of inflammation, 
whether by directly inhibiting cytokines or upstream processes, can benefit depressed 
patients who are experiencing inflammation-associated depression, without a 
significant risk of immunological complications. 
 
1.2.4 Depression co-morbidity with inflammatory diseases 
Another observation that may support the concept of inflammation-induced 
depression is the finding that people experiencing chronic inflammatory disorders are 
more likely to develop MDD. Inflammatory disorders, such as rheumatoid arthritis, 
lupus, Alzheimer’s disease, multiple sclerosis and HIV, have an estimated prevalence 
of depression greater than the general population (Iwata et al., 2013; Evans et al., 
2005). However, this finding should be interpreted with caution, as these reviews that 
have compiled the rates of depression for various illnesses have not incorporated the 
impact of reduced quality of life. People with debilitating, painful, stressful and/or 
chronic disorders may be expected to have a higher incidence of depression when 
compared to the otherwise healthy general population. 
 
1.2.5 From psychological stressors to inflammation 
The mechanisms by which an emotional state could result in endogenous 
cytokine expression are unclear. NF-κB is a highly conserved transcription factor that is 
critical in the innate immune response by regulating the expression of proteins involved 
in inflammation. NF-κB signalling can be induced by upstream detection of stimuli such 
as pathogens, cytokines or ultraviolet irradiation, and can induce the expression of 
proinflammatory cytokines (Gilmore, 2006). It has been shown in humans that acute 
psychological stress, induced by speaking and performing mental tasks in front of an 
audience (Trier social stress test; TSST), causes an immediate increase in the level of 
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NF-κB in the peripheral blood mononuclear cells (PBMCs) taken from blood samples 
(Bierhaus et al., 2003). Furthermore, it has also been shown that depressed patients 
have a higher baseline level of NF-κB than healthy controls as well as a greater 
increase in NF-κB following the TSST (Pace et al., 2006). These findings demonstrate 
a pathway by which psychological stress is conveyed into a physiological change that 
stimulates inflammation.  
In addition, psychological stressors induce HPA activity and the transient 
production of glucocorticoids, whereby cortisol suppresses the immune system, 
increases blood glucose levels and contributes to the acute stress response (McEwen 
et al., 1998). However, people experiencing chronic psychological stress, such as the 
familial caregivers of brain-cancer patients, is associated GR dysfunction (Miller et al., 
2008). This impairment in GR signalling and immunoregulation can lead to an 
enhanced inflammatory signalling (Cohen et al., 2012). 
 
1.2.6 Genetics of inflammation and depression 
With the accumulating evidence of the involvement of inflammation in 
depression, the genetic variation of proinflammatory proteins may convey some risk or 
resilience to the influence of inflammation on mood. A genetic polymorphism in the 
gene encoding IL-6 have been shown to be associated with reduced depressive 
symptoms following chronic interpersonal stress (Tartter et al., 2015). Furthermore, a 
polymorphism in the gene encoding IL-1β was associated with higher depressive 
symptoms in people that exhibited elevated IL-1β following chronic interpersonal stress 
(Tartter et al., 2015). In addition to genetic variation, there are epigenetic factors that 
may also influence mood disorders. FK506 binding protein 5 (FKBP5) is a protein that 
is involved in the regulation of the GR and important in the negative feedback loop of 
HPA axis activation via its upregulation. Allele-specific demethylation of the FKBP5 
gene has been reported to be associated with the development of depression and 
suicide in people that have experienced trauma or abuse during childhood (Klengel et 
al., 2013). Such findings demonstrate the risk of particular genetic polymorphisms in 




1.3 Central nervous system inflammation 
1.3.1 Overview of microglia 
First described in 1919 by Pio del Rio-Hortega, microglia are mononuclear 
phagocytes known as the tissue-resident macrophages and primary immune cells of 
the central nervous system (CNS) (del Rio-Hortega, 1919). Microglia in mice originate 
from haematopoietic stem cells in the yolk sac that migrate to the neuroepithelium 
during early embryonic development at embryonic day (E)9.5, and are in the brain at 
E10.5, as opposed to neuronal and other non-neuronal cells which are derived from 
the neuroectoderm (Ginhoux et al., 2013). Microglia comprise between 5 and 20 % of 
glial cells, alongside astrocytes and oligodendrocytes (Lawson et al., 1990). The 
primary function of microglia is to support homeostasis and to protect the brain from 
infection and injury. In addition, microglia play an important role in the development of 
the brain and neuronal networks via the pruning of synapses (Paolicelli et al., 2011). In 
the absence of any stimulation, a ‘resting’ or ‘ramified’ microglia has a highly branched 
morphology that enables the surveillance of its local microenvironment, with a vast 
range of extracellular receptors to detect any pathogen- or danger-associated 
molecular patterns (PAMPs or DAMPs), as well as neurotransmitters and 
neuromodulators (Kettenmann et al., 2011). Such receptors include chemokine 
receptors, cytokines receptors (including TNF-α, INF-α, IL-1β, IL-10, IL-2 and IL-6), 
Toll-like receptors (such as TLR4 which recognises lipopolysaccharide, LPS), 
purinergic receptors (such as P2X7 which recognises extracellular ATP) and 
monoamine receptors (including serotonin, noradrenaline and dopamine), amongst 
many others.  
Upon stimulation, whether by detection of tissue damage or pathogenic 
material, the morphology and function of microglia transform into what is generally 
referred to as an ‘active’ state, though the implication that a ramified microglia is 
inactive would be misleading (Kettenmann et al., 2011). An activated microglia will 
retract much of its processes and form a more amoeboid morphology, allowing 
increased motility to migrate towards the site of stimulation. Microglia can phagocytose 
cell debris or microbes and produce inflammatory cytokines and chemokines that 
propagate an inflammatory response via the attraction of other microglia and peripheral 
immune cells (Napoli and Neumann, 2009; Hanisch and Kettenmann, 2007). In 
addition, the activation states of microglia are thought to exhibit a range functions that 
can be proinflammatory and anti-inflammatory, similar to the ‘M1’ and ‘M2’ activation 
states of macrophages (Figure 1.1) (Orihuela et al., 2016). Such states can be induced 
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by certain cytokines and PAMPs, and can result in different expression profiles, though 
this theory has not been tested as rigorously in microglia as it has in macrophages 
(Martinez and Gordon, 2014). Following a period of activation, microglia will seek 
resolution of acute inflammation through the activity of anti-inflammatory proteins, such 
as IL-10, and can eventually return to a ramified state (Cherry et al., 2014). 
 
Figure 1.1. Microglia activation. 
Ramified microglia is the ‘resting’ form of microglia that exhibit a branched morphology 
for environment surveillance. Microglia become activated upon detection of pathogen-
associated molecular patterns (PAMPs), such as LPS, or danger-associated molecular 
patterns (DAMPs), such as proinflammatory cytokines. Activated microglia produce 
proinflammatory cytokines, generate reactive oxygen species (ROS) and have a more 
amoeboid morphology to enable migration. Activated microglia can return back to a 
resting state following stimulation with anti-inflammatory signals, such as IL-10, or can 
undergo cell death. Wickens original artwork. 
 
1.3.2 Microglia in disease 
Microglia activation is neurotoxic, and therefore, exaggerated or chronic 
responses can have negative effects on homeostasis. Diseases associated with 
activated microglia include neurodegenerative and inflammatory disorders, such as 
Alzheimer’s disease (AD), Parkinson’s disease and multiple sclerosis (Saijo and Glass, 
2011). For example, in AD, microglia are considered to have both neuroprotective and 
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neurodegenerative roles. Microglia are activated by amyloid-β (Aβ) and have been 
shown to aid the degradation of Aβ in mice (Majumdar et al., 2007; Takata et al., 
2007). However, the chronic activation of microglia is thought to be detrimental via the 
effects of inflammatory cytokines that inhibit Aβ degradation (Koenigsknecht-Talboo 
and Landreth, 2005). The administration of minocycline, an anti-inflammatory agent 
that can penetrate the brain and inhibit microglia activation, can improve behavioural 
deficits in a genetic mouse model of AD (Fan et al., 2007). 
Post-mortem analyses of brains from depressed suicide victims have indicated 
enhanced microglia activation, as assessed by expression of a marker of 
neuroinflammation, HLA-DR (Steiner et al., 2008). Additionally, microglia priming, as 
assessed by microglia morphology, was increased in depressed suicides as well as the 
expression of the proinflammatory chemokine MCP-1, which attracts circulating 
monocytes (Torres-Platas et al., 2014). The authors reported an association between 
the elevated levels of cytokines in depressed suicides, low-level neuroinflammation 
and the recruitment of monocytes. However, this finding is not consistent with an 
earlier study reporting only one of six depressed suicides showing signs of microglia 
activation (Bayer et al., 1999). In vivo assessment of depressed patients by PET 
scanning using a marker of inflammation (translocator protein) has also shown 
increased microglia activation (Setiawan et al., 2015).  
Microglia activation can be evaluated with far more ease in rodents than in 
humans and can be correlated with various behaviours associated with depression. 
Acute stress, chronic stress and inflammatory insults can all induce robust microglia 
activation (Sugama et al., 2009; Alcocer- Gómez et al., 2015; Hines et al., 2013; 
Yirmiya et al., 2015). For example, brief restraint stress and water submersion stress in 
rats causes a significant increase in morphological microglia activation (Sugama et al., 
2007). Inescapable shock stressor in rats also induces microglia activation, as well as 
potentiating the ex vivo microglia response to inflammatory insult with LPS (Frank et 
al., 2007). Chronic unpredictable mild stress has been shown to increase microglia 
activation, which could be reversed with antidepressant treatment (Pan et al., 2014). 
Neuroinflammation in rodent models of depression will be discussed in detail in 
Chapter 3. 
 
1.3.3 Effects of inflammation on the brain 
Preclinical data demonstrates that stress and inflammatory insults can induce 
the production of proinflammatory cytokines, which in turn leads to microglia activation 
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and inflammatory signalling within the brain. The resulting neuroinflammation leads to 
pathophysiological and behavioural changes. Here, the effects of cytokines and 
inflammation in the brain are detailed. 
 
1.3.3.1 Immune signals from the periphery to the brain 
Circulating cytokines are a common feature of depression and intravenous 
administration of cytokines can induce depression in humans (Dowlati et al., 2010; 
Musselman et al., 2001). Many animal models use systemic inflammatory insults to 
induce and study neuroinflammation. The method by which peripheral inflammation is 
transmitted to the brain and induces microglia activation is unclear. The main obstacle 
of brain-immune communication is the blood brain barrier (BBB). The BBB separates 
circulating blood and the CNS, tightly controlling the movement of molecules and 
preventing the entry of pathogens and toxins. The BBB consists of endothelial cells 
with structural and functional support from astrocytes and pericytes (Ballabh et al., 
2004). The endothelial cells of the BBB have intercellular tight junctions that restrict 
paracellular movement and forces transcellular movement. Transcelluar movement is 
highly selective via the control of transport proteins and receptor-mediated 
transcytosis, though some lipophilic molecules can pass through the lipid membrane 
(Abbott et al., 2006; Obermeier et al., 2013). 
The mechanisms by which inflammatory signals overcome the BBB have 
generally been studied in rodents. The main theories include 1) the stimulation of 
endothelial cells and the subsequent release of secondary messengers, 2) the active 
transport of cytokines across the BBB, 3) the passage of cytokines through leaky 
regions of the BBB, 4) signal transduction via afferent nerves and 5) the infiltration of 
peripheral immune cells (Figure 1.2) (Quan and Banks, 2007). The administration of 
LPS in rats caused the activation of endothelial cells in the BBB and the expression of 
the enzyme COX-2 and its prostaglandin product, PGE2 (Inoue et al., 2002). The PGE2 
expression correlated with the time-point at which sickness behaviour was observed, 
indicating that the behavioural response occurred after once inflammatory signals have 
entered the CNS. In addition, endothelial cells express receptors for various cytokines, 
including TNF-α, IL-1β and IL-6, which can result also in COX-2 expression (Skelly et 
al., 2013). TNF-α has also been reported to be transported across the BBB and into the 
CNS via its receptor (Pan and Kastin, 2002; Gutierrez et al., 1993). Leaky regions of 
the BBB include circumventricular organs (Ganong, 2000), which are areas of the BBB 
that are less tightly regulated and allow the passage of certain molecules, such as IL-1 
(Breder et al., 1988). The vagal nerve is the most common example of afferent nerve 
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signal transduction in inflammation. Inflammatory insult causes an upregulation of IL-1β 
in the vagal nerve as well as increased plasma levels, and the behavioural sickness 
can be blocked by severance of the vagal nerve (Goehler et al., 1999; Goehler et al., 
1997). Finally, although the brain was once considered immune-privileged, i.e. being 
inaccessible to peripheral immune cells, it has since been shown that immune cells, 
such as monocytes, can infiltrate the CNS in response to TNF-α signalling (D’Mello et 
al., 2009). Whilst LPS is commonly used as an inflammatory insult, its ability to cross 
the BBB itself is very limited and its neuroinflammatory effects are considered to be via 
mechanisms secondary to systemic inflammation (Figure 1.2) or direct stimulation of 
endothelial cells in the BBB (Banks and Robinson, 2010). 
 
Figure 1.2. Inflammatory signalling from the periphery into the brain.  
The five mechanisms by which systemic inflammatory signals are thought to be 
transmitted across the BBB and into the CNS. Wickens original artwork. 
 
1.3.3.2 Neurotransmission 
The severity of depressive symptoms induced during IFN-α treatment in cancer 
patients has been shown to correlate with the reduction of circulating tryptophan 
(Capuron et al., 2002). This indicates that IFN-α may exert its depressive actions by 
reducing the availability of the precursor to serotonin, tryptophan, and in turn reduce 
serotonin neurotransmission. The processing of tryptophan can follow two routes: into 
serotonin or into kynurenine. The conversion of tryptophan to kynurenine can be 
performed by indoleamine 2,3 dioxygenase (IDO); an enzyme which is highly induced 
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by inflammatory cytokines, including IFN-α, IL-1β and TNF-α (Figure 1.3) (Campbell et 
al., 2014). Cytokines have been shown in rodents to mediate the increased expression 
of IDO, contributing to inflammation-induced depressive-like behaviours (O’Conner et 
al., 2009a; O’Conner et al., 2009b). LPS-induced expression of IDO in monocytes is 
mediated through inflammatory signalling pathways including NF-κB and p38 MAPK 
(Fujigaki et al., 2006). p38 MAPK activity also mediates the proinflammatory cytokine-
induced activity of serotonin transporters, which reduces synaptic serotonin levels (Zju 
et al., 2006). In mice, systemic LPS has been shown to increase kynurenine levels 
within the brain, as well as quinolinic acid, presumably by IDO activation and 
tryptophan metabolism towards the kynurenine pathway (Lawson et al., 2013a; Walker 
et al., 2013; Dobos et al., 2012; O’Connor et al., 2009a). Blocking the activity of IDO, 
either by genetic knockout or pharmacological inhibition, results in protection from 
centrally administered LPS-induced depressive-like behaviour in mice (Lawson et al., 
2013b; Parrott et al., 2013; Corona et al., 2013), suggesting the behaviours are 
mediated by IDO activation and subsequent neuroinflammation within the brain. In 
humans, tryptophan depletion has been shown to increase depressive symptoms in 
patients, though this finding was only observed in around one third of patients (Delgado 
et al., 1994). IFN-α treatment in humans has also been shown to enhance circulating 
levels of kynurenine and reduce levels of tryptophan and serotonin, alongside the 
increase in depressive symptoms (Bonaccorso et al., 2002). These findings 
demonstrate the potential of proinflammatory cytokines to diminish serotonin 
neurotransmission. Whilst tryptophan depletion has been shown to enhance 
depressive behaviour, the effect of kynurenine alone also has the ability to induce 
depressive-like behaviour in mice (O’Connor et al., 2009a). In addition, when 
tryptophan is metabolised into kynurenine, it can subsequently be metabolised into 
quinolinic acid in microglia cells (Heyes et al., 1996). Quinolinic acid is an NMDA 
receptor agonist that can be used in high doses to induce excitotoxicity in 
neurodegenerative disease mouse models (Sanberg et al., 1989). Quinolinic acid is 
increased in microglia in the anterior cingulate cortex of depressed suicide brains, and 
the level of CSF quinolinic acid is associated with cytokine-induced depression (Steiner 
et al, 2011; Raison et al., 2010).  
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Figure 1.3. IDO signalling. 
Indoleamine 2,3 dioxygenase (IDO) converts tryptophan (TRP) to kynurenine (KYN). 
This reduces the processing of TRP towards 5-HT. KYN can be metabolized towards 
the production of NMDA receptor agonist quinolinic acid (QUIN). Inflammatory 
cytokines (including TNF-α, IL-1β and IFN-α) and LPS can enhance IDO expression 
and activity. Wickens original artwork. 
 
In in vitro experiments, cytokines have been shown to induce the release of 
glutamate from astrocytes, which would contribute to excitotoxicity within the CNS (Ida 
et al., 2008). Dopaminergic signalling has also been implicated in cytokine-induced 
depression. IFN-α treatment in humans causes a reduction in the activity of the 
enzyme tetrahydrobiopterin (BH4), which converts phenylalanine to tyrosine, a 
dopamine precursor. Following IFN-α treatment, CSF tyrosine is decreased, whilst 
phenylalanine and the inactive oxidised form of BH4 is increased (Felger et al., 2013). 
Cytokine-induced activity of nitric oxide synthase (NOS) and the production of nitric 
oxide (NO) is thought to increase BH4 oxidation and reduce the availability of BH4 and 
dopamine in rats (Kitagami et al., 2003). Together, these findings support the role of 
inflammatory cytokines in reduced monoamine production as well as enhanced 
excitotoxicity and glutamatergic signalling within the depressed brain. 
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1.3.3.3 HPA axis 
Paradoxically, depression is associated with inflammation as well as increased 
levels of cortisol, which is anti-inflammatory. However, cortisol fails to exert anti-
inflammatory effects due to impaired GR feedback (Figure 1.4) (Pace and Miller, 2009). 
Whilst IFN-α treatment can acutely induce HPA axis hyperactivity with increased levels 
of ACTH and cortisol, this response is not present after chronic treatment, indicating 
cytokines do not induce sustained cortisol expression (Capuron et al., 2003). Instead, 
the actions of inflammation on the HPA axis are thought to primarily be through 
impairing GR function and inhibiting the anti-inflammatory actions of cortisol (Pariante, 
2006). Proinflammatory cytokines, such as IL-1α, TNF-α and IFN-α, have been shown 
to inhibit GR translocation to the nucleus and subsequent GR-mediated gene 
expression via the activation of glucocorticoid response elements (GRE) (Pariante et 
al., 1999; Kino et al., 2003; Hu et al., 2009). Furthermore, antidepressant compounds 
are able to enhance dexamethasone-induced GR translocation and gene expression 
by inhibiting active transport of dexamethasone or cortisol from the cell (Pariante et al., 
2001). p38 MAPK has been implicated in the process of cytokine-induced GR 
dysfunction, with p38 MAPK inhibition reversing the cellular effects of IL-1α (Wang et 
al., 2004). Other cytokine-induced inflammatory signalling proteins, including NF-κB, c-
Jun amino-terminal kinase (JNK) and signal transducer and activator of transcription 5 
(STAT5), have also been shown to impair GR expression, translocation and/or function 
(Pace and Miller, 2009; Hu et al., 2009). These data indicate that the induction of 
proinflammatory cytokines can impair the inhibitory feedback role of GR receptors by 
altering downstream signalling pathways. 
 
1.3.3.4 Neurogenesis and neuroplasticity 
Reduced adult neurogenesis has been implicated in the pathology of depression 
(Sahay et al., 2007). Much work focuses on the hippocampus, due to its role in learning 
and memory, its apparent atrophy in MDD and the relatively high basal level of adult 
neurogenesis (Sapolsky, 2001). For example, depression is associated with reduced 
hippocampal and frontal lobe volume as assessed by magnetic resonance imaging 
(Frodl et al., 2006; Videbech and Ravnkilde, 2004). Such findings are interpreted as an 




Figure 1.4. HPA axis. 
Psychological stress stimulates hypothalamic-pituitary-adrenal (HPA) axis activity. 
Corticotrophin-releasing factor (CRF) is released from the hypothalamus and 
stimulates adrenocorticotrophic hormone (ACTH) release from the anterior pituitary 
gland. ACTH stimulates cortisol release from the adrenal gland, which binds 
glucocorticoid receptors (GR) to inhibit HPA activity and suppress the immune system. 
Chronic psychological stress and proinflammatory cytokines can impair GR function, 
increasing HPA activity yet reducing the anti-inflammatory activity of cortisol. Wickens 
original artwork. 
 
In animal models, proinflammatory cytokines have been shown to have negative 
effects on neurogenesis (Song and Wang, 2011). LPS, inflammatory cytokines 
(including TNF-α and IL-1β) and chronic stress have all been shown to reduce 
neurogenesis in the hippocampus of mice (Iosif, 2006; Koo and Duman, 2008; Monje 
et al., 2003). IL-1R-knockout or the administration of an IL-1R antagonist can reverse 
both the depressive behaviours and the reduced neurogenesis induced by chronic 
stress (Koo and Duman, 2008). In IL-1R knockout mice, chronic stress also failed to 
increase levels of corticosterone, the murine analogue of cortisol, and the depressive-
like behaviour was attenuated. Subsequently, the direct administration of chronic 
corticosterone induced depressive-like behaviour and reduced neurogenesis in both IL-
1R knockout and wildtype mice (Goshen et al., 2008). These data indicate a role of 
HPA axis activity in IL-1-mediated suppression of neurogenesis and increased 
depressive-like behaviour. IL-1β has been shown to regulate anti-neurogenic effects of 
IFN-α treatment in the mouse hippocampus (Kaneko et al., 2006). Furthermore, 
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mechanisms by which IL-1β inhibits neurogenesis may be via the neurotoxic effects of 
the kynurenine-quinolinic acid pathway following IDO activation, as inhibition of 
kynurenine 3-monooxygenase prevents quinolinic acid production and enhances 
neurogenesis (Zunszain et al., 2012). These data demonstrate the ability of 
inflammation and the production of inflammatory cytokines to inhibit neurogenesis, 
alongside altering GR function and monoamine neurotransmission, supporting the 
hypothesis of inflammation-induced pathophysiological changes in depression. 
 
1.4 The NLRP3 inflammasome 
The primary function of the innate immune system is to detect and remove 
pathogens or damaged tissue. Immune cells, including macrophages and microglia, 
express the necessary receptors for the detection of a range of stimuli and the 
machinery necessary for the induction of an inflammatory response (Kettenmann et al., 
2011). First identified in 2002, the inflammasome is an intracellular multi-protein 
complex that, upon activation and assembly, leads to the production of the 
proinflammatory cytokines IL-1β and IL-18 (Martinon et al., 2002). These cytokines are 
important to many inflammatory processes, such as the recruitment of immune cells. 
The NLRP3 inflammasome is the most regularly studied inflammasome, though there 
are a number of other inflammasomes formed with other NLR proteins (Figure 1.5A) 
(Tschopp et al., 2003). The NLRP3 inflammasome is expressed in many tissues, 
including the CNS, and has been studied extensively due to its activity in response to a 
broad range of stimuli (Ying et al., 2009). The activity of the NLRP3 inflammasome 
signalling is dependent upon two stages: firstly, the upregulation of the necessary 
proteins (priming), and secondly, the assembly of the inflammasome resulting in its 
activation. The NLRP3 inflammasome is important in the innate immune response, 
responding to a wide range of stimuli including pathogen-associated molecular patterns 
(PAMPs) and danger-associated molecular patterns (DAMPs). The activation and 
induction of an inflammatory response via the actions of IL-1β and IL-18 ultimately lead 
to the clearance of pathogenic material or damaged tissue. 
 
1.4.1 Components 
NOD-like receptors (NLRs) are a family of pathogen-recognition receptors 
(PRRs) that can sense a range of intracellular stimuli in response to PAMPs and 
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DAMPs (Davis et al., 2011). There are a number of NLRs that result in the formation of 
different inflammasomes, sensitive to specific stimuli (Figure 1.5A). NLRs contain a 
NACTH nucleotide-binding domain (NBD), a leucine-rich repeat (LRR) and a variable 
N-terminus. There are a number of NLRs that have an N-terminal pyrin domain, 
including NLRP3 (also referred to as NOD-, LRR- and pyrin domain-containing 3) (Ting 
et al., 2008). The NBD required for the oligomerisation of NLRP3, whilst the LRR is 
considered to be the ligand-interaction domain, though an official ligand has not yet 
been identified. Due to the wide range of stimuli NLRP3 responds to, it is likely there is 
a converging intermediate signalling process responsible for the induction of NLRP3 
inflammasome activation. Finally, the pyrin domain allows for pyrin-pyrin interactions, 
vital in the formation of the inflammasome (Martinon et al., 2002).  
Along with NLRP3, there are two other proteins in the NLRP3 inflammasome 
(Figure 1.5B). ASC (apoptosis speck-like protein containing a CARD or PYCARD) is an 
adaptor protein that consists of a pyrin domain and a CARD (caspase activation and 
recruitment domain). The pyrin domain interacts with the pyrin domain of NLRP3, 
whilst the CARD domain enables interaction with other CARD domains (Agostini et al., 
2004). The third and final component of the NLRP3 inflammasome is procaspase-1, 
which contains a CARD domain that can interact with the CARD domain of ASC. 
Procaspase-1 is the precursor to caspase-1. NRLP3 inflammasome assembly induces 
the auto-cleavage of procaspase-1 and the formation of the active caspase-1. 
Subsequently, caspase-1 can cleave proIL-1β and proIL-18 into their mature and 
biologically active forms, IL-1β and IL-18. These inflammatory cytokines are then 
rapidly secreted from the cell to propagate the inflammatory response (Schroder and 
Tschopp, 2010). 
Other inflammasomes include NLRP1, NLRP6, NLRP7 and NLRP12, which all 
contain a LRR, a NBD and a pyrin domain. NRLC4 contains a CARD domain instead of 
a pyrin domain, whilst NLRP1 has both a pyrin domain and a CARD domain. This 
enables NLRP1 and NLRC4 to directly interact with procaspase-1 without ASC, though 
ASC interaction allows for a greater magnitude of response due to the formation of 
large protein filaments to amplify capsase-1 activity (Faustin et al., 2007). In addition to 
the NLR inflammasomes, there is the absent in melanoma 2 (AIM2) inflammasome 
which contains a DNA-sensing HIN domain and a pyrin domain for ASC interaction. 
NLRP1, NLRC4 and AIM2 inflammasome expression has all been reported within the 
CNS (Yin et al., 2009; Denes et al., 2015). 
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Figure 1.5. The inflammasomes.  
Components of the NLRP3, NLRP1, NLRP4 and AIM2 inflammasomes (A). NLRP3 
contains a pyrin domain (PYD), a nucleotide-binding domain (NBD) and a leucine-rich 
repeat (LRR). AIM2 contains a DNA-sensing HIN domain. NLRP3 stimulation leads to 
the activation of the NLRP3 inflammasome (B). NLRP3 oligomerises and its PYD 
domain interacts with the PYD domain of ASC and enables the formation of large ASC 
filaments, amplifying the inflammasome response. The CARD domain of ASC interacts 
with the CARD domain of procaspase-1, allowing autocleavage and the production of 
active caspase-1. Wickens original artwork. 
 
1.4.2 Priming 
The activity of the NLRP3 inflammasome is dependent upon two distinct 
signalling pathways that converge: priming and activation. Both are necessary but not 
sufficient for inflammasome activation and IL-1β production (Bauernfeind et al., 2009).  
The priming step, referring to the upregulation of NLRP3 and proIL-1β, is 
dependent upon NF-κB signalling (Figure 1.6). Toll-like receptors (TLRs) are a family of 
receptors that recognise a range of microbial molecular patterns and culminate in the 
activation of the transcription factor NF-κB (Kawai and Akira, 2007). TLRs can respond 
to bacterial, fungal and viral components (Akira and Takeda, 2004). LPS is a 
component of the Gram-negative bacterial cell wall and is recognised by the TLR4 
receptor. LPS-TLR4 signalling activates downstream signalling molecules, including 
myeloid differentiation primary response gene 88 (MyD88), resulting in NF-κB 
disinhibition via the phosphorylation of the inhibitor of NF-κB (IκB) proteins. 
Subsequently, NF-κB components can translocate to the nucleus and induce 
transcription (Lawrence, 2009). Inhibition of NF-κB dose-dependently reduces NLRP3 
inflammasome priming (Bauernfeind et al., 2009). Priming is also induced in response 
to endogenous signals. Proinflammatory cytokines, such as TNF-α IL-1β, can induce 
NF-κB signalling and have been shown to enable ATP-induced NLRP3 inflammasome 
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activation by inducing NF-κB-mediated protein expression (Franchi et al., 2009). NF-κB 
inhibition abrogates extracellular ATP-induced inflammasome activation following 
priming with both TNF-α and LPS, indicating that both stimulants converge onto NF-κB 
signalling in order to prime cells (Franchi et al., 2009). In addition to de novo protein 
synthesis, the NLRP3 inflammasome can also be primed via the process of 
deubiquitination of NLRP3. This is thought to be the early stage of priming following 
TLR4 or ATP signalling (Juliana et al., 2012). Therefore, there are two sources of 
functional NLRP3 following stimulation: the deubiquitination enables rapid immediate 




Figure 1.6. Cell priming.  
LPS- and IL-1β-induced protein expression via TLR4 and IL-1R, respectively. MyD88 
activation leads to the recruitment of IRAK and TRAF6, and the activation of TAK1. 
TAK1 activates the IKK complex, which phosphorylates IκB and allows NF-κB 
translocation to the nucleus. TAK1 also leads to MAPK phosphorylation and the 
activation of AP-1. Both NF-κB and AP-1 induce transcription of proinflammatory 




Activation of the inflammasome refers to the assembly of the inflammasome 
following the stimulation, which enables the production of IL-1β and IL-18 via caspase-
1 activity (Figure 1.7) (Martinon et al., 2002). Upon activation of the NLRP3 
inflammasome, ASC dimerises and forms large filament aggregates within the cell, 
which can be detected via immunofluorescence and often referred to as ASC-specks 
(Fernandes-Alnemri et al., 2007; Lu et al., 2014). This speck formation has been 
shown to be dependent upon both priming and inflammasome activation (Bauernfeind 
et al., 2009). Linear ubiquitination of ASC, via the linear ubiquitination assembly 
complex (LUBAC), has been show to be necessary for assembly of the NLRP3 
inflammasome in macrophages following stimulation with the ionophore nigericin 
(Rodger et al., 2014). The function of ASC aggregation is to amplify inflammasome 
activation and cytokine production. In addition, oligomeric NLRP3 inflammasome 
particles are released from macrophages into the extracellular space following ATP or 
nigericin stimulation, where caspase-1 activity continues and further amplifies the local 
inflammatory response extracellularly (Baroja-Mazo et al., 2014).  
Exogenous PAMPs that have been shown to activate the NLRP3 
inflammasome include influenza, adenovirus, Staphylococcus aureus, Neisseria 
gonorrhoeae and some bacterial pore-forming toxins such as nigericin (Allen et al., 
2009; Muruve et al., 2008; Mariathasan et al., 2006; Duncan et al., 2009; Walev et al., 
1995). Sterile signals that activate the NLRP3 inflammasome include endogenous 
stimuli such as extracellular ATP, Aβ, uric acid, high glucose or cholesterol crystals, as 
well as exogenous stimuli such as asbestos and silica (Mariathasan et al., 2006; Halle 
et al., 2008; Martinon et al., 2006; Duewell et al., 2010; Cassel et al., 2008; Dostert et 
al., 2008; Trueblood et al., 2011). Due to the wide range of stimuli that can induce 
NLRP3 inflammasome activation, it is assumed that these stimuli converge onto certain 
intracellular signals that indicate stress or damage and subsequently activate the 
inflammasome. 
The resulting activation of caspase-1 can lead to a form of cell-programmed 
inflammation-associated cell death, called pyroptosis (Miao et al., 2011). Pyroptosis in 
macrophages has been shown to be dependent upon ASC and caspase-1 and the 
processing of gasdermin D (GSDMD), which causes the formation of membrane pores, 
cell swelling and rupture (Sborgi et al., 2016). Non-canonical pathways for NLRP3 
inflammasome activation have been reported to involve the activation of caspase-11 in 
response to cytosolic triggers including LPS, in the absence of TLR4 activation 
(Kayagaki et al., 2011). LPS that has entered the cell can bind directly to the CARD 
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domain of caspase-11 and culminates in the activation of the NLRP3 inflammasome 
and caspase-1 through mechanisms currently unknown (Kayagaki et al., 2013). Whilst 
caspase-11 is not required for ATP-induced IL-1β production, it is required for E. coli 
activation of caspase-1, and caspase-11 knockout provided protection from lethal 
doses of LPS in mice (Kayagaki et al., 2011). 
 
 
Figure 1.7. NLRP3 inflammasome activation.  
Mechanisms of activation for the NLRP3 inflammasome include P2X7 receptor-
mediated potassium efflux, ROS generation, endocytosis (including silica, asbestos 
and amyloid-β) and the release of cathespin B following lysosomal damage. Wickens 
original artwork. 
 
1.4.3.1 Potassium efflux and P2X7 
Intracellular signals that are thought to mediate NLRP3 inflammasome 
activation following stimulation include potassium (K+) efflux, the generation of reactive 
oxygen species and lysosomal damage, with many activators stimulating more than 
one of these cellular processes (Guo et al., 2015). Inflammasome activation via K+ 
efflux is mediated primarily by the P2X7 receptor. P2X receptors are trimeric ligand-
gated cation channels that, upon interaction with extracellular ATP, enable calcium 
(Ca2+), sodium (Na+) and K+ movement between the cytosol and extracellular space 
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(Suprenant et al., 1996). The P2X7 receptor responds to high extracellular 
concentrations of ATP, with an EC50 of 160 µM in mice (Vitiello et al., 2012; Donnelly-
Roberts et al., 2009). The inhibition of the P2X7 receptor blocks ATP-induced NLRP3 
inflammasome activation and IL-1β release in neutrophils, monocytes and microglia 
(Karmakar et al., 2016; Piccini et al., 2008; Murphy et al., 2012). THP-1 monocytes 
lysed in low K+ buffers (< 70 mM) exhibit spontaneous inflammasome assembly and 
activation, as demonstrated by immunoprecipitation (Pétrilli et al., 2007). When the K+ 
concentration of the lysis buffer was raised above 70 mM, NLRP3 inflammasome 
assembly and activity did not occur. This suggests that ATP-induced K+ efflux lowers 
the cytosolic K+ concentration from 140-150 mM to below 70 mM, the threshold for 
NLRP3 inflammasome activation. In addition, increasing the extracellular K+ can inhibit 
K+ efflux and NLRP3 inflammasome activity. Raising the extracellular K+ concentration 
from 5 mM to 30 mM inhibited NLRP3 inflammasome activation in bone marrow-
derived macrophages (BMDMs) by ATP, nigericin, lysosomal destabilization (by Leu-
Leu methyl ester hydrobromide), alluminium, silica and crystals (Muñoz-Planillo et al., 
2013).  
ATP is released by many cells as a DAMP in response to infection or damage 
and acts as a local signalling molecule, exerting autocrine and paracrine functions 
directed towards mediating an immune system response (Praetorius and Leipziger, 
2009). Extracellular ATP release has also been shown to mediate NLRP3 
inflammasome activation induced by uric acid crystals, silica, alum crystals and 
nigericin (Muñoz-Planillo et al., 2013; Riteau et al., 2012). Whilst high concentrations of 
ATP act as a proinflammatory danger signal by binding the P2X7 receptor (Piccini et 
al., 2008), other P2X receptors (P2X1 and P2X4) can respond to lower concentrations 
of ATP and have different roles in immune signalling, such as T cell activation 
(Woehrle et al., 2010). P2X4 receptors have also been reported to mediate high 
glucose-induced NLRP3 inflammasome activation in epithelial cells (Chen et al., 2013). 
High extracellular Ca2+ can also induce NLRP3 inflammasome activation via calcium-
sensing receptors (Rossol et al., 2012; Muñoz-Planillo et al., 2013). The role of 
intracellular Ca2+ in NLRP3 inflammasome activation is controversial. Some reports 
state that inhibition of cytosolic Ca2+ signalling attenuates ATP-induced NLRP3 
inflammasome signalling (Murakami et al., 2012). However, Ca2+ signalling in ATP-
induced NLRP3 inflammasome activation is reportedly neither necessary nor sufficient 
(Katsnelson et al., 2015). As well as inducing K+ efflux, extracellular ATP has been 
shown to induce the formation of pores via P2X7 receptor interaction, which enables 
the movement of large molecules up to 1 kDa across the lipid membrane (Pelegrin and 
Surprenant, 2006; Kanneganti et al., 2007). This can be demonstrated by the uptake of 
large-molecule dyes, and could enable the entry of PAMPs and DAMPs into the cell for 
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cytosolic interactions. These pores are formed by pannexins, as inhibition of pannexin-
1 (Panx1) blocks P2X7 receptor-mediated uptake of dye, and has been shown to be 
important in ATP-induced release of IL-1β (Pelegrin and Surprenant, 2006). 
Conversely, pannexin-1-knockout macrophages have been reported to have impaired 
ATP release as a DAMP, but unaffected ATP-induced inflammasome activation (Qu et 
al., 2011). However, examination of the Panx1 knockout mouse strain has revealed 
only a 70 % reduction in Panx1 mRNA expression (Hanstein et al., 2013). 
 
1.4.3.2 Reactive oxygen species 
The generation of reactive oxygen species (ROS) is considered a vital signal in 
NLRP3 inflammasome response to cell stress (Tschopp and Schroder, 2010; Harijith et 
al., 2014). The production of ROS such as superoxide (O2−) and hydroxyl radicals 
(OH) occurs primarily within the mitochondrial electron transport chain as a by-product 
of cellular respiration (Figure 1.8). ROS generation can also be a result of enzymes 
such as NADPH oxidases (NOXs) with a direct role in cell signalling (Bedard and 
Krause, 2007). ROS levels are normally controlled by the induction of antioxidant 
proteins, such as superoxide dismutase (SOD). High levels of ROS are associated with 
cellular stress and can lead to cell damage and cell death (Fleury et al., 2002). 
Inhibition of ROS, both general ROS and NOX-dependent ROS, reduces NLRP3 
inflammasome activity (Bauernfeind et al., 2011). However, this was reported to be a 
result of reduced expression of inflammatory protein such as NLRP3 and not reduced 
inflammasome activity. These findings indicate that ROS can increase NLRP3 
inflammasome activity by enhancing cell priming. 
 However, a number of studies have reported that ROS signalling is required for 
NLRP3 inflammasome activation. ATP stimulation and activation with particulates, 
such as asbestos and silica, have all been shown to induce the generation of ROS 
(Cruz et al., 2007; Dostert et al., 2008). Blocking NOX-mediated ROS generation can 
inhibit ATP- or nigericin-mediated activation of the NLRP3 inflammasome and IL-1β 
release in macrophages (Cruz et al., 2007; Hewinson et al., 2008). Silica-induced 
NLRP3 inflammasome activation has been shown to require NOX-mediated ROS 
signalling, which is upstream of inflammasome activity as demonstrated by silica-
induced ROS in NLRP3-/- macrophages (Cassel et al., 2008). Mitochondrial ROS has 
also been shown to be important in NLRP3 inflammasome activity, with enhanced 
mitochondrial ROS resulting in increased NLRP3 inflammasome activity (Zhou et al., 
2011). ATP and nigericin have been shown to induce lysosomal damage and 
inflammasome activation via mitochondrial ROS (Heid et al., 2013). Blocking 
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mitochondrial ROS via a mitochondria-targeted antioxidant can inhibit ATP-induced 
NLRP3 inflammasome activation (Nakahira et al., 2011). Mitochondrial ROS-mediated 
NLRP3 inflammasome activity is also responsible for the release of mitochondrial DNA 
into the cytosol, which was shown to further enhance IL-1β release in macrophages 
(Nakahira et al., 2011). Subsequently, ATP-induced IL-1β release is attenuated in 
macrophages lacking mitochondrial DNA (Shimada et al., 2012). 
Whilst ROS have repeatedly been shown to be important in NLRP3 
inflammasome activation, the mechanisms by which ROS can cause activation are 
unclear. ROS have also been shown to interact with proteins that directly alter NLRP3 
inflammasome function. ROS oxidise thioredoxin (TRX), causing it to dissociate from 
TRX-interacting protein (TXNIP) and, subsequently, TXNIP associates with NLRP3 
leading to NLRP3 inflammasome activation. Furthermore, TXNIP knockout can impair 
IL-1β secretion, whilst TRX knockout enhances IL-1β secretion in macrophages, 
demonstrating the role of ROS-TXNIP-NLRP3 signalling in IL-1β production (Zhou et 
al., 2010). However, this finding was not replicated with TXNIP-/- macrophages in 
another research group (Masters et al., 2010). TXNIP can also translocate to the 
mitochondria, bind TRX2 and cause enhanced ROS generation (Li et al., 2009; Lane et 
al., 2013). In addition, ATP-induced ROS generation was shown to stimulate 
extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) phosphorylation and 
PI3K activation, which can mediate processes such as apoptosis and metabolism 
(Cruz et al., 2007). Contradicting the theory of ROS generation stimulating NLRP3 
inflammasome activity, SOD1-/- macrophages exhibit enhanced superoxide production 
and reduced caspase-1 and NLRP3 inflammasome activity in response to ATP, 
nigericin and S. aureus (Meissner et al., 2008). Increased superoxide levels resulted in 
caspase-1 inactivation via oxidation. In addition, SOD-1-/- provided protection from 
LPS-induced septic shock. Cell-type, ROS-type and spatio-temporal differences in 
ROS may contribute to these differences. 
 44 
 
Figure 1.8. ROS generation.  
Reactive oxygen species (ROS) are generated in the mitochondria as a by-product of 
the electron transport chain (ETC). Superoxide radicals (O2−) are produced following 
the reduction of oxygen (O2). Superoxide can be converted to hydrogen peroxide 
(H2O2) by superoxide dismutases (SODs), which can then be reduced to water (H2O) 
by glutathione peroxidases (GPXs) or peroxiredoxins (PRXs). Superoxide can also be 
generated in the cytosol by membrane-bound NADPH oxidases (NOXs). ROS 
generation can induce NLRP3 inflammasome activation. Wickens original artwork. 
 
1.4.3.3 Lysosomal damage 
In addition to ROS and K+ efflux, lysosomal rupturing can result in NLRP3 
inflammasome activation. Lysosomes mediate the degradation and digestion of 
intracellular waste material and of material phagocytosed from outside of the cell. 
Phagocytosis of certain NLRP3 inflammasome activators, including amyloid-β, 
asbestos and silica, have been shown to induce lysosomal damage in macrophages 
and microglia, leading to the activation of the NLRP3 inflammasome (Halle et al., 2008; 
Hornung et al., 2008; Dostert et al., 2009). In addition, inhibition of phagocytosis with 
cytochalasin D (which impairs actin filament assembly) can block amyloid-β- and silica-
mediated inflammasome activation and subsequent IL-1β release (Halle et al., 2008; 
Hornung et al., 2008). Imaging of macrophage endolysosomes reveals crystal-induced 
leakage of lysosomal contents (Hornung et al., 2008). It has been reported that the 
release of cathepsin B (a lysosomal protease usually contained within the lysosome) 
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contributes to this activation. Inhibition of cathepsin B (selective inhibitor CA-074-Me) 
can inhibit crystal-induced NLRP3 inflammasome activation (Hornung et al., 2008), 
though contrasting data have been reported using cathepsin B knockout macrophages 
(Dostert et al., 2008). Whilst ATP and nigericin causes lysosomal rupturing after 
NLRP3 inflammasome activation, lysosomal rupturing alone (via lysosomal 
destabilising agent LLOMe) can also trigger inflammasome activation (Lima et al., 
2013). It has been reported that the ATP- and nigericin-induced lysosomal damage is a 
result of mitochondrial ROS generation (Heid et al., 2013). These findings indicate 
agents that induce lysosomal damage, such as amyloid-β, can induce inflammasome 
activation via mechanisms independent of K+ efflux. 
 
1.5 Modeling inflammation and depression 
1.5.1 The validity of modeling depressive-like behaviour in mice 
The validity of any animal model is based on three main concepts: construct 
validity, face validity and predictive validity (Willner and Mitchell, 2002). Construct 
validity refers to the methodological approach used to induce and assess a disease-
like state, face validity refers to the similarity between the model and the disease 
condition, both behaviourally and neuropathologically, and predictive validity refers to 
the ability of a model to respond to pharmacological treatments in a similar way to the 
human condition (Willner and Mitchell, 2002). 
Animal models are an integral part of studying mood disorders and the 
underlying pathophysiology (Krishnan et al., 2011; Nestler and Hyman, 2010). 
However, modeling depression in rodents entails greater difficulties in comparison to a 
purely physical or genetic disorder. Whilst construct validity can be accomplished with 
relative ease in genetic conditions, modeling a psychiatric disorder like depression is 
difficult as the etiology is unclear and no disease-causing genes have been identified 
(Nestler and Hyman, 2010). Neurobiological and behavioural changes have to be 
induced by environmental or pharmacological manipulation. In addition, any 
behavioural assessment in mice following a particular manipulation is dependent upon 
locomotion, which is subsequently interpreted to indirectly represent a particular 
emotional state. Therefore, the construct validity of behavioural paradigms used in 
models of mood disorders is also weak. For face validity, many symptoms apparent in 
depression cannot be modeling in rodents, such as guilt or suicidal thoughts. 
Therefore, there is a focus on specific behavioural components, such as anhedonic 
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and behavioural despair. Predictive validity has been established with many 
antidepressants in mice (Lucki et al., 2001), though many argue that assessing the 
behavioural effects of antidepressant compounds is not a model of depression, but just 
a comparison of behaviour output to a reference compound (Nestler and Hyman, 
2010).  
A complete model of depression cannot be attained. Depression is a 
multifaceted disorder with great variability in an individual’s symptoms, biochemistry 
and treatment response, and no reliable biomarkers that can be modeled. This 
obstacle is overcome in part by creating models of specific aspects of disease, such as 
certain symptoms or pathophysiological processes. By doing so, research into mood 
disorders is broken down into ‘endophenotypes’ as opposed to trying to replicate a 
depression as a whole (Slattery et al., 2014). For example, to study the inflammation 
exhibited in a subpopulation of depressed patients, inflammation can be induced 
environmentally or artificially (the independent variable) and behavioural and 
biochemical output can be assessed (the dependent variable). Whilst considering the 
limitations in construct and face validity, a greater understanding of the neurobiological 
processes that contribute to behaviour and pathophysiology associated with 
depression can be attained. 
 
1.5.2 Inflammation-based models of depressive-like behaviour in 
mice 
There are several ways to study inflammation and its influence on behaviour in 
mice. The most straightforward route is the direct administration of an inflammatory 
agent that induces an inflammatory response. LPS induces a broad inflammatory 
response when administered in vivo and can be administered systemically to induce 
depressive-like behaviours (O'Connor et al., 2009a). Such models assess a transient 
period of inflammation (further discussed in Section 3.1.1). Repeated LPS can also be 
used to model sustained inflammation (Kubera et al., 2013), though repeated LPS 
does induce tolerance (Engeland et al., 2001). In addition, LPS can be administered 
directly into the CNS via intracerebroventricular (i.c.v.) injection, enabling 
neuroinflammation to be assessed without systemic inflammation (Lawson et al., 
2013b). To study a specific inflammatory signalling pathway, proinflammatory 
cytokines, such as TNF-α, can also be administered to induce depressive-like 
behaviour (Kaster et al., 2012). Poly(I:C), a synthetic double-stranded RNA agonist for 
TLR3, can also be used to stimulate viral infection-induced inflammation (Gibney et al., 
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2013). Such approaches enable consistent induction of predictable inflammatory 
signalling, and can therefore be replicated and dissected. An alternative approach to 
studying inflammation in vivo is stress-induced inflammation, which would have greater 
construct validity, as it is an endogenous inflammatory process. For example, chronic 
stress can increase serum cytokine levels, microglia activation and depressive-like 
behaviours in mice (Alcocer-Gómez et al., 2015). However, such approaches have 
greater variability, due to protocol differences and individual differences. 
 
1.5.3 Assessing depressive-like behaviour 
1.5.3.1 Forced swim test 
The forced swim test (FST) is a behavioural paradigm used to assess the 
antidepressant efficacy of drugs (Lucki et al., 2001). The FST has also been used to 
infer pro-depressive behaviours in response to a variety of pharmacological and 
environmental interventions (O’Reilly et al., 2006; O’Connor et al., 2009a; Bogdanova 
et al., 2013). The test consists of placing a rodent in a cylinder of water for whilst 
behaviour is recorded and scored. First developed for rats in 1978, the FST measures 
time spent immobile to assess escape-directed behaviour and behavioural despair 
(Porsolt et al., 1978), and has since been adapted for use with mice (Lucki et al., 
2001). The longer the mouse spends immobile, the greater the depressive-like 
behaviour. This has been interpreted as a reduction in motivation to escape a negative 
environment.  
The FST is regularly used in drug development as many current antidepressants 
can reduce immobility times (Lucki et al., 2001). This predictive validity is seen with a 
range of acutely administered SSRI antidepressant drugs, including fluoxetine and 
citalopram, as well as other monoamine reuptake inhibitors, such as bupropion, and 
TCAs, such as imipramine and desipramine (David et al., 2003; Lucki et al., 2001). 
However, there are some significant flaws in the FST in drug development. The FST is 
based on the ability of current antidepressants to reduce immobility, and as animal 
models are often defined by this predictive validity, new drugs are generally similar to 
existing drugs, which are only effective in 50 – 60 % of MDD patients (Hendrie et al., 
2013). Antidepressant-like activity in the FST can also be observed in mice following 
treatment with the NMDA receptor antagonist ketamine, which has been shown to 
exert rapid antidepressant activity in humans (Fond et al., 2014; Koike et al., 2013).  
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However, the FST is sensitive to the strain of mouse used as different strains 
have different baseline behaviours and different response profiles to antidepressant 
drugs (David et al., 2003; Lucki et al., 2001). The FST can also be used as an endpoint 
readout in other models of depression, including chronic mild stress (Zhang et al., 
2015), maternal separation (Desbonnet et al., 2010) or inflammation-based models 
such as LPS (O’Connor et al., 2009a) or poly(I:C) (Gibney et al., 2013), which can all 
induce increases in immobility.  This demonstrates the ability of the FST to assess both 
anti- and pro-depressive interventions. As the readout is highly dependent on 
locomotion, the effect any intervention has on locomotor activity should be assessed to 
avoid false positives or negatives. 
 
1.5.3.2 Sucrose preference test and female urine sniffing test 
Reward-seeking behaviours, such as the sucrose preference test (SPT) and the 
female urine sniffing test (FUST), allow an endpoint measurement that can assess 
natural hedonic behaviours (Lewis et al., 2005; Mendleson et al., 1989). The SPT gives 
mice a choice between water and a palatable sucrose or saccharin solution, whereby 
mice exhibit a preference for the sweet solution (Lewis et al., 2005), demonstrating 
hedonic behaviour. The test was originally used to show a reduced sucrose preference 
following chronic mild stress, which was reversible with desipramine (Willner et al., 
1987). The SPT has since been used in inflammation-based models of depression 
(Frenois et al., 2007) and exhibited predictive validity with chronic SSRI treatment, 
including citalopram and fluoxetine (Rygula et al., 2006; Muscat et al., 1992). One 
advantage of the SPT over the FST is that it allows for behavioural assessment over 
extended periods of time, as mice can be constantly housed with water and sucrose.  
The FUST is a recently developed behavioural task that assesses hedonic 
behaviour in the form of sexual motivation. Male mice are exposed to water or female 
urine and an exploratory preference towards the female urine is observed (Malkesman 
et al., 2010). It was also shown that mice have a greater preference for female urine 
over novel odours, eliminating novelty as a factor. This task has been validated in a 
learned helplessness model of depression, where mice show a reduction in urine 
sniffing (Malkesman et al., 2010), but has not yet been assessed in other models of 
depression. Furthermore, this reduction in urine sniffing can be reversed following 
chronic treatment with citalopram, demonstrating predictive validity (Malkesman et al., 
2010). A similar paradigm that assesses social interaction with female versus male 
intruders is based upon the same sexual motivation concept, but utilises mice instead 
of urine (Ago et al., 2015). The preference for female interaction over male interaction, 
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which only develops once sexually mature, was abolished after castration and was 
reduced in an acute inflammation model of depression (Ago et al., 2015). These tasks 
allow an alternative social hedonic behaviour to be assessed that is based upon the 
innate influence of pheromones. These tasks also allow assessment at a specific time 




1.6 Aims of thesis 
The NLRP3 inflammasome is important in the inflammatory response and has 
been previously shown to mediate depressive-like behaviours in a chronic stress model 
in mice. It was hypothesized that NLRP3 inflammasome signalling is important in the 
development of LPS-induced depressive-like behaviours in mice. To test this 
hypothesis, LPS-based mouse models of depressive-like behaviour were tested and 
developed, before using NLRP3-/- mice to investigate the role of NLRP3 in LPS-induced 
behavioural changes.  
Neuroinflammation is mediated by microglia, which exist in low O2 conditions 
within the brain. It was hypothesized that in 5 % O2 conditions, similar to the in vivo 
microenvironment, inflammatory signalling in microglia would differ from that seen in 20 
% O2. To test this hypothesis, BV2 microglia and primary microglia were exposed to 




1 – To model LPS-induced depressive-like behaviours in mice 
2 – To study NLRP3 inflammasome function in microglia and the effect of 5 % O2 
hypoxia 
3 – To investigate the involvement of NLRP3 in microglia function and 
inflammation-induced depressive behaviour using NLRP3-/- mice 
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Chapter 2: Methods 
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2.1 In vivo methods 
2.1.1 Animals – Janssen Pharmaceutica 
Experiments were performed on 10-14 week old male C57BL/6J mice obtained 
from Charles River (France). Mice were normally housed in groups of 2-4 except when 
singly housed as indicated in the test. Cages (L x W x H: 36 X 20 X 13 cm) contained 
wood shavings, nesting material and a plastic shelter (Mouse hut, Bio-Serve; L x W x 
H: 9.5 x 7.6 x 4.8 cm), with access to food and water ad libitum. Mice were under a 12-
hour light cycle, with normal lighting conditions being lights on at 06:00 h and reversed 
lighting conditions being lights on at 18:00 h, with 30 min dim/rise phases. In some 
experiments, reversed lighting conditions were used and mice were habituated to these 
conditions for two weeks prior to the experiments. Temperature was maintained at 22 ± 
2 °C and humidity at 50 ± 2 %. All mice were acclimatised to the animal facility for a 
minimum of 2 weeks and handled daily for one week prior to random assignment to 
treatment groups and experimentation. All protocols were approved by the Institutional 
Ethical Committee on Animal Experimentation, in compliance with Belgian law (Royal 
Decree on the protection of laboratory animals dd. April 6, 2010) and conducted at 
Janssen Pharmaceutica facilities accredited by the Association for the Assessment and 
Accreditation of Laboratory Animal Care. 
 
2.1.2 Animals – University of Bath 
Experiments were performed on 10-14 week old male C57BL/6J or NLRP3 
homozygous knockout mice on a C57BL/6J background (B6.129S6-Nlrp3<tm1Bhk>/J - 
ref:021302; Jackson Laboratory, Maine, US via Charles River, Margate, UK). Both 
NLRP3+/+ and NLRP3-/- mice were maintained in homozygous colonies (Figure 2.1). All 
F1 generation mice were genotyped and mated. Homozygous F2 littermates were 
mated to produce mice for all behavioural experiments. Mice used for primary microglia 
cultures were F2 or F3. Mice were normally housed in groups of 3-4 except when 
singly housed as indicated in the test. Cages (L x W x H: 35 X 20 X 15 cm) contained 
wood shavings, nesting material and a plastic shelf, with food and water available ad 
libitum. Mice were under a 12-hour light cycle (lights on at 07:00 h). Temperature was 
maintained at 21 ± 1 °C and humidity at 50 – 60 %. Mice were handled daily for one 
week prior to random assignment to treatment groups and experimentation. All 
procedures were carried out under a Home Office project license held in accordance 
with the Animals (Scientific Procedures) Act 1986 and European Directive 2010/63/EU. 
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Figure 2.1. Breeding plan for NLRP3+/+ and NLRP3-/- mice. 
First generation mice were genotyped and maintained in homozygous colonies. 
Primary microglia were obtained from F2 and F3 mice, and behavioural experiments 
were carried out on F3 mice. Wickens original artwork. 
 
2.1.3 Treatments 
Lipopolysaccharide (LPS) from Escherichia coli (serotype 055:B5, Sigma-
Aldrich) was prepared fresh in sterile saline (0.9 % NaCl) prior to intraperitoneal 
injection at a volume of 10 ml/kg. LPS doses were selected based on previously 
observed acute LPS-induced depressive-like behaviours in mice (O'Connor et al., 
2009a).  
For acute studies, mice were injected with 0.415 or 0.83 mg/kg LPS or saline. 
For repeated LPS studies, there were four different groups that were treated for 3 or 5 
days: control (saline was injected each day); acute LPS (LPS was administered only on 
the final day); constant dose (CD) LPS (0.83 mg/kg LPS was injected each day) or 
increasing dose (ID) LPS (Figure 2.2). For ID LPS, the following doses of LPS were 
used: 0.052 / 0.104 / 0.208 / 0.415 / 0.83 mg/kg (5-day) or 0.208 / 0.415 / 0.83 mg/kg 
(3-day). Body weights were recorded daily prior to injections, which took place between 




Figure 2.2. Schedule for 3-day and 5-day repeated injection experiments.  
Mice were divided into four treatment groups: saline, acute LPS, constant dose (CD) 
LPS and increasing dose (ID) LPS. Mice were injected daily with either saline (SAL) or 
LPS (0.05 – 0.83 mg/kg; i.p.). 
 
Drugs with known antidepressant activity were used as positive controls in 
these experiments (Table 2.1). In the forced swim test drugs were administered 30 min 
prior to testing (ketamine / bupropion / desipramine / fluoxetine). When ketamine was 
investigated for its role in alleviating acute LPS-induced depressive-like behaviour, 
administration occurred either 24 h or 30 min prior to testing. 
When investigating the effect of centrally administered LPS, mice were injected 
with 100 ng of LPS (1 µl) or saline, via direct injection or cannula into the lateral 
ventricle (see Section 2.1.4 and 2.1.5). 
 
Table 2-1. Compounds used for in vivo assessment. 
 
Compound Source Doses (mg/kg) Route 
Lipopolysaccharide Sigma 0.05-0.83 i.p. 
Ketamine Lipomed 5-10 s.c. 
Desipramine Sequoia Research Products 10-20 i.p. 
Bupropion Janssen Research Foundation 10-20 i.p. 
Fluoxetine Abcam 20 i.p. 
 55 
2.1.4 Intracerebroventricular injection  – Janssen Pharmaceutica 
Mice were administered the opioid analgesic Dipidolor (Janssen, BE) 30 min 
prior to surgery (4 mg/kg; subcutaneously). Mice were then anaesthetised with 5 % 
isoflurane (Abbott IsoFlo, 100 % w/w). Once unconscious, the mouse’s head was 
shaved and iso-Betadine (10% povidone-iodine; Meda) was applied topically. Opticrom 
Ad Eye Ointment (Ecuphar) was applied to the eyes to avoid drying. Mice were then 
transferred to a stereotaxic frame and isoflurine was kept at 2 %. Once the mouse was 
fixed into position, an incision was made along the scalp to expose the skull. Xylocaine 
(10 % lidocaine; Astrazeneca) was topically applied to the exposed tissue for local 
anaesthesia. A hole was drilled through the skull to allow injection at the following 
coordinates: lateral 1.5 mm / posterior 0.6 mm / dorsal 2.3 mm with respect to Bregma. 
Coordinates were tested on a culled mouse by injecting a dye (Figure 2.3A). Saline or 
LPS (10 ng) was injected at a volume 1 µl at a rate of 1 µl/min using a Hamilton 
syringe. Following injection, the syringe was carefully withdrawn and the scalp was 
joined back together using Vetbond glue (3M). Mice were placed in a clean cage and 
allowed to recover at a temperature of 27-28 °C for 24 h. Mice were tested at either 6 
or 24 h after surgery in the OFT and FST. 
 
2.1.5 Intracerebroventricular cannulation  – Janssen Pharmaceutica 
 Mice were prepared for surgery as described for ICV injection (Section 2.1.4). 
After drilling a hole at the appropriate location in the skull of the mouse, the guide 
cannula was inserted to the appropriate depth (2.3 mm dorsal). An anchoring screw 
was attached to the opposite side of the skull. Veterinary cement was then used to fix 
the cannula in place, with the anchoring screw minimizing movement of the cannula. 
The scalp was joined back together over the cement with veterinary glue and the 
dummy cannula was inserted into the guide cannula. Mice were placed in a clean cage 
and allowed to recover at a temperature of 27-28 °C for 24 h. Mice were given 2 weeks 
to recover from surgery before being anaesthetized with isoflurane (5 %) prior to 
injection. The dummy cannula was replaced with the injection cannula and saline or 
LPS (10 ng) was injected at a volume 1 µl at a rate of 1 µl/min using a Hamilton 
syringe. After injection, the dummy cannula was replaced into the guide cannula and 
mice were returned to their home cage. Mice were tested either 6 or 24 h later in the 
OFT and FST. After experimentation, mice were culled and a blue dye was injected to 




Figure 2.3. ICV injection of dye.  
Direct injection of dye post-mortem at the following coordinates: lateral 1.5 mm / 
posterior 0.6 mm / dorsal 2.3 mm with respect to Bregma (A). Mice with cannulas 
implanted were injected with a dye post-mortem (B). Both brains show injection of dye 
into the lateral ventricle and diffusion across the ventricle. 
 
2.1.6 Behavioural assessment 
Mice were moved into experimental rooms ≥1 h prior to experimentation to 
allow habituation and returned to their home cage after testing, unless stated 
otherwise. No mouse underwent testing in more than two behavioural paradigms, with 
an interval of at least 12 h. In LPS experiments, mice were typically tested in the OFT 
and subsequently in the FST, or just in the SPT / FUST alone. 
 
2.1.7 Open Field Test (OFT) – Janssen Pharmaceutica 
The OFT protocol used was as described previously (Biesmans et al., 2013). 
The experimental apparatus consisted of 4 separate arenas (each 40 X 40 X 40 cm), 
allowing 4 mice to be tested simultaneously. Locomotor activity was assessed as a 
measure of sickness behaviour in a 10 min OFT under low light conditions (2-3 lux). An 
infrared camera, mounted above each arena, tracked the mice using Noldus 
EthoVision (version 6.1). Tracking began 2 seconds after the detection of a mouse in 
the arena and the total distance travelled was recorded. Arenas were cleaned with 70 




2.1.8 Open Field Test (OFT) – University of Bath 
The OFT protocol used was as described previously (Almatroudi et al., 2015). 
The experimental apparatus consisted of a single arena (L x W x H: 41 X 41 X 38 cm) 
with 32 infrared lasers (16X x 16Y) to detect locomotion (SmartFrame Open Field 
System, Kinder Scientific). Locomotor activity was assessed as a measure of sickness 
behaviour in a 10 min OFT under low light conditions (<10 lux). Infrared beam breaks 
within the arena was used to track mice using Kinder Scientific MotorMonitor software. 
Tracking began 2 seconds after a mouse was placed in the arena and the total 
distance travelled recorded. Arenas were cleaned with 70 % ethanol in between each 
mouse. 
 
2.1.9 Forced swim test (FST) – Janssen Pharmaceutica 
The FST protocol used was as described previously (Biesmans et al., 2013). 
The experimental apparatus consisted of 4 separate cylinders (11 cm diameter and 10 
cm deep water), which were automatically washed and filled with water at 24-25 ˚C 
between each mouse. Mice were placed in the cylinders for 6 min, whilst a fixed 
camera perpendicular to the cylinder was used to capture 4 mice simultaneously. 
Immobility was manually scored, blind to treatment, over the 6 min test period. For 
automated scoring (pharmacological validation and i.c.v. LPS experiments), movement 
was tracked using Noldus EthoVision (version 9.0) for 6 min beginning 2 seconds after 
detection of a mouse and immobility was scored. 
 
2.1.10 Forced swim test (FST) – University of Bath 
The FST protocol used was as described previously (Almatroudi et al., 2015). 
The experimental apparatus consisted of a glass cylinder (22 cm diameter), which was 
cleaned with 70 % ethanol and filled with water (23 cm deep) at 25 ± 1 ˚C between 
each test. Mice were placed in the cylinders for 6 min, whilst a camera placed 
perpendicular to the cylinder was used to record the mice. Immobility was manually 
scored, blind to treatment, over the 6 min test period. 
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2.1.11 Rotarod – Janssen Pharmaceutica 
Mice were assessed in two test sessions: a ‘baseline’ test immediately prior to 
LPS or saline administration and a final test at either 6, 24 or 48 h after treatment. Mice 
first underwent four training sessions in succession the day before treatment where 
mice were placed on the rotarod for 5 min each time at progressively faster speeds: 16, 
20 and 24 revolutions per minute (rpm), and finally an accelerating speed from 0-40 
rpm (Med Associates, model CT-ENV-575M-X5). During training, mice that had fallen 
off the rotarod were placed back on. Subsequently, the baseline test and final test 
sessions were 5 min at an accelerating speed of 0-40 rpm. Latency to fall off the 
rotarod was recorded automatically via infrared cameras and mice were not replaced 
back onto the rotarod once off (Figure 2.4). 
 
Figure 2.4. Rotarod protocol.  
Mice underwent 4 training sessions of increasing difficulty. A baseline trial was 
measured prior to injection and a final test trial was measured at either 6, 24 or 48 h 
post-administration of either saline or LPS (0.83 mg/kg; i.p.). rpm – revolutions per 
minute. 
 
2.1.12 Sucrose consumption – University of Bath 
 Preliminary experiments were conducted to establish a palatable sucrose 
solution for C57BL/6J mice, since strain differences in sucrose sensitivity have been 
reported (Lewis et al, 2005). Mice were deprived of water for 4 h prior to 
experimentation (16:30 – 20:30). Bottles containing water or a sucrose solution (2.5 or 
5 % in tap water) were placed in the cage for 1 h (20:30 – 21:30). The test portion of 
the experiment was carried out at the start of the dark phase (lights out at 19:00), as 
this is when mice will normally drink. Bottles were weighed before and after testing to 
calculate the total amount of liquid consumed. 
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2.1.13 Sucrose Preference Test (SPT) – Janssen 
Pharmaceutica 
The SPT protocol used was as described previously (Biesmans et al., 2013). 
Animals were housed individually in customized Plexiglas cages (35 X 31 X 16 cm; 
Techniplast, Italy) that fitted two water bottles. Bottles were filled with either tap water 
(W) or 2.5 % sucrose dissolved in tap water (S) during the habituation phase prior to a 
testing phase. During the habituation phase, mice were housed with W/W or W/S 
alternating for 24 h periods over 4 days. Bottles were removed at the same time every 
morning (09:00-10:00) and consumption determined by weighing the bottles. Mice 
were then weighed and placed back in their cage with fresh pre-weighed bottles 
containing the appropriate solutions. The test phase was carried out for 2 days 
immediately following the administration of LPS or saline (Figure 2.5). Total 
consumption was calculated (water and sucrose consumption combined) as well as the 
preference for sucrose (sucrose consumption as percentage of total consumption). In 
the event of leaking bottles, values were replaced by the mean of all bottles for the 
appropriate solution for that time period. This happened in less than 5 % of all bottle 
measurements. 
 
Figure 2.5. Sucrose preference test.  
Mice underwent 4x 24 h training sessions prior to testing with access to two water 
bottles either both containing water (W/W) or one water and one 2.5 % sucrose 
solution (W/S). For the test period, mice were injected with saline or LPS (0.83 mg/kg; 
i.p.) and allowed access to water and sucrose (W/S) for 24 h sessions. Volume 
consumed from each bottle at the end of 24 h session was measured by weighing 
bottle before and after session. 
 
2.1.14 Female Urine Sniffing Test (FUST) – Janssen 
Pharmaceutica 
The FUST has previously been validated using the learned helplessness (LH) 
model of depressive behaviour and the action of the antidepressant citalopram in mice 
(Malkesman et al., 2010). Prior to the experiment, adult female mice were housed in 
groups of 4 in metabolic cages with grid floors for 2 h to collect urine (approximately 1 - 
2 ml per cage). 4 cotton-bud applicators (Assistent, Germany; product code 4302) were 
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soaked in test tubes containing female urine or water immediately prior to and during 
the experiment. 
Under normal light levels, male mice were weighed and placed individually in a 
novel cage (with wood shavings only) containing two dry cotton-bud applicators for the 
30 min habituation phase. The applicators (15 cm long) were fixed in place by a 
custom-made device that clips onto the cage and points the applicators down at an 
angle of 45 degrees, with the cotton-buds 2.5 cm above the cage floor and 15 cm 
apart, and cage lids on (Figure 2.6). The protocol used here was adapted from 
Malkesman et al. (2010) to incorporate one test period with two applicators (water and 
urine) as opposed to two test periods each with one applicator. For the test phase, the 
applicators and the holding device was removed (whilst the mouse was still in the 
cage) and replaced with a new holding device with two new applicators: one soaked in 
water and the other soaked in female urine (left versus right was randomized to avoid 
positional preference). Timing and live manual scoring of behaviour began immediately 
after the addition of the new applicators. During the test phase, time spent sniffing each 
applicator. Sniffing was scored when the mouse was sniffing the bud of the applicator 
directly from close range (biting the applicator is not counted) with an observation timer 
for 3 min. Total times spent sniffing each applicator was recorded. Mice were then 
returned back to their home cage and the applicators placed back into the appropriate 
test tube for re-use. Greater time spent sniffing female urine over water reflects a sex-
driven hedonic behaviour. In a validation experiment to confirm a sexual bias, male 
urine was also tested in direct comparison with female urine or water. 
 
Figure 2.6. The female urine sniffing test. 
Mice were exposed to two cotton buds soaked in ether water or female urine. Time 
spent sniffing was recorded. 
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2.1.15 Statistical Analysis 
In vivo data were analysed using a Student’s t-test or a one-way analysis of 
variance (ANOVA) followed by Dunnett’s posthoc test or two-way ANOVA followed by 
Bonferroni or Dunnett posthoc tests for multiple comparisons where appropriate (p < 
0.05). All data are represented as mean ± SEM.  
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2.2 Tissue genotyping 
2.2.1 DNA extraction 
DNA samples were prepared from ear clippings taken from NLRP3+/+ and 
NLRP3-/- mice as previously describes (Truett et al., 2000). Tissue samples were lysed 
in an alkaline lysis buffer (0.5 ml; 25 mM sodium hydroxide; 0.2 mM EDTA; pH 12). 
Samples were boiled at 95°C for 1 h before being cooled to 4°C. An equal volume of 
neutralization buffer (0.5 ml; 40 mM tris; pH 5) was added. Samples were centrifuged 
(10 min; 1400 G; 4°C) and supernatants were collected and stored at -80°C for 
analysis at a later time. 
 
2.2.2 Polymerase chain reaction (PCR) 
PCR was used to identify the presence of NLRP3 or a previously validated 
internal positive control (GRCm38) provided by Jackson Laboratories (Yu et al., 2013) 
in DNA samples obtained from mice. A Taq DNA Polymerase kit (New England 
Biolabs) was used with gene-specific primers outlined in Table 2. 2. 4 µl of a master 
mix containing Taq DNA polymerase, dNTPs and primers in a buffer (outlined in Table 
2.3) was added to 1 µl of each sample in 0.2 ml PCR tubes. Volume was adjusted to 
20 µl with DNase free water and PCR was performed: 30 seconds at 95°C, 40 cycles 
of 15 seconds at 95°C / 30 seconds at 60°C / 30 seconds at 68°C, 5 min at 68°C and 
cooled to 4°C until removed. PCR products were kept at 4°C until gel electrophoresis. 
 
2.2.3 Gel electrophoresis 
10 µl of PCR product was added to 2 µl of 6X loading dye (New England 
Biolabs; B7021S). Samples were run alongside a 100 – 1000 bp DNA ladder (Thermo 
Scientific; SM0241) on a 1.5 % agarose gel containing ethidium bromide (2 drops of 
0.625mg/ml; Severn Biotech Ltd; 14485) at 90 volts for 1 h. Gels were visualized using 
GeneSnap (SynGene) software. 
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Target Primer sequence Amplicon 














Table 2-2. PCR primers for genotyping.  
NLRP3 primers were designed via PrimerBlast and compared with a positive internal 
control obtained from Jackson Laboratories genotyping protocols (primer references: 
oIMR7338 and oIMR7339) and developed by the Genome Reference Consortium. 
 
 
Table 2-3. PCR mastermix.  
Components of the mastmix used for the PCR reaction. 
  
Component Source Product 
code 








M0320 2.5 µl 1X 
25 mM MgCl2 New England 
Biolabs 
M0320 1.5 µl 1.5 mM 
10 mM dNTPs Thermo 
Scientific 
R0191 0.5 µl 200 µM 
10 mM forward 
primer 
Sigma - 0.5 µl 0.2 µM 
10 mM reverse 
primer 





M0320 0.125 µl 1.25 units 
Nuclease-free water Thermo 
Scientific 
R0581 18.4 µl - 
DNA sample - - 1 µl - 
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2.3 In vitro methods 
2.3.1 Immortalized cell lines 
The BV2 cell line (gift from Prof. Michel Mallait, Hôpital de le Pitié-Salpêtrière, 
Paris, France) is an immortalized murine microglial cell line, first obtained from /6 mice 
(Blasi et al., 1990). BV2 microglia were cultured as described previously, with 
modifications (Sheng et al., 2011). Briefly, BV2 microglia were maintained in culture 
medium consisting of Dulbecco’s modified eagles medium/nutrient mixture F12 
(DMEM/F12) with 4.5 g/L D-glucose, 10 % fetal bovine serum (FBS), 100 units/ml 
penicillin, 100 µg/ml streptomycin and 0.25 µg/ml amphotericin B (Gibco, Life 
Technologies, UK). The J774.2 cell line (Health Protection Agency, Salisbury, UK) is 
an immortalized murine macrophage cell line. J774.2 macrophages were maintained in 
culture medium consisting of DMEM/F12 with 10 % fetal bovine serum (FBS), 100 
units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine. Cell lines were 
routinely cultured at 37 ˚C in 5 % CO2/air). For experiments, BV-2 and J774.2 cells 
were plated in 24-well clear plates (0.5 x 106 cells per well) or 96-well black plates (0.1 
x 106 cells per well) 24 h before testing. 
 
2.3.2 Neonatal primary microglia 
Primary neonatal mouse microglia cells were obtained from C57BL/6J pups 
(P0-2) using the low trypsinisation method described previously (Saura et al., 2003). 
Newborn mouse pups (male and female) were euthanized via cervical dislocation 
before whole brains were collected. In ice-cold phosphate buffered saline (PBS), the 
cortices were dissected and the meninges were removed prior to mincing with scissors. 
The tissue was centrifuged (150 G; 3 min) and PBS removed before the tissue 
underwent enzymatic dissociation with 12 ml of 0.25 % (v/v) trypsin with 0.5 ml of 
DNase I (30 Units final concentration) for 15 min in a shaking water bath (37 ˚C). 
DMEM/F12 with 10 % fetal bovine serum (FBS), 100 units/ml penicillin, 100 µg/ml 
streptomycin and 0.25 µg/ml amphotericin B (Gibco, Life Technologies, UK) was added 
and tissue was mechanically dissociated by pipetting. Cells were centrifuged (350 G; 7 
min) and resuspended in fresh DMEM/F12 medium before being passed through a 70 
µm cell strainer. The mixed cell population was plated in at a density of 300,000 
cells/well in a clear 12 well plate coated with poly-D-lysine (20 µg/ml). Fresh 
DMEM/F12 medium was added once a week for 3 weeks. After 21 days in vitro (DIV) 
from plating, the conditioned medium was collected from the mixed cell culture and the 
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cells were washed with serum-free medium before being incubated with diluted trypsin 
(0.0625% v/v) for 20 min at 37 ˚C to remove the upper astrocytic layer without 
detaching the majority of lower layer adhered microglia. Cells were then washed with 
complete medium twice and conditioned medium was re-added. Experimentation took 
place 24 h later. 
 
2.3.3 Cell stimulation 
In order to prime cells, primary microglia, BV2 microglia and J774.2 
macrophages were treated with lipopolysaccharide (LPS; Escherichia coli; serotype 
055:B5) or left untreated as a control. To stimulate inflammasome activation following 
LPS priming, cell medium was replaced with a microglia extracellular solution buffer: 
130 mM NaCl, 3 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM HEPES, 10 mM glucose, 
pH 7.3 with NaOH (Toulme et al., 2010). Cells were incubated for 30 min in the 
presence or absence of 5mM ATP. The irreversible caspase-1 inhibitor Ac-YVAD-cmk 
was used to assess inflammasome function and applied during the 4 h LPS priming 
step prior to ATP stimulation, with DMSO as a vehicle control. 
 
2.3.4 Western Blotting 
Cells were treated with a lysis buffer containing 1 % (v/v) Triton X-100 and 
protease inhibitor cocktail (2 mM AEBSF, 0.3 mM aprotinin, 130 mM bestatin 
hydrochloride, 14 mM E-64, 1 mM EDTA and 1 mM leupeptin hemisulfate salt) in a 
buffered saline (150 mM NaCl, 20 mM Tris pH 7.4, 1 mM MgCl2, 1 mM CaCl2) and the 
cell lysates were collected. Samples were then centrifuged at 3000 rpm (1400 G) for 10 
min at 4 °C and supernatants were stored at -20 ˚C. Laemmli loading buffer (2X) was 
added to samples before being heated at 100 ˚C for 5 min to denature the protein. 
Samples were resolved by electrophoresis (200 V for 30 min) on 12 % SDS PAGE gels 
(Mini Protean Tetra-Cell, Bio-Rad). Protein was then transferred to a nitrocellulose 
membrane (150 mA for 120 min; Mini Trans-Blot Cell, Bio-Rad). Membranes were 
blocked with 5 % milk (w/v; Sigma, UK) in PBS containing 0.1 % Tween-20 for 1 h at 
ambient room temperature before being incubated with the primary antibody overnight 
on a rocker at 4 °C in 2.5 % milk (w/v). The primary antibodies used were as follows: 
mouse anti-IL-1β (1 µg/ml; Thermo Scientific), mouse anti-β-actin (2.1 µg/ml; Abcam), 
rabbit anti-β-actin (2.1 µg/ml; Abcam), mouse anti-NLRP3 (0.5 µg/ml; Adipogen), rabbit 
anti-P2X7 (0.6 µg/ml; Alomone) and rabbit anti-ASC (1 µg/ml; Santa Cruz). Membranes 
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were washed 3 times in PBS-0.1 % Tween-20 for 5 min at ambient room temperature 
before secondary antibody incubation. 
For quantitative fluorescent analysis, membranes were incubated with 
fluorescent secondary antibodies (donkey anti-mouse IRDye 800CW or donkey anti-
rabbit IRDye 680RD; 0.1 µg/ml; Li-cor) at ambient room temperature on a rocker for 45 
min, before being washed at least 3 times in PBS-0.1 % Tween-20 (v/v). Infrared 
fluorescence was detected to provide a signal proportional to protein concentration, 
allowing protein quantification (Odyssey CLx, Li-cor). All values are given relative to β-
actin levels of the same blot.  
For semi-quantitative densitometry analysis, membranes were incubated with 
HRP secondary antibodies (rabbit anti-mouse or swine anti-rabbit, 1.3 µg/ml; Dako, 
UK) at room temperature on a rocker for 1 h, before being washed 3 times in PBS-0.1 
% Tween-20. Antibody binding was detected via enhanced chemiluminescence using 
ImageQuant-RT ECL (Biological Industries, UK) and quantified using ImageQuant TL 
software (GE Healthcare). To evaluate equal loading of proteins, the blots were 
stripped by incubating membranes in 0.77 % (v/v) 2-mercaptoethanol at 50 °C with 
agitation for 40 min. Membranes were then washed, blocked with 5 % milk in PBS-0.1 
% Tween-20 for 1 h and re-probed for β-actin using the same method as previously 
described. 
 
2.3.5 Detection of cytokine secretion 
Following ATP stimulation in cell cultures, supernatants were collected and 
centrifuged (10 min; 1400 G) at 4 °C and stored at -20 ˚C. Samples were subsequently 
assessed using commercially available IL-1β ELISA kits (eBioscience, USA) or V-
PLEX proinflammatory panel 1 kit (TNF-α & IL-6, Meso Scale Discovery, UK) according 
to the manufacturers instructions. Standards were provided by the manufacturer. 
Absorbance measurements performed using a FLUOstar Optima plate reader (BMG 
Labtech, Germany) for IL-1β ELISAs and a MSD Sector Imager 6000 (Meso Scale, 
US) for the Mesoscale mouse proinflammatory cytokine plate.  
 
2.3.6 Immunocytochemistry 
Sterile glass cover slips were treated with poly-D-lysine (20 µg/ml; ≥1 h; 37 ˚C) 
before being washed with sterile water and PBS. Mixed glia cells were then plated onto 
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PDL-coated cover slips following isolation from brain tissue and microglia were isolated 
after 3 weeks via mild trypsinisation, as previously described. Cells were washed with 
PBS and treated with 4 % formaldehyde (w/v) and 2 % Triton X-100 (v/v) in PBS for 30 
min to fix and permeabalise cells before being blocked for 1 h with 3 % (w/v) milk in 
PBS with 0.2 % Triton X-100 at room temperature. After being washed 3 times in PBS-
0.1 % Tween-20, cells were incubated with the primary antibody diluted in antibody 
diluent (1 % milk in PBS with 0.1 % triton X-100) at 4 °C overnight. Primary antibodies 
include mouse anti-IL-1β (10 µg/ml), mouse anti-NLRP3 (5 µg/ml), rabbit anti-CD11b 
(10 µg/ml) or rabbit anti-GFAP (10 µg/ml). Cells were washed 3 times PBS-0.1 % 
Tween-20 for 5 min and incubated with secondary antibody Alexa Fluor 488 secondary 
goat anti-rabbit antibody (2 µg/ml), Alexa Fluor 488 secondary rabbit anti-mouse (2 
µg/ml) and/or Alexa Fluor 647 secondary donkey anti-mouse (2 µg/ml) in antibody 
diluent for 1 h at room temperature. Cells were washed 3 times in PBS-0.1 % Tween-
20 and incubated with 600 nM DAPI for 20 min before being washed again and 
mounted onto glass slides with 7 µl mowiol and left to dry overnight. Confocal images 
were obtained with a Zeiss LSM510 Meta confocal microscope (Zeiss Plan 
Apochromat 63x / 1.4 oil Ph3 microscope objective). The primary antibody was omitted 
for negative. Images were processed using ImageJ software (version 1.46r). 
 
2.3.7 Fluorescent measurements 
BV-2 cells were plated on 96-well black plates at 100,000 cells per-well 24 h 
prior to experiments. Primary microglia were isolated 24 h prior to experiments in 24-
well clear plates. Cell medium was replaced with a microglia extracellular solution 
buffer (see above) containing 25 µM ethidium bromide. P2X7 receptor antagonist A-
740003 or DMSO as a vehicle control was used to assess ATP-P2X7 activity. Fluostar 
Optima plate reader (BMG Labtech, Germany) at 37 ˚C was used to measure ethidium 
fluorescence (F) at 525 nm (excitation wavelength) and 605 nm (emission wavelength) 
every 60 seconds. 5 initial readings were averaged for a baseline (F0) before ATP (5 
mM) or buffer was added to each well. For a final maximal reading (Fmax), Triton X-100 
was added to each well (0.2 % v/v) to lyse cells for 10 min for a final maximal reading. 
Fluorescence values were then calculated as a percentage of the maximal response as 
follows: y = ((F – F0) / Fmax) * 100 
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2.3.8 Reactive oxygen species (ROS) measurement 
Primary microglia were isolated 24 h prior to experiments in 24-well clear plates 
and primed with LPS for 4 h. Cells were loaded with 2’,7’-dichlorofluorescin diacetate 
(20 µM; H2DCFDA) in serum-free medium for 40 min. Cells were then washed and 
microglia extracellular solution buffer containing 25 µM ethidium bromide was added. 
Fluostar Optima plate reader (BMG Labtech, Germany) at 37 ˚C was used to measure 
DCF fluorescence at 485 nm (excitation) and 520 nm (emission) every 60 seconds, as 
well as ethidium fluorescence (F) at 525 nm (excitation) and 605 nm (emission). 5 
initial readings were averaged for a baseline (F0) before ATP (0 – 5 mM) or buffer was 
added to each well. 
 
2.3.9 Cell density assessment 
To assess cell density of mixed glia and microglia cultures, cells were cultured 
in 24-well plates for 1-3 weeks. DNA content was assessed using the CyQuant NF Cell 
Proliferation Assay Kit (Thermo Fisher, UK). Cell medium was aspirated and replaced 
with CyQuant dye reagent in Hank’s balanced salt solution (HBSS), prepared 
according to the manufacturers instructions, for a 1 h incubation period at 37 ˚C. 
Fluorescence was measured with excitation at 485 nm and emission detection at 530 
nm using a CLARIOstar plate reader (BMG Labtech, Germany). 
 
2.3.10 LDH release 
Necrotic/pyroptotic cell death was assessed by lactate dehydrogenase (LDH) 
release into the supernatant using the CytoTox 96 Non-radioactive Cytotoxicity Assay 
kit (Promega, UK). Following cell stimulation with LPS and/or ATP, supernatants were 
collected and centrifuged (10 min; 1400 G). Samples (50 µl) were then transferred to a 
96-well plate and incubated with the assay substrate for 30 min at room temperature 
before the stop solution (1 M acetic acid) was added. Absorbance (490 nm) was then 
measured with a FLUOstar Optima plate reader (BMG Labtech, Germany). 
 
 69 
2.3.11 Data Analysis 
All in vitro data were expressed as the mean ± SEM of n ≥ 3 independent 
biological repeats. Data distribution was assumed to be normal, though not formally 
tested. Statistical analysis was carried out with a one-way or two-way ANOVA. If 
ANOVA assessment revealed significance (p < 0.05), Tukey or Dunnett post hoc 
analysis was carried out. 
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2.3.12 Reagents and consumables 
 
Reagents	  for	  cell	  culture	   Source	   Product	  code	  
Lipopolysaccharides,	  from	  Escherichia	  coli	  055:B5	   Sigma,	  UK	   L2880	  
DMEM	  (F-­‐12)	   Gibco,	  UK	   11520396	  
DMEM	  (F-­‐12)	  +	  glucose	   Gibco,	  UK	   11594486	  
FBS	   Gibco,	  UK	   11533387	  
Penecillin	  /	  streptomycin	   Gibco,	  UK	   11548876	  
Penecillin	  /	  steptomycin	  /	  amphotericin	  B	   Gibco,	  UK	   11570486	  
Glutamine	   Gibco,	  UK	   25030024	  
Trypsin	  (2.5	  %	  v/v)	   Gibco,	  UK	   10590046	  
Trypsin	  (0.25	  %	  v/v)	   Gibco,	  UK	   11570626	  
Phosphate	  buffered	  saline	   Gibco,	  UK	   11590476	  
Sterile	  water	   Gibco,	  UK	   15230089	  
Poly-­‐D-­‐lysine	   Sigma,	  UK	   P1024	  
Deoxyribonuclease	  I	   Sigma,	  UK	   D5025	  
Phosphate	  buffered	  saline	  tablets	   Sigma,	  UK	   P4417	  
HBSS	   Gibco,	  UK	   11530476	  
12	  well	  clear	  cell	  culture	  plates	   Greiner	  BioOne	   665-­‐180	  
24	  well	  clear	  cell	  culture	  plates	   Greiner	  BioOne	   662-­‐160	  
96	  well	  black	  cell	  culture	  plates	   Greiner	  BioOne	   655-­‐086	  
Cell	  scraper	   Fisher	  Scientific	   08-­‐100-­‐241	  
Cell	  strainer	  100um	   Fisher	  Scientific	   FB35181	  
T25	  cell	  culture	  flask	   BD	  Bioscience	   353109	  
T75	  cell	  culture	  flask	   BD	  Bioscience	   353136	  
T175	  cell	  culture	  flask	   BD	  Bioscience	   353112	  
DAPI	   Sigma,	  UK	   5748	  
Table 2-4. Reagents and consumables for cell culture. 
 
 
Table 2-5. Drugs used for in vitro assessment. 
  
Drugs	   Source	   Product	  code	  
DMSO	   Sigma,	  UK	   D8418	  
A-­‐740003	   Sigma,	  UK	   A0862	  
Ac-­‐YVAD-­‐cmk	   Sigma,	  UK	   SML0429	  
Ketamine	   Sigma,	  UK	   K2753	  
Desipramine	   Sigma,	  UK	   D3900	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Reagents	  for	  SDS	  page	  and	  transfer	   Source	   Product	  code	  
Tris(hydroxymethyl)amino-­‐methane	   Sigma,	  UK	   252859	  
Sodium	  dodecyl	  sulfate	   Sigma,	  UK	   L3771	  
30	  %	  (w/v)	  acrylamide	   National	  Diagnostics	   EC-­‐890	  
Ammonium	  persulfate	   Acros	  Organics	   AC327081000	  
TEMED	   Fisher	  Scientific	   T/P190/04	  
Glycine	   Sigma,	  UK	   G8898	  
Methanol	   Sigma,	  UK	   34860	  
Nitrocellulose	  membrane	   Bio-­‐Rad	   162-­‐0112	  
Skimmed	  milk	  powder	   Sigma,	  UK	   70166	  
PageRuler	  Prestained	  Protein	  Ladder	   Fisher	  Scientific	   11812124	  
Protease	  inhibitor	  cocktail	   Sigma,	  UK	   P2714	  
BSA	   Sigma,	  UK	   A7906	  
EZ	  enhanced	  chemiluminescence	  (ECL)	   Biological	  Industries	   20-­‐500-­‐120	  
Laemmli	  sample	  buffer	  (2X)	   Sigma,	  UK	   S3401	  
Table 2-6. Reagents for SDS page and transfer. 
 
 
Antibodies	   Source	   Product	  code	  
Primary	  antibodies	  
anti-­‐β-­‐actin	  (mouse	  host)	   Abcam	   ab6276	  
anti-­‐β-­‐actin	  (rabbit	  host)	   Abcam	   ab8227	  
anti-­‐proIL-­‐1β	   Fisher	  Sci.	   10405184	  
anti-­‐NLRP3	   Adipogen	   AB-­‐20B-­‐0014-­‐C100	  
anti-­‐ASC	   Santa	  Cruz	   Sc-­‐22514-­‐R	  
anti-­‐P2X7	   Alomone	  Labs	   APR-­‐004	  
anti-­‐CD11b	   Abcam	   Ab75476	  
Anti-­‐GFAP	   Abcam	   Ab7260	  
Secondary	  antibodies	  
IRDye	  800CW	  Donkey	  anti-­‐mouse	  (fluorescent)	   Li-­‐cor	   925-­‐32212	  
IRDye	  680RD	  Donkey	  anti-­‐rabbit	  (fluorescent)	   Li-­‐cor	   926-­‐68073	  
polyclonal	  rabbit	  anti-­‐mouse	  (HRP)	   Dako,	  UK	   P0260	  
polyclonal	  swine	  anti-­‐rabbit	  (HRP)	   Dako,	  UK	   P0217	  
Alexa	  Fluor	  488	  rabbit	  anti-­‐mouse	   Invitrogen	   A11059	  
Alexa	  Fluor	  488	  goat	  anti-­‐rabbit	   Invitrogen	   A21206	  
Alexa	  Fluor	  647	  donkey	  anti-­‐mouse	   Abcam	   Ab150103	  
Table 2-7. Primary and secondary antibodies. 
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Assays	   Source	   Product	  code	  
Bradford	   Sigma,	  UK	   B6916	  
Mouse	  IL-­‐1β	  ELISA	  Ready-­‐SET-­‐Go!	   Affymetrix	  eBioscience	   88-­‐7013-­‐88	  
CyQuant	  NF	  Cell	  Proliferation	  Assay	  Kit	   Life	  Technologies	   C35007	  
CytoTox	  96	  non-­‐redioactive	  Cytotoxicity	  assay	   Promega,	  UK	   G1780	  
MSD	  mouse	  pro-­‐inflammatory	  cytokine	  plate	   Meso	  Scale	  Discovery	   K15048D-­‐1	  
H2DCFDA	   Fisher	  Scientific	   D399	  
Table 2-8. Assay kits. 
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Chapter 3: Modeling LPS-induced 




In order to investigate the effects of inflammation in depression, inflammatory 
insults can be assessed in mice via behavioural and molecular analysis (see Section 
1.5.2). Inflammatory agents used include LPS, Bacillus Calmette-Guerin (BCG), 
proinflammatory cytokines and poly(I:C) (Kaster et al., 2012; O’Connor et al., 2009b; 
Cunningham et al., 2007). Alternatively, neuroinflammation has been demonstrated in 
chronic stress models of depression. In this thesis, LPS has been used to study 
inflammation and depressive-like behaviour. 
 
3.1.1 Acute LPS model of inflammation-induced depression 
LPS is a component of the Gram-negative bacterial cell wall and is recognised 
by the TLR4 receptor on immune cells. LPS induces a robust inflammatory response 
and the production of pro-inflammatory cytokines both in vivo and in vitro (O'Connor et 
al., 2009a; Hanisch, 2002; Lee et al., 1993). Acute administration of LPS in mice has 
been used to assess inflammation-induced sickness, consisting of reductions in a 
range of behaviours including locomotor activity, exploratory behaviour, social and 
sexual behaviour, food and water consumption, self-grooming and impairments in 
learning and memory (Dantzer, 2001). These behavioural effects of LPS can be 
observed when administered both systemically and centrally into the lateral ventricle of 
the brain, with the latter enabling one to assess neuroinflammation in isolation from 
systemic inflammation (Lawson et al., 2013b). Sickness behaviours peak at around +6 
h, and are generally considered to have disappeared by +24 h post-administration, 
although sickness behaviours have been observed at +24 h time-points and later 
(Biesmans et al., 2013; Godbout et al., 2008; Lawson et al., 2013a; Corona et al., 
2010). Sickness behaviours in LPS studies are typically assessed by observing 
distance travelled, such as in an open field, but have also been measured by 
food/water consumption or social interaction (O’Connor et al., 2009a; Henry et al., 
2008; Couch et al., 2016).  
Sickness behaviour is paralleled with an increase in pro-inflammatory cytokines 
in the blood and brain, including TNF-α, IL-1β and IL-6, and reductions in brain BDNF 
(Biesmans et al., 2013; Zhang et al., 2016; Yang et al., 2016; O'Connor et al., 2009a; 
Lawson et al., 2013a). Cytokine expression in response to endotoxin exposure is 
broadly similar in mice to that of humans, though mice require a higher dose of 
endotoxin (Copeland et al., 2005). In humans, an acute LPS insult (0.8 ng/kg) induced 
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increased serum levels of TNF-α and IL-6 (Hannestad et al., 2011). Sickness 
behaviours are considered to mimic the behavioural changes experienced in humans 
during illness whilst the immune system is activated (Dantzer, 2001). Such behaviours 
are thought to have evolutionary benefits in conserving energy, limiting danger and 
avoiding exposure to more pathogens (Miller and Raison, 2016). 
Typically, depressive-like behaviours are assessed at +24 h after LPS 
administration, when the overt symptoms of sickness have subsided (O'Connor et al., 
2009a). At this point, subtle changes in behaviour can be assessed without the 
confounding effect of reduced locomotion. Increased immobility in the FST or TST and 
anhedonia in the SPT are often observed at +24 h, though high doses of acute LPS 
can cause depressive-like behaviours to last up to 1 month post-administration 
(Anderson et al., 2016; Anderson et al., 2015). In humans, acute LPS (0.8 ng/kg) can 
also induce mild depressive-like symptoms, which can be attenuated with citalopram 
pretreatment (Hannestad et al., 2011). Acute LPS models of depressive-like behaviour 
do not intend to model depression as a whole, but rather focus on an endophenotype 
observed in depressed patients in an attempt to understand some of the underlying 
molecular processes contribute to depression pathology. 
A literature search of “lipopolysaccharide + depression + mice” returned 59 
studies that assessed depressive-like behaviour following LPS administration in 
wildtype adult mice (neonatal/juvenile mice not included). Of the 59 studies, 54 were 
acute intraperitoneal (i.p.) administration of LPS (Table 3.1). In the last two years there 
has been a significant rise in the usage of the acute LPS model of depression, as 50 % 
(27) of the studies identified were been published in 2015/16, with 30 % (16) being 
used to assess the antidepressant activity of natural products (Table 3.1). Whilst 26 
experiments reported depressive-like behaviour in the absence of sickness behaviour, 
15 experiments showed either no significant depressive-like behaviour or the presence 
of sickness behaviour at the same time-point at which depressive-like behaviour was 
assessed, failing to rule out the confounding influence of sickness. A further 16 
experiments failed to report any sickness behaviour assessment at all. Despite the 
inconsistencies in acute LPS studies, LPS induces a replicable and robust sickness 
behaviour, which has usually subsided by +24 h, when depressive-like behaviours are 
typically observed. 
Treatment with SSRI antidepressants, including fluoxetine and paroxetine, have 
been shown to inhibit the development of acute LPS-induced depressive like 
behaviours in mice (Li et al., 2016; Yao et al., 2015; Dong et al., 2016; Ohgi et al., 
2013). Ketamine administration has also been shown to attenuate LPS-induced 
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depressive-like behaviours in mice, without affecting sickness behaviour (Walker et al., 
2013). These findings support the idea that excessive glutamatergic signalling and 
excitotoxicity plays a key role in inflammation-induced depression. 
The acute LPS model has very low construct validity, with a single high dose 
inflammatory insult not replicating the chronic and subtle nature of inflammation in 
depression. Several recent studies have attempted to model chronic inflammation in 
mice using repeated LPS administration. In mice, 10 consecutive injections of high 
dose LPS (0.83 mg/kg) (Guo et al., 2014) or 8 injections (every other day) of low dose 
LPS (0.1 mg/kg) (Xie et al., 2012) resulted in the development of depressive-like 
behaviours. In rats, 7 injections (every other day) of 0.5 mg/kg LPS resulted in 
depressive-like behaviours in the FST and SPT (Guo et al., 2016). These sustained 
inflammation-based model of depressive-like behaviour in mice have greater face 
validity than acute LPS, as they better represent the sustained inflammation associated 
with the human condition. 
 
3.1.2 Environmental factors influencing depressive-like behaviour 
As detailed in Table 3.1, LPS doses used to provoke depression-related 
behaviours range from 0.1 – 5 mg/kg. However, information on the housing conditions, 
including light phase and group or individual housing, are often partially or completely 
absent from reports. Depressive-like behaviours can be sensitive to a range of factors, 
including animal strain, gender, social isolation, lighting, experimenter handling and 
diet (Bogdanova et al., 2013). As nocturnal animals, rodents naturally exhibit increased 
locomotion during the dark-phase of the light cycle (Kopp et al., 1998). Changes in 
locomotion may influence behaviours that require movement, including the FST. 
Unnatural manipulation of the circadian rhythm by extending the light period can 
increase FST immobility in mice (Fonken et al., 2009). Changes in locomotion, anxiety- 
and depressive-like behaviour following chronic stress in rats has been shown to be 
influenced by the light cycle (Huynh et al., 2011). In addition, female rats have been 
shown to exhibit increased FST immobility in the dark cycle, whilst male rats are 
unaffected (Verma et al., 2010). Social isolation in rats has returned mixed findings, 
with some studies reporting increased depressive-like behaviours (Kokare et al., 2010; 
Brenes et al., 2008), whilst others report no depressive-like behaviour (Hall et al., 
1998) (Fischer et al., 2012). Increased immobility has been reported in female mice 
following isolation, which was reversible with fluoxetine (Martin and Brown, 2010). In a 
learned helplessness model of depression, group housing of mice attenuated 
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depressive behaviour (Chourbaji et al., 2005). Furthermore, the behavioural response 
to acute inflammation has been shown to be influenced by group housing, whereby an 
increase in inflammation-induced FST immobility is seen in group-housed CD-1 mice, 
but not when individually housed (Painsipp et al., 2011). No increase in immobility was 
reported in group or individually housed C57Bl/6J mice (Painsipp et al., 2011). Due to 
the sensitivity of depressive-like behaviour, such changes in experimental conditions 
may account for some of the variation seen throughout the literature. 
 
3.1.3 Aims of Chapter 3 
The aim of this chapter was to assess the acute LPS model of depressive-like 
behaviour in a number of behavioural tasks, including the FST, SPT and FUST. The 
influence of environmental conditions on behaviour following acute LPS was assessed, 
including light cycle and group / individual housing. The effect of ketamine on sexual 
motivation in the FUST was also investigated. Sickness and depressive-like behaviour 
was assessed following central administration of LPS directly into the lateral ventricle, 
thereby avoiding systemic inflammation. Finally, repeated LPS administration was used 
to develop a novel model of sustained inflammation-induced depressive-like behaviour. 
All experiments in this chapter were carried out at Janssen Pharmaceutica, except the 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3.2.1 Pharmacological validation of depressive-like behaviour in 
mice 
In preliminary experiments, the FST was pharmacologically validated using a 
range of antidepressant drugs with proven clinical efficacy and pre-clinical efficacy in 
the mouse FST. Time spent immobile was assessed in control adult male C57BL/6J 
mice in the FST 30 min after the administration of antidepressants including 
desipramine, ketamine, bupropion, and fluoxetine (Figure 3.1A-D). Bupropion (one-way 
ANOVA, F(2,27) = 5.477, p = 0.01) and ketamine (one-way ANOVA, F(2,27) = 10.83, p < 
0.001) both revealed a significant effect on time spent immobile during a 6 minute FST. 
20 mg/kg bupropion and 10 mg/kg ketamine significantly reduced FST immobility (p < 
0.01 & p < 0.001, respectively), indicating anti-depressant activity. Desipramine (one-
way ANOVA, F(2,24) = 1.388, p = 0.2688) and fluoxetine (t test, p = 0.4492) failed to 
significantly affect immobility time.  
Bupropion and ketamine were subsequently assessed in a 10-minute OFT in 
low light, 30 min after administration, to measure the effect on locomotion (Figure 3.1E-
F). Bupropion induced a significant increase in distance travelled (t test, p < 0.001), 
whilst ketamine had no effect on distance travelled (t test, p = 0.5789) compared to 
saline treated controls. Neither bupropion (t test, p = 0.4211) nor ketamine (t test, p = 
0.8342) affected time spent in the centre of the OFT (Figure 3.1G-H), though it should 
be noted that a low level of light (2 – 3 lux) was used, so the centre of the maze was 




Figure 3.1. Pharmacological validation of antidepressant compounds in the 
forced swim test and open field test in adult male C57BL/6J mice.  
Fluoxetine (i.p.; A), desipramine (i.p.; B), bupropion (i.p.; C) and ketamine (s.c.; D) 
were all tested for 6 min in the FST, 30 min after administration. Total distance 
travelled in a 10 min OFT (E, F). Time spent in the centre of the OFT (G, H). Values 
shown are mean ± SEM of n=8-10 per group. **p < 0.01, ***p < 0.001 compared to 
saline injected controls. Data was analysed by Students t-test (A, E - H) or one-way 




3.2.2 Assessment of acute LPS induced depressive-like behaviours 
3.2.2.1 Effect of housing and lighting conditions on acute LPS-induced 
behaviours 
The influence of housing and lighting conditions on acute LPS-induced 
behaviours has not been systematically studied. Mice were housed either in groups or 
individually and then tested during the light phase (lights on 06:00 h) or the dark phase 
(lights off at 06:00 h, behaviours assessed under red light) of the light cycle (Figure 
3.2). As an indication of sickness behaviour, body weight and total locomotion in the 
OFT was monitored (Figure 3.2A-B). A two-way ANOVA revealed a significant effect of 
treatment (F(2,161) = 337.3, p < 0.001) and housing (F(3,161) = 4.923, p < 0.01) on body 
weight change at +24 h after injection, but no interaction between the two (F(6,161) = 
1.807, p = 0.101). All LPS-treated mice showed a significant reduction in body weight, 
following acute LPS administration at both doses (all p < 0.001), compared to saline-
treated controls. A two-way ANOVA revealed a significant effect of treatment (F(2,133) = 
284.7, p < 0.001) and housing (F(3,133) = 5.56, p < 0.01) on distance travelled in the OFT 
at +6 h after injection, but no interaction between the two (F(6,133) = 1.695, p = 0.127). A 
significant reduction in the total distance travelled in the OFT was seen 6 h after acute 
administration of LPS, at both 0.42 and 0.83 mg/kg, in all housing conditions when 
compared to saline-treated controls (all p < 0.001). There was no significant difference 
between housing conditions in LPS-treated mice. However, in saline-treated mice, the 
mice group-housed and tested in the dark travelled further than mice group-housed 
and tested in the light (p < 0.05). On average, locomotion was reduced to 40 % and 32 
% of control following 0.42 and 0.83 mg/kg LPS, respectively, consistent with a 
pronounced sickness behaviour 6 h following acute LPS administration. Furthermore, 
acute LPS treatment did not significantly influence the time spent in the centre portion 
of the OFT, indicating that LPS did not induce anxiety-like behaviour, though the OFT 
setup was not optimised to detect anxiety-related behaviours (Figure 3.2C). 
Depressive-like behaviour was subsequently assessed in the FST, 24 h after 
acute LPS administration because overt sickness behaviour is often no longer present 
at this time (Figure 3.2D) (O'Connor et al., 2009a). A two-way ANOVA revealed a 
significant effect of treatment (F(2,131) = 3.334, p < 0.05), though posthoc comparisons 
between saline and LPS groups did not reveal any significant differences. There was 
no significant effect of housing (F(3,131) = 0.4783, p = 0.6979) on FST immobility and no 
significant interaction between the two (F(6,131) = 1.665, p = 0.1345). Following post hoc 
analysis, no group showed a significant increase in FST immobility following LPS 
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administration compared to saline-treated mice. In subsequent experiments with acute 
LPS all mice were group housed and tested in the light phase unless otherwise stated. 
 
3.2.2.2 Time course of acute LPS-induced behaviours 
Having established evident sickness behaviour at +6 h in the OFT, the duration 
of this behaviour was investigated (Figure 3.3A). At +24 h after injection, there was a 
significant effect of LPS on distance travelled in the OFT (one way ANOVA, F(3,68) = 
6.458, p < 0.001). Both 0.42 and 0.83 mg/kg LPS produced a significant reduction in 
total distance travelled in the OFT to 81 ± 3 % (n = 17) and 79 ± 5 % (n = 18) of control, 
respectively (p < 0.01 and p < 0.001, respectively). 0.21 mg/kg LPS did not significantly 
affect distance travelled. There was a significant effect of LPS on immobility in the FST 
at +48 h after injection (one way ANOVA, F(2,25) = 7.727, p < 0.01), although no group 
exhibited significantly greater immobility levels compared to control (Figure 3.3B). The 
rotarod test was also used to assess motor coordination at +6, +24 and +48 h after 
acute LPS administration in separate groups of mice (Figure 3.3C). A two-way ANOVA 
revealed a significant effect of treatment (F(1,54) = 13.22, p < 0.001), but no significant 
effect of treatment time (F(5,54) = 0.07, p = 0.9964) or interaction between the two (F(5,54) 
= 1.045, p = 0.4008). Posthoc analysis revealed a reduction in post-LPS performance 
compared to baseline performance +6 h after LPS administration (p < 0.05), but not at 
+24 h or +48 h after administration. 
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Figure 3.2. Sickness and depressive-like behaviour following acute LPS in adult 
male C57BL/6J mice.  
Change in body weight +24 h after LPS or saline administration (A). Distance travelled 
(B) and time spent in the centre (C) of the OFT was assessed +6 h post-administration 
of LPS. Time spent immobile in the FST +24 h post-administration of LPS (D). Mice 
were group housed (n=3/4 per cage) or individually housed (“Group” & “Individual”). 
Behaviours were assessed during the light (lights on 06:00 hr) or the dark (lights off 
06:00 hr) phase (“Light” & “Dark”). Values shown are mean ± SEM of n=10-15 per 
group. ***p < 0.001 compared to saline injected controls, #p < 0.05. Data was analysed 




Figure 3.3. Time course of behavioural effects of acute LPS administration in 
adult male C57BL/6J mice.  
Distance travelled in the OFT +24 h post-administration of saline or LPS (A). Time 
spent immobile in the FST (B) +48 h post-administration of saline or LPS (n=9-18 per 
group, **p < 0.01, ***p < 0.001 compared to saline injected controls). In a separate 
group of animals, motor coordination in a 3 min rotarod test was examined at 6, 24 or 
48 h post-administration of saline or LPS (C; n=10 per group, #p < 0.05 compared to 
pre-treatment baseline performance). Mice were group housed (n=3/4 per cage) and 
behaviour assessed in the light cycle. All values are mean ± SEM and analysed by 
one-way ANOVA with Dunnett’s posthoc test (A, B) or two-way ANOVA with 
Bonferroni’s posthoc test (C). 
 
 
3.2.2.3 Effect of acute LPS on anhedonic behaviours 
The SPT and FUST were used as additional methods of testing depressive-like 
behaviours, in particular, hedonic behaviour. In a preliminary experiment carried out at 
the University of Bath, the palatability of sucrose was assessed in adult male C57BL/6J 
mice in a sucrose consumption test (Figure 3.4B). Following a 4 h food and water 
restriction, there was a significant effect of sucrose on volume consumed (one way 
ANOVA; F(2,9) = 10.89; p = 0.004). Mice consumed significantly more 2.5 % or 5 % 
sucrose solution when compared to mice that had just water (p < 0.01 & p < 0.05, 
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respectively). These data indicate that 2.5 % sucrose solution is enough to induce a 
significant preference and a hedonic behaviour. 
In the SPT (performed at Janssen Pharmaceutica), mice have a choice 
between two bottles: one containing water and one containing sucrose dissolved in 
water). During the 4 days training prior to LPS administration, mice had access to 
either two water bottles (days 1 & 3), or water and sucrose (days 2 & 4). There was a 
significant effect of day on preference (one way repeated measures ANOVA, F(2.4,109.2) 
= 382.4; p < 0.001; Figure 3.4C). Mice exhibited a significant preference for 2.5 % 
sucrose solution over water (~90%; p < 0.001) compared to the preference of right over 
left when only water was available (50%). This indicates that there was no positional 
preference of bottles. In addition, there was a significant effect of day on total volume 
consumed (one way repeated measures ANOVA, F(2,91.8) = 50.82; p < 0.001; Figure 
3.4D). A significant increase in total volume consumed was observed on training days 
2 and 4, which included sucrose solution (p < 0.001 for both), as well as training day 3, 
which did not include sucrose solution (p < 0.001). The increase seen on day 3 could 
be explained by an increase in mice sampling the water bottles in anticipation of 
sucrose solution. 
A two-way repeated measures ANOVA revealed a significant effect of treatment 
(F(2,43) = 4.941, p = 0.0117) and time (F(1,43) = 8.513, p = 0.0056) on sucrose preference 
following acute LPS administration, as well as a significant interaction between the two 
(F(2,43) = 4.515, p = 0.0166; Figure 3.4E). A significant effect of treatment (F(2,43) = 
34.31, p < 0.001) and time (F(1,43) = 28.65, p < 0.001) on total volume consumed was 
also observed following acute LPS administration, as well as a significant interaction 
between the two (F(2,43) = 10.53, p < 0.001; Figure 3.4F). Both doses of LPS tested, 
0.415 and 0.83 mg/kg, produced a significant reduction in volume consumed to 56 ± 7 
% (n = 16) and 42 ± 5 % (n = 15) of control and sucrose preference to 81 ± 6 % (n = 
16) and 79 ± 4 % (n = 15) of control, respectively, in the first 24 h after injection (all p < 
0.001). No significant reductions in volume consumed or sucrose preference was 
observed from 24-48 h after injection. 
The FUST was used to assess sexually motivated behaviour at +6 h and +24 h 
(separate groups of mice) after acute LPS administration (0.42 & 0.83 mg/kg; Figure 
3.5B-C). The task was first validated by assessing the preferences of male mice for 
female urine over male urine or water (Figure 3.5A). A two-way repeated measures 
ANOVA revealed a significant effect of odour (F(1,30) = 55.81, p < 0.001) on sniffing 
behaviour in the FUST. Male mice had a preference for sniffing at female urine over 
male urine and water (p < 0.001 for both). No preference for male urine over water was 
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observed, indicating the preference towards female urine is likely sex-based and not 
novelty-based. 
Acute LPS-induced behavioural changes were then assessed in the FUST. At 
+6 h after saline or LPS administration, a two-way repeated measures ANOVA 
revealed a significant effect of treatment (F(2,17) = 19.06, p < 0.001) and odour (F(1,17) = 
33.35, p < 0.001) on FUST sniffing behaviour, and a significant interaction between 
treatment and odour (F(2,17) = 11.51, p < 0.001). Saline-injected control mice spent 
significantly more time sniffing urine when compared to water (p < 0.001), but this was 
not seen in LPS-treated mice (Figure 3.5B). Furthermore, time spent sniffing urine was 
significantly reduced to 23 ± 8 % (n = 7) and 17 ± 6 % (n = 7) following 0.42 or 0.83 
mg/kg LPS treatments, respectively, when compared to control mice (p < 0.001 for 
both). Similarly, a two-way repeated measures ANOVA revealed a significant effect of 
treatment (F(2,17) = 7.06, p = 0.0059) and odour (F(1,17) = 85.66, p < 0.001) on FUST 
sniffing behaviour at +24 h after saline or LPS administration, and a significant 
interaction between treatment and odour (F(2,17) = 6.932, p = 0.0063). Again, saline-
injected control mice spent significantly more time sniffing urine compared to water (p < 
0.001) and this effect was also evident in both 0.42 and 0.83 mg/kg LPS treated groups 
(p < 0.001 and p < 0.05, respectively; Figure 3.5C). However, at +24 h post-LPS 
administration, time spent sniffing urine was significantly reduced to 62 ± 10 % (n = 7) 
and 44 ± 7 % (n = 7) following 0.42 or 0.83 mg/kg LPS treatments, respectively, when 
compared to control mice (p < 0.01 and p < 0.001, respectively). In addition, there was 
not a significant effect of LPS treatment on time spent sniffing water. These results 
demonstrate that acute LPS administration produced a significant effect on hedonic 




Figure 3.4. Effects of acute LPS administration in the sucrose preference test in 
adult male C57BL/6J mice.  
Mice were given the choice of two bottles containing either water (w) or sucrose 
solution (s) during the SPT (A). Consumption of sucrose solutions (0, 2.5 or 5 %) was 
measured (B; n=4 per group, *p < 0.05, **p < 0.01 compared to 0 % sucrose). During 
the 4-day SPT training, mice were given either two water bottles (Days 1 & 3), or one 
water bottle and one 2.5 % sucrose solution (Days 2 & 4). Preference of sucrose 
solution over water or left water bottle over right water bottle was calculated (C), as 
well as total consumption (D). Following LPS or saline administration, sucrose 
preference (E) and total consumption (F) was recorded during 0-24 h and 24-48 h 
(n=15-16, ***p < 0.001 compared to saline injected controls). Mice were singly housed 
throughout the experiment, lights on at 06:00 h. Values shown are mean ± SEM and 
analysed by one-way repeated measures ANOVA with Dunnett’s posthoc test (B) or 




Figure 3.5. Effects of acute LPS administration on sexual motivation in the 
female urine sniffing test in adult male C57BL/6J mice. 
During a 3 min FUST test period, time spent sniffing water, male urine or female urine 
soaked cotton buds was assessed to validate sex-driven behaviour (A). FUST 
behaviour was assessed at +6 h (B) and +24 h (C) post-administration of saline or 
LPS. Mice were group housed (n=3/4 per cage) and behaviour assessed during the 
light phase. Values shown are mean ± SEM of n=6-7 per group. **p < 0.01, ***p < 
0.001 compared to urine sniffing saline injected controls) and #p < 0.05, ###p < 0.001 
within group comparison vs water. Data was analysed by two-way repeated measures 
ANOVA with Bonferroni’s posthoc test. 
 
 
3.2.3 The effect of ketamine on LPS-induced depressive-like 
behaviour 
In preliminary experiments, ketamine exhibited antidepressant-like activity in the 
FST without affecting locomotion (Figure 3.1). The potential antidepressant activity of 
ketamine on LPS-induced depressive-like behaviour was assessed in the FUST at +24 
h post-LPS administration. Ketamine (10 mg/kg; s.c.) was administered 30 min before 
the FUST (Figure 3.6A). A two-way repeated measures ANOVA revealed a significant 
effect of odour on FUST behaviour (F(1,24) = 73.03, p = 0.009) and a significant 
interaction between treatment and odour (F(3,24) = 4.833, p < 0.001), though no 
significant effect of treatment alone (F(3,24) = 2.87, p = 0.0575). All mice showed a 
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significantly greater time spent sniffing female urine compared to water (p < 0.001 for 
saline treated controls; p < 0.05 for all other groups), indicating sexual motivation. LPS 
alone significantly reduced time spent sniffing urine when compared to saline treated 
control mice (p < 0.01). Interestingly, ketamine alone significantly reduced time spent 
sniffing urine (p < 0.01), indicating a pro-depressive-like effect. Mice administered LPS 
24 h before testing and ketamine 30 min before testing still exhibited a significant 
reduction in time spent sniffing urine (p < 0.01), with no significant difference between 
LPS alone and LPS with ketamine. These data suggest that ketamine administered 30 
min prior to the FUST failed to abrogate the depressive-like effects of acute LPS 
administered 24 h prior. Furthermore, ketamine alone induced depressive-like 
behaviour, though alongside LPS, it did not enhance the depressive-like effects of LPS.  
Subsequently, ketamine (10 mg/kg; s.c.) was administered alongside LPS, 24 h 
prior to the FUST, in an attempt to block the development of inflammation-induced 
depressive-like behaviour in the FUST (Figure 3.6B). A two-way repeated measures 
ANOVA revealed a significant effect of odour (F(1,37) = 131.9, p < 0.001) and treatment 
(F(3,37) = 4.868, p = 0.0059), with a significant interaction between odour and treatment 
(F(3,37) = 3.611, p = 0.022). All mice showed a significantly greater time spent sniffing 
female urine compared to water (p < 0.01 for LPS alone; p < 0.001 for all other 
groups). LPS alone significantly reduced the time spent sniffing urine (p < 0.001). 
Ketamine alone, administered alongside LPS 24 h prior to testing, did not significantly 
alter the time spent sniffing urine when compared to saline treated controls. When 
ketamine was co-administered with LPS, there was still a significant reduction in time 
spent sniffing female urine compared to the control mice (p < 0.05), and no significant 
difference compared to LPS alone. These findings suggest ketamine failed to reverse 




Figure 3.6. Effects of ketamine on acute LPS-induced depressive-like behaviour 
in the female urine sniffing test in adult male C57BL/6J mice.  
LPS (0.83 mg/kg; i.p.) was administered 24 h prior to the FUST. Ketamine (10 mk/kg; 
s.c.) was administered either 30 min (A) or 24 h (B) before the FUST. Mice were group 
housed (n=3/4 per cage) and behaviour assessed in the light cycle. Values shown are 
mean ± SEM of n=7-11 per group. *p < 0.05, ***p < 0.001 compared to urine sniffing 
saline injected controls; #p < 0.05, ##p < 0.01, ###p < 0.001 within group comparison vs 




3.2.4 Intracerebroventricular (ICV) administration of LPS 
By administering LPS directly into the CNS, the influence of peripheral 
inflammation can be avoided and neuroinflammation can be assessed in isolation. 
Here, LPS (100 ng) was administered directly into the lateral ventricle of the brain 
(lateral 1.5 mm / posterior 0.6 mm / dorsal 2.3 mm with respect to Bregma) via 
intracerebroventricular (ICV) injection in an attempt to induce a depressive-like 
behaviour in mice (Section 2.1.12). Firstly, central administration of LPS during surgery 
was assessed, with mice receiving an injection of LPS or saline (1 µl) directly into the 
lateral ventricle and tested in the OFT and the FST at +6 h and +24 h, respectively, or 
+24 h and +48 h, respectively. Body weight following LPS was significantly reduced at 
+24 h compared to saline treated mice (92 ± 1 %; n = 12; t test, p < 0.001; Figure 
3.7E). Distance travelled in the OFT was significantly reduced at +6 h after 
administration (33 ± 3 %; n = 4; t test, p < 0.001; Figure 3.7A), and was not significantly 
reduced after +24 h after administration (72 ± 10 %; n = 6; t test, p = 0.0989; Figure 
3.7B). When tested in the FST, no significant increase in immobility was observed at 
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+24 h (t test, p = 0.535; Figure 3.7C) or +48 h (t test, p = 0.454; Figures 3.7D). In order 
to avoid any confounding factors of carrying out behavioural tests within 24 h of 
surgery, ICV administration via a cannula surgically implanted 2 weeks prior was also 
tested (Section 2.1.13). Body weight following LPS was significantly reduced at +24 h 
compared to saline treated mice (92 ± 2 %; n = 6; t test, p < 0.001; Figure 3.8B). 
Distance travelled in the OFT at +6 h was significantly reduced in LPS treated mice 
compared to saline treated mice (50 ± 12 %; n = 6; t test, p = 0.0027; Figure 3.8A). At 
+24 h, FST immobility was not significantly different between LPS and saline treated 
mice (t test, p = 0.341, n = 6; Figure 3.8C).  
 
Figure 3.7. Effects of i.c.v. injection of LPS on open field test and forced swim 
test behaviour in adult male C57BL/6J mice.  
LPS (100 ng) or saline was injected directly into the lateral ventricle during surgery. 
Distance travelled in the OFT at +6 h (A) and +24 h (B) after saline or LPS 
administration. Time spent immobile in the FST at +24 h (C) or +48 h (D). Body weight 
+24 h after saline or LPS administration (E). Mice were individually housed and 
behaviour assessed in the light cycle. Values shown are mean ± SEM of n=4-6 per 




Figure 3.8. Effects of i.c.v. administration of LPS via cannula on open field test 
and forced swim test behaviour in C57BL/6J mice.  
LPS (100 ng) or saline was injected directly into the lateral ventricle via a cannula 
surgically implanted 2 weeks prior to injection. Distance travelled in the OFT at +6 h 
after saline or LPS administration (A). Body weight at +24 h after saline or LPS 
administration (B). Time spent immobile in the FST at +24 h after saline or LPS 
administration (C). Mice were individually housed and behaviour assessed in the light 
cycle Values shown are mean ± SEM of n=6 per group. **p < 0.01, ***p < 0.001 
compared to saline injected controls. Data was analysed by Student’s t-test. 
 
 
3.2.5 A repeated LPS model of depressive-like behaviour in mice 
In order to develop a protocol for assessing the effects of a period of sustained 
inflammation on depression-related behaviours, repeated daily dosing with LPS was 
carried out. A 3-day and 5-day model tested with four groups: saline treated controls, 
acute LPS (0.83 mg/kg), constant dosing (CD) of 0.83 mg/kg and increasing dosing 
(ID) doubling up to 0.83 mg/kg on final day. Sickness behaviour was assessed by 
tracking body weight and assessing locomotor behaviour in the OFT at +6 h after the 
final injections. Depressive-like behaviour in the FST was investigated at +24 h after 
the final injection. 
 
3.2.5.1 Effects of repeated daily LPS administration for 3 days 
In the 3-day experiment, there was a significant interaction between treatment 
and time on body weight (two way repeated measures ANOVA, F(9,156) = 84.54, p < 
0.001; Figure 3.9B). Body weight at the start of the experiment was similar in all 
groups: 24.5 ± 0.5 g (n = 14) for saline, 24.2 ± 0.3 g (n = 14) for acute LPS, 24.6 ± 0.3 
g (n = 14) for CD LPS and 24.9 ± 0.5 g (n = 14) for ID LPS. At +24 h after the final 
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injection, there was a significant effect of treatment of body weight (one way ANOVA, 
F(3,52) = 78.82, p < 0.001; Figure 3.9C). Body weight at +24 h was increased by +0.4% 
for the saline group, reduced by -8.6% for acute LPS, by -12.1% for CD LPS and by -
11.9% for ID LPS, with the reductions in body weight for all LPS treatments being 
statistically significant compared to saline-treated controls (p < 0.001 for all). In 
addition, the reduction in body weight observed in CD and ID LPS was significantly 
greater than that seen in acute LPS (p < 0.01 for both). 
A significant effect of treatment on distance travelled in the OFT was observed 
at +6 h after administration (one way ANOVA, F(3,52) = 107.9, p < 0.001; Figure 3.9D). A 
significant reduction in the distance travelled in the OFT was evident for all LPS-treated 
groups in the 3-day experiment (all p <0.001). Taken together, the reduction in body 
weight and the reduction in locomotion are consistent with sickness behaviour following 
LPS administration. Interestingly, the CD LPS mice showed an attenuated reduction in 
locomotion (61 ± 3 % of control; n = 14) that was significantly different from that seen in 
either the ID LPS (38 ± 2 % of control; n = 14) or acute LPS (37 ± 3 % of control; n = 
13) treated mice (p < 0.001 for both). This observation may reflect the development of 
tolerance to CD LPS in sickness behaviour as repeated stimulation with high dose LPS 
resulted in attenuated sickness behaviour. 
Depressive-like behaviour was assessed in the FST at +24 h after the final 
injection (Figure 3.9E). After the 3-day LPS treatment, there was a significant effect of 
LPS on FST immobility (one way ANOVA, F(3,52) = 3.919, p < 0.05). Only ID LPS 
treatment caused a significant increase in immobility (166 ± 10 % of control; n = 14) 




Figure 3.9. Effects of repeated 3-day LPS administration on body weight and 
behaviour in adult male C57BL/6J mice.  
Mice were treated with saline or LPS for 3 consecutive days. The four groups were 
constant dose (CD) LPS; increasing dose (ID) LPS; acute LPS; saline controls (A). 
Body weight throughout the 3-day injection schedule was tracked (B), and body weight 
at +24 h after the final injection is shown (C). Distance travelled in the OFT at +6 h 
after final injection (D). Time spent immobile in the FST at +24 h after final injection (E). 
Values shown are mean ± SEM of n=13-15 per group. Data was analysed by one-way 
ANOVA with Bonferroni’s posthoc test. **p < 0.01, ***p < 0.001 compared to saline 




In a separate group of mice, the effect of 3-day CD LPS (0.83 mg/kg) 
administration was tested in the SPT. Saline treated mice were compared to 3-day CD 
LPS-treated mice to assess the development of LPS tolerance in the SPT.  During the 
4 days training prior to LPS administration, mice had access to either two water bottles 
(days 1 & 3), or water and sucrose (days 2 & 4). There was a significant effect of day 
on preference (one way repeated measures ANOVA, F(2.1,46.7) = 106.4; p < 0.001; 
Figure 3.10B). Mice exhibited a significant preference for 2.5 % sucrose solution over 
water (~90%; p < 0.001) compared to the preference of right over left when only water 
was available (50%). This indicates that there was no positional preference of bottles. 
In addition, there was a significant effect of day on total volume consumed (one way 
repeated measures ANOVA, F(2.1,45.8) = 117.2; p < 0.001; Figure 3.10C). A significant 
increase in total volume consumed was observed on training days 2 and 4, which 
included sucrose solution (p < 0.001 for both.  
A two-way repeated measures ANOVA revealed a significant effect of treatment 
on sucrose preference (F(1,13) = 31.6; p < 0.001) and a significant interaction between 
treatment and time (F(2,26) = 4.195; p = 0.0264; Figure 3.10D). After LPS administration 
on Day 1 and Day 2, sucrose preference was significantly reduced (p < 0.001 for both). 
On Day 3, after the third LPS injection, mice did not show a significant reduction in 
sucrose preference. A two-way repeated measures ANOVA revealed a significant 
effect of treatment (F(1,13) = 37.77; p < 0.001) and time (F(2,26) = 59.28; p < 0.001) on 
total volume consumed, and a significant interaction between treatment and time (F(2,26) 
= 12.03; p < 0.001; Figure 3.10E). Total volume consumed was also significantly 
reduced after the first and second injections on Day 1 and 2 (p < 0.001 & p < 0.01, 
respectively). On Day 3, after the third LPS injection, mice did not show a significant 
reduction in consumption. These findings support the suggestion that repeated CD 
LPS resulted in the development of tolerance. 
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Figure 3.10. Effects of repeated 3-day constant dose LPS administration on the 
sucrose preference test in adult male C57BL/6J mice.  
Mice were given the choice of two bottles containing either water (w) or sucrose 
solution (s) during the SPT (A). SPT training took place before mice were treated with 
saline or 0.83 mg/kg constant dose (CD) LPS for 3 consecutive days. During the 4-day 
SPT training, mice were given either two water bottles (Days 1 & 3), or one water bottle 
and one 2.5 % sucrose solution (Days 2 & 4). Preference of sucrose solution over 
water or left water bottle over right water bottle was calculated (B), as well as total 
consumption (C). Sucrose preference (D) and total consumption (E) was measured for 
24 h windows beginning immediately after injection. Values shown are mean ± SEM of 
n=7-8 per group. Data was analysed by one-way repeated measures ANOVA with 
Dunnett’s posthoc test (B & C), or two-way repeated measures ANOVA with 
Bonferroni’s posthoc test (D & E). **p < 0.01, ***p < 0.001 compared to saline injected 
controls, or to Day 1 in SPT training. 
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3.2.5.2 Effects of repeated daily LPS administration for 5 days 
In the 5-day experiment, again there was a significant interaction between 
treatment and time on body weight (two way repeated measures ANOVA, F(15,330) = 
137.8, p < 0.001; Figure 3.11B). Body weight at the start of the experiment was similar 
in all groups: 25.1 ± 0.3 g (n = 20) for saline, 24.7 ± 0.3 g (n = 19) for acute LPS, 24.7 ± 
0.3 g (n = 20) for CD LPS and 25.1 +/- 0.4 g (n = 11) for ID LPS. At +24 h after the final 
injection, there was a significant effect of treatment of body weight (one way ANOVA, 
F(3,66) = 71.01, p < 0.001; Figure 3.11C). Body weight at +24 h was increased by 1.8% 
in the saline group and reduced by -7.1% for acute LPS, by -6.0% for CD LPS and by -
4.5% for ID LPS, with the reductions in body weight for all LPS treatments being 
statistically significant compared to saline-treated controls (p < 0.001 for all; Figure 
3.10C). The reduction in body weight observed in CD and ID LPS was significantly 
attenuated when compared to acute LPS (p < 0.001 & p < 0.01, respectively), 
indicating the development of LPS tolerance. 
A significant effect of treatment on distance travelled in the OFT was observed 
at +6 h after administration (one way ANOVA; F(3,66) = 31.47, p < 0.001; Figure 3.11D). 
A significant reduction in the distance travelled in the OFT was evident for all LPS-
treated groups in the 5-day experiment (all p <0.001). The reduction in body weight and 
the reduction in locomotion indicate the presence of sickness behaviour during the 5-
day LPS administration. However, the reduction in locomotion observed following acute 
LPS (47 ± 3 % of control; 19) was significantly greater than the reductions seen in both 
CD LPS (76 ± 3 % of control; n = 20; p < 0.001) and ID LPS (72 ± 8 % of control; n = 
11; p < 0.01). This finding suggests the development of tolerance to both constant and 
increasing doses of LPS in sickness behaviour. There was no significant effect of LPS 
on FST immobility at +24 h after the final injection in the 5-day experiment (Figure 




Figure 3.11. Effects of repeated 5-day LPS administration on body weight and 
behaviour in adult male C57BL/6J mice.  
Mice were treated with saline or LPS for 5 consecutive days. The four groups were 
constant dose (CD) LPS; increasing dose (ID) LPS; acute LPS; saline controls (A). 
Body weight throughout the 5-day injection schedule was tracked (B), and body weight 
at +24 h after the final injection is shown (C). Distance travelled in the OFT at +6 h 
after final injection (D). Time spent immobile in the FST at +24 h after final injection (E). 
Values shown are mean ± SEM of n=11-20 per group. Data was analysed by one-way 
ANOVA with Bonferroni’s posthoc test. ***p < 0.001 compared to saline injected 
controls; ##p < 0.01, ###p < 0.001. 
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3.3 Summary of findings 
• Acute LPS (0.42 – 0.83 mg/kg; i.p.) induced a robust sickness behaviour that 
was not influenced by light phase or group / individual housing, but failed to 
produce a depressive-like behaviour. 
• Depressive-like behaviours were observed in the SPT and, for the first time, in 
the FUST following acute LPS (0.42 – 0.83 mg/kg; i.p.). 
• Reduced locomotion was observed at +24 h after acute LPS administration 
(0.42 – 0.83 mg/kg; i.p.), indicating the presence of sickness and a potentially 
confounding factor. 
• Ketamine (10 mg/kg; s.c.) failed to inhibit the depressive-like effects of acute 
LPS (0.83 mg/kg; i.p.) in the FUST. 
• ICV LPS (100 ng) also induced sickness behaviour and failed to produce a 
depressive-like behaviour in the FST. 
• A 3-day increasing dose LPS protocol (0.21 – 0.83 mg/kg; i.p.) induced a 
depressive-like behaviour in the FST, whilst avoiding the development of LPS 
tolerance seen in OFT locomotion. 
• Extending this protocol to 5-day increasing dose LPS (0.05 – 0.83 mg/kg; i.p.) 
enabled the development of LPS tolerance and failed to induce a depressive-




Acute LPS is regularly used to study inflammation-induced depressive-like 
behaviours in mice (O'Connor et al., 2009a). In this chapter, various acute LPS-
induced behavioural changes were assessed in adult male C57BL/6J mice, as well as 
the influence of lighting and social isolation on such behaviours. Systemic acute LPS 
(0.42 & 0.83 mg/kg; i.p.) failed to induce a depressive-like behaviour in the FST, 
regardless of environmental adjustments. Systemic acute LPS did induce anhedonic 
depressive-like behaviours in the FUST and SPT. However, reduced locomotion was 
observed in the OFT at +24 h after systemic LPS administration, indicating the 
presence of sickness. Central acute LPS also induced sickness and failed to induce a 
depressive-like behaviour in the FST. In an attempt to model sustained inflammation 
and induce depressive-like behaviour, a novel protocol for repeated LPS administration 
was developed and assessed. A 3-day increasing dose LPS protocol induced the 
development of depressive-like behaviour in the FST, whilst circumventing the 
development of tolerance in the OFT. 
 
3.4.1 Pharmacological validation of behavioural tests 
The FST was pharmacologically validated with ketamine (10 mg/kg) and bupropion 
(20 mg/kg), both of which have been previously shown to exhibit antidepressant-like 
activity in the FST (Browne and Lucki, 2013; David et al., 2003). Ketamine did not 
influence distance travelled in the OFT, whilst bupropion increased distance travelled. 
Consistent with this finding, it has been reported that 16 mg/kg bupropion increased 
locomotion in C57BL/6J mice, though doses as low as 2 mg/kg were shown to reduce 
FST immobility (David et al., 2003). An increase in locomotion is therefore a 
confounding factor for its antidepressant activity in the FST. Ketamine has been shown 
to attenuate depressive-like behaviours induced by acute LPS when co-administered 
(Walker et al., 2013). Consistent with some studies in C57BL/6J mice, both fluoxetine 
(20 mg/kg) and desipramine (10 – 20 mg/kg) failed to exert antidepressant-like activity 
in the FST (Lucki et al., 2001; David et al., 2003). The utility of the FST is based upon 
its predictive validity for classical antidepressants, though its predictive validity is strain-
dependent and can be variable across studies (Lucki et al., 2001). The TST has 
previously demonstrated predictive validity with a range of antidepressant drugs in 
C57BL/6J mice, including desipramine and citalopram, and may therefore provide an 
alternative to the FST for assessing depressive-like behaviour in mice (Ripoll et al., 
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2003). The SPT was not pharmacologically validated here, but has been previously 
with chronic treatment of SSRIs and TCAs (Willner et al., 1987; Muscat et al., 1992). 
Whilst the FUST has been previously pharmacologically validated with chronic 
citalopram (Malkesman et al., 2010), it was shown here that acute ketamine (10 mg/kg) 
induced a pro-depressive effect in the FUST when administered 30 min prior to testing. 
This novel finding was unexpected and suggests the test may be more sensitive to 
chronic treatment. 
 
3.4.2 Acute LPS model of depressive-like behaviour 
3.4.2.1 Acute LPS induced sickness 
 Acute LPS is known to induce a transient profile of sickness behaviours, 
including reduced exploratory behaviour and reduced food and water consumption 
(Dantzer, 2001). Consistent with the robust induction of sickness behaviour detailed in 
the literature (Table 3.1), all LPS treatments here induced a reduction in locomotion at 
+6 h and a reduction body weight +24 h after administration. However, sickness 
behaviour, as assessed by OFT hypolocomotion, was still present at +24 h and is 
therefore a confounding factor to depressive-like behaviours assessed at that time-
point. Within the literature, acute LPS (0.2 to 0.83 mg/kg) is regularly used to assess 
depressive-like behaviours at +24 h, with many reporting no significant effect in 
locomotion (Frenois et al., 2007; O'Connor et al., 2009a; Viana et al., 2010; Walker et 
al., 2013; Custódio et al., 2013; Ohgi et al., 2013; Mello et al., 2013; Sulakhiya et al., 
2014; Wang et al., 2014; André et al., 2014; Ji et al., 2014; Medeiros et al., 2015; Yao 
et al., 2015; Couch et al., 2015; Sriram et al., 2015; Zhang et al., 2015). Conversely, a 
number of studies have reported the presence of significant hypolocomotion in the OFT 
at +24 h after LPS, including lower doses of 0.5 and 0.63 mg/kg, consistent with the 
findings presented here (Biesmans et al., 2013; Corona et al., 2010; Godbout et al., 
2008; Lawson et al., 2013a; Salazar et al., 2012). Evidently, there is a great amount of 
variation in the literature regarding the time course of LPS-induced hypolocomotion. 
One factor may be the technology used to assess locomotion. The data presented here 
were assessed using infrared tracking, similar to earlier studies that also reported 
reduced locomotion (Salazar et al., 2012; Biesmans et al., 2013). However, of the 
acute LPS studies detailed in Table 3.1, almost all studies that assessed OFT 
locomotion used manual scoring of line crossings, which may be insensitive to the 
small reductions in locomotion. Only one study used distance-tracking software and 
reported no significant effect of acute LPS (0.8 mg/kg) on locomotion at +24 h 
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(Medeiros et al., 2015). Three studies also utilised a system of infrared beams that also 
reported no significant effect of acute LPS (0.5 mg/kg) at +24 h (Ohgi et al., 2013; Yao 
et al., 2015; Dong et al., 2016). Other measures of sickness, such as food consumption 
and social interactions, have also been reported to be significantly decreased at +24 h 
and beyond (Godbout et al., 2008; Painsipp et al., 2011; Jangra et al., 2014; Shaikh et 
al., 2016; Yang et al., 2016). It was also shown here that performance on the rotarod 
was impaired at +6 h after LPS, but not at +24 h. This finding is consistent with other 
studies that have reported no significant effect of LPS on rotarod performance at +24 h 
(Krzyszton et al., 2008; Custódio et al., 2013). Therefore, hypolocomotion in the OFT 
does not translate to reduced performance on the rotarod, suggesting that there is no 
locomotor deficit at 24 h, but rather a reduction in exploratory behaviour, a hallmark of 
sickness. Overall, these data demonstrate the variability of the reported LPS-induced 
sickness time-course. 
Throughout the literature, the environmental conditions used for acute LPS 
studies, such as the light cycle and group or individual housing, vary and are often not 
reported (Table 3.1). Of the 54 studies detailed, 17 studies used group housing, 12 
used individual housing, whilst 25 did not report housing. 28 of the studies had a 
normal light cycle and tested in the light phase and 10 studies did the opposite. 16 
studies did not report lighting conditions. Mice are nocturnal and exhibit increased 
locomotion throughout the dark phase (Kopp et al., 1998). Based on this, it might be 
expected that LPS-treated mice assessed during the dark phase will travel further than 
LPS-treated mice assessed during the light phase. Here, the light phase used for 
testing had no effect on LPS-induced sickness, indicating that whilst the natural 
locomotion of mice may be influenced by the light phase, the sickness induced by high-
dose LPS is not sensitive to such environmental changes. Low dose LPS (0.01 mg/kg) 
has been shown to induce the expression of IL-1β, IL-6 and TNF-α in the hippocampus 
of rats at +3 h when administered during the light phase but not the dark phase of the 
light cycle (Fonken et al., 2016). Similarly, LPS-induced neuroinflammation following 
inescapable foot shock stress is also sensitive to the light cycle, with enhanced 
neuroinflammation when stress was administered during the light phase. Such findings 
indicate the light phase could increase LPS-induced neuroinflammation, though this 
theory did not translate into enhanced LPS-induced hypolocomotion during the light 
phase. The effects of the light cycle on LPS-induced hypolocomotion in a non-novel 
open field apparatus has been assessed in rats using a lower dose of 0.2 mg/kg LPS 
(Franklin et al., 2003). Rats were administered LPS at either the onset or 2 h into the 
light phase or the dark phase of the light cycle, and locomotion was assessed at +2 h. 
Similar to the findings detailed here, reductions in body weight were significant in all 
groups and LPS-induced reductions in locomotion were not significantly altered by the 
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light phase in which locomotion was tested. However, these experiments used rats and 
tested locomotion at a +2 h time-point, and therefore are not directly comparable to the 
findings presented here. Whilst baseline behaviour is influenced by the light cycle, the 
robust sickness induced by LPS appears to be not overtly affected. There was also no 
effect of group / individual housing on OFT locomotion. Some studies have shown that 
social isolation, used as a stressor, can enhance locomotion and depressive-like 
behaviour (Ieraci et al., 2016), whilst others have shown no effect of social isolation on 
locomotion in mice (Arndt et al., 2009). 
 
3.4.2.2 Acute LPS-induced depressive-like behaviour 
Acute administration of LPS failed to induce a depressive-like behaviour in the 
FST, regardless of light phase or group / individual housing. This finding is incongruent 
with the majority of, but not all, published acute LPS studies. As in this thesis, acute 
LPS does not consistently induce depressive-like behaviours (Painsipp et al., 2011; 
Corona et al., 2013; Biesmans et al., 2013; André et al., 2014; Couch et al., 2016). In 
previous experiments conducted at Janssen, using the same experimental equipment 
as in this thesis, LPS doses as high as 1.25 mg/kg failed to induce depressive-like 
behaviour in NMRI mice in both the FST and TST at +6 h and +24 h after 
administration (Biesmans et al., 2013).  Systemic 0.83 mg/kg LPS has also failed to 
induce a significant increase in FST immobility in acute LPS studies with C57BL/6J 
mice (Lawson et al., 2013a; André et al., 2014). In addition, some studies have 
reported group / individual housing to influence the development of FST depressive-
like behaviours following acute LPS treatment. LPS (0.83 mg/kg) increased FST 
immobility in group housed CD1 mice, but not in individually housed CD1 mice 
(Painsipp et al., 2011). LPS also failed to increase FST immobility in individually 
housed C57BL/6J mice, and actually reduced FST immobility in group housed 
C57BL/6J mice (Painsipp et al., 2011). Social isolation can be used as a stressor in 
mice, inducing an increased baseline TST immobility in C57BL/6J mice (Ieraci et al., 
2016). As chronic stress can induce neuroinflammation (Alcocer-Gómez et al., 2015), 
social isolation may also be expected to influence LPS-induced behaviours. These 
findings contrast the data presented here that suggest housing conditions can 
influence the development of acute LPS-induced depressive-like behaviour. Direct 
comparisons between acute LPS studies within the literature can be difficult due to the 
number of variables within the protocol. Alongside lighting, housing and dose (all 
detailed in Table 3.1), other variables include FST cylinder diameter, handling 
protocols and environmental enrichment. Nevertheless, no FST depressive-like 
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behaviours were observed in any of the housing or lighting conditions tested in this 
thesis following acute LPS. 
Whilst acute LPS failed to induce increased immobility in the FST, reduced 
pleasure-seeking behaviours were observed in the SPT, which assesses the 
preference for a palatable substance (Papp et al., 1991). C57BL/6J mice exhibited a 
preference for 2.5 % sucrose solution, consistent with previous findings (Lewis et al., 
2005). Acute LPS reduced sucrose preference and consumption during the 0-24 h test 
period, consistent with previous acute LPS studies using the same test window (Zhang 
et al., 2016; Jaehne et al., 2015; Salazar et al., 2012). The reduced overall 
consumption in this first test window can be attributed to sickness, consistent with 
previous acute LPS studies (Painsipp et al., 2011; Jangra et al., 2014). However, 
during this test period, a preference for sucrose is still present following LPS 
administration at around 70 %, indicating an attenuated hedonic behaviour, as 
opposed to complete anhedonia. If robust sickness were present for the entire 24 h 
window, no sucrose preference would be expected. Therefore, it could be argued that 
during the first test period, mice exhibit an attenuated sucrose preference and a 
depressive-like behaviour that is not entirely due to sickness. A reduced sucrose 
preference was not observed during the 24-48 h test period. However, such large test 
periods make the separation of sickness and depressive-like behaviour difficult. If a 
depressive-like behaviour is present around the +24 h mark, it may not be observable 
as the anhedonia is confounded by sickness in the 0-24 h period, and the anhedonia 
strength may be weakened during the 24-48 h period. Shorter test windows of 12 h, 4 h 
or 1 h may be better to identify a depressive-like behaviour at more specific time points 
and have been used previously following acute LPS administration (Henry et al., 2008; 
Walker et al., 2013; Li et al., 2015). Furthermore, the concentration of sucrose used is 
important in the anhedonic response, as a high sucrose concentration (10 %) can 
overcome LPS-induced anhedonic behaviours in NMRI mice that are seen with lower 
sucrose concentrations (Biesmans et al., 2013). 
Acute LPS also induced a depressive-like behaviour in the FUST. The FUST is 
a behavioural paradigm that enables the assessment of an alternative innate hedonic 
behaviour based on sexual motivation (Malkesman et al., 2010). Whilst the creators of 
the FUST used novel odours to demonstrate the preference for female urine was not 
novelty-based, it was not established whether the preference was sex-based or just 
social interaction-based. By directly comparing male and female urine in the FUST, it 
was shown here that the preference for female urine is sex-driven. The test has not 
previously been used in the acute LPS model of depression, but has been validated in 
the learned helplessness model of depression and pharmacologically validated with 
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chronic citalopram in C57BL/6J mice (Malkesman et al., 2010). In addition, the FUST 
has been used to evaluate the role of the neurokinin-1 receptor in depressive-like 
behaviour, whereby knockout C57BL/6 mice exhibit diminished sexual motivation 
(Berger et al., 2012). Following LPS, the preference for female urine sniffing is 
abolished at +6 h, and is only partially restored at +24 h. As the time spent sniffing 
water is unaffected, this indicates there is a depressive-like behaviour with no overt 
effect of sickness. The effect of acute LPS (0.5 mg/kg) has recently been assessed in a 
novel, but similar, behavioural test that assesses social interaction of a male mouse 
with a female or male intruder mouse as a direct comparison, called the female 
encounter test (Ago et al., 2015). Acute LPS reduced the social interaction preference 
for females over males at +24 h in CD1 mice, indicating a reduction in sexual 
motivation and supporting the findings presented in this thesis. In contrast to our 
findings and the findings in the female encounter test, acute low-dose LPS (0.05 – 0.25 
mg/kg) in males rats did not impair sexual behaviours (sexual mounts) in at +2 h to +6 
h (Avitsur et al., 1997). A higher dose may be required to reduce sexual behaviour. In 
addition, the FUST and female encounter test only measure interaction with a stimulus 
(urine or a mouse in a separated cage) and not direct sexual behaviours such as 
mounting. The data presented here demonstrates an LPS-induced reduction in sexual 
motivation and depressive-like behaviour in the FUST at +24 h, without overt sickness 
behaviour present. No later time points were assessed. As opposed to the SPT 
protocol used here, the FUST enabled assessment of anhedonic behaviour at a 
specific time-point and avoided the potentially confounding factor of a 24 h test period 
in the SPT. 
 
3.4.3 Ketamine failed to abrogate the depressive effects of acute 
LPS 
Ketamine can exert rapid antidepressant activity in humans (Berman et al., 
2000) and has been shown to successfully treat patients with TRD (aan het Rot et al., 
2010). Ketamine has also been shown to have antidepressant-like activity in rodents 
(Browne and Lucki, 2013), similar to findings presented earlier in the FST (Section 
3.2.1). LPS was administered 24 h before testing, whilst ketamine was administered 
either 30 min before testing (as this time-point demonstrated antidepressant-like 
activity in the FST) or 24 h before testing, to test whether it could protect against LPS-
induced effects. In both experiments, ketamine failed to abrogate the depressive-like 
effect of LPS. This contrasts a previous study that reported ketamine reversed the 
depressive-like behaviours induced by acute LPS (0.83 mg/kg) in the FST and SPT 
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(Walker et al., 2013). The mechanisms by which ketamine was hypothesised to 
abrogate the effects of acute LPS was the inhibition of excitotoxicity by inhibiting the 
glutamatergic NMDA receptor and enhancing AMPA signalling (Walker et al., 2013). 
Furthermore, when administered 30 min before testing, ketamine caused a significant 
reduction in female urine sniffing, demonstrating a pro-depressive effect. These 
findings show that whilst ketamine could influence FUST behaviour, it could not 
abrogate the LPS-induced reduction. The effects of ketamine on sexual behaviour has 
not previously been studied, though ketamine has been shown to induce impairments 
in an odour-based memory task (Rushforth et al., 2011). SSRI antidepressants would 
usually be more typical drugs to test, but many SSRIs, such as fluoxetine, have been 
shown to be ineffective in the FST in C57BL/6J mice (Section 3.2.1; Lucki et al., 2001). 
Earlier work has shown predictive validity in 129S1/SVlmJ mice in the FUST with 
chronic citalopram, suggesting the model may be more sensitive to chronic treatment 
(Malkesman et al., 2010). The FUST appears to have poor predictive validity in 
comparison to the FST, but a greater face validity as sexual dysfunction is associated 
with depression (Baldwin, 2001). 
 
3.4.4 Centrally administered LPS 
The advantage of centrally administered LPS compared to systemically 
administered LPS is that direct administration within the CNS enables one to study the 
influence of neuroinflammation on behaviour, circumventing the transmission of a 
systemic inflammatory insult from the periphery into the brain. Furthermore, LPS does 
not cross the BBB well (Banks and Robinson, 2010), and so by administering LPS 
centrally, TLR4 activation within the CNS can be investigated, as opposed to a broader 
inflammatory response. Central LPS-induced behavioural changes were caspase-1-
dependent in mice. However, caspase-1-/- did not protect against systemic LPS 
(Lawson et al., 2013a). These findings demonstrate differences between central and 
peripheral LPS administration on behaviour and the potential compensatory 
mechanisms that may occur during systemic LPS administration. 
Here, central administration of LPS, either via direct injection during surgery or 
via cannula injection, sickness was observed at +6 h but no depressive-like behaviour 
in the FST at +24 h. An earlier study has shown that surgical injection of a far greater 
dose of 5 µg LPS induced a significant increase in FST immobility 3 days after 
administration, without any confounding hypolocomotion (Dobos et al., 2012). Inhibiting 
IDO activity reversed the LPS-induced depressive-like behaviour. The same LPS dose 
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has been used prior to SPT assessment and revealed a significant effect of LPS on 
sucrose preference, though no significant effect between groups (van Buel et al., 
2015). Both of these studies used higher doses of LPS and assessed depressive-like 
behaviours several days after administration, allowing mice to overcome the effects of 
surgery. Here, behavioural tests were carried out as early as +6 h after surgery. Whilst 
saline-treated mice exhibited normal behaviour, the behavioural effects of LPS may be 
influenced by the invasive surgical procedure for i.c.v. injection. The implantation of a 
cannula overcame this problem, but still failed to induce a depressive-like behaviour in 
the FST. In contrast to these findings, previous studies using cannulas to inject LPS 
into the lateral ventricle have used the same dose (100 ng), but reported significant 
depressive-like behaviours in the FST and SPT in the absence of overt sickness 
behaviour (Lawson et al., 2013a; Fu et al., 2010). The clear induction of sickness in 
body weight loss and hypolocomotion demonstrates centrally administered LPS 
exerted its inflammatory actions within the brain and influenced behaviour, but the FST 
failed to detect any changes in behaviour. These findings indicate further variability 
between studies of acute LPS-induced depressive-like behaviour. Automated software 
was used to detect FST immobility in central LPS administered mice, as earlier 
validated with bupropion and ketamine. Manual scoring may provide a more sensitive 
analysis that could detect subtle behavioural changes. However, manual scoring was 
utilised for the systemic acute LPS experiments earlier but still failed to detect a 
depressive-like behaviour in the FST. 
  
3.4.5 Acute LPS as a model of depressive-like behaviour 
The popularity of systemic LPS administration is due to its well-characterised 
ability to induce a broad inflammatory response in vivo that can transmit a signal 
across the BBB, incorporating the upregulation of various pro-inflammatory proteins 
within the brain and microglia activation (O'Connor et al., 2009a). Behavioural 
measures can be used to investigate the transient rise and fall of sickness as an 
indirect measure of inflammation. As demonstrated in this thesis, the reported 
behavioural time-course of LPS-induced sickness behaviour is inconsistent across the 
literature and can be confounding in the assessment of depressive-like behaviours 
(Table 3.1). The separation of sickness and depressive-like behaviour can be difficult 
due to the overlap of behaviours. However, behavioural time-courses must be 
established prior to further behavioural assessment to avoid the confounding influence 
of sickness. Similarly to LPS-induced sickness, LPS-induced depressive-like 
behaviours exhibit considerable variability between studies (Table 3.1), and between 
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behavioural paradigms, as demonstrated in this thesis. Furthermore, many studies fail 
to report the environmental conditions in which mice are housed and tested in, which 
can influence the subtle changes in behaviour being assessed in models of 
depressive-like behaviour (Bogdanova et al., 2013). The FST has poor face validity, 
and FST scoring is a variable factor due to its subjectivity. This subjectivity can be 
eliminated with the use of mouse tracking software, though such software may not be 
sensitive enough to discriminate accurately between different behaviours in the FST. 
Accordingly, the acute LPS experiments here also assessed using automated 
software, though no significant depressive-like behaviours were observed. More 
objective measures, such as the FUST and SPT may provide a more robust 
behavioural profile. 
The findings presented here, along with the variability within the literature 
(Table 3.1), demonstrate that acute LPS is not a very robust or consistent model of 
depression. Furthermore, the inflammation exhibited by many depressed patients is a 
chronic condition that can predict the onset of depression or depressive symptoms 
years in advance (Zalli et al., 2016). For this reason, whilst acute inflammatory insults 
can provide insight into the mechanisms of peripheral inflammation, neuroinflammation 
and the influence on behaviour, it does not model sustained inflammation or accurately 
represent the human condition.  
 
3.4.6 Repeated LPS model of depressive-like behaviour 
In an attempt to model sustained inflammation and induce depressive-like 
behaviour, a novel protocol for repeated LPS administration was developed. It was 
found that a 3-day increasing dose LPS protocol induced the development of 
depressive-like behaviour, whilst circumventing the development of tolerance. 5-day 
LPS protocols failed in producing a depressive-like behaviour. This model enables the 
study of a period of sustained inflammation on depressive-like behaviours and 
therefore could have greater translatability than the acute LPS model. There is high 
variability between acute LPS studies (Table 3.1) and the few studies that utilise 
repeated LPS to model depressive-like behaviour exhibit even greater variation.  
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3.4.6.1 Sickness following repeated LPS 
The primary restriction in using repeated LPS to induce an inflammatory 
response in mice is the development of tolerance towards LPS. Tolerance is a 
transient period of desensitisation whereby a pyrogen induces a diminished 
inflammatory response, whilst a normal response can be reinstated following a period 
of non-exposure (Beeson, 1947). Repeated exposure to LPS results in an attenuated 
sickness response as well as a reduced induction of pro-inflammatory cytokines 
(Zeisberger and Roth, 1998). In this thesis, repeated administration of constant dose 
(CD) LPS (0.83 mg/kg) for 3 or 5 consecutive days induced the development of 
‘behavioural tolerance’, evident as attenuated locomotor reductions in response to 
repeated LPS. Congruent with this, LPS-induced anhedonic behaviour in the SPT was 
no longer present following the third injection in the CD paradigm. The development of 
tolerance and attenuated or absent hypolocomotion has been reported before following 
numerous repeated LPS protocols in rats (Franklin et al., 2003; Franklin et al., 2007) 
and in mice (Engeland et al., 2001; Kohman et al., 2010). In CF-1 mice, repeated 
administration of 0.05 – 0.2 mg/kg LPS (3 injections over one week) resulted in an 
attenuated locomotor reduction after the second administration and no reduction after 
the third (Engeland et al., 2001). In BALB/c mice, 4 daily consecutive injections of 3 µg 
LPS (~0.1 mg/kg) completely abolished the hypolocomotion in the OFT at +3 h induced 
by a single administration of LPS (Kohman et al., 2010). These data confirm the ability 
of repeated LPS to rapidly and consistently induce the development of tolerance. In the 
data presented here, whilst the reduced locomotion was attenuated after 3- and 5-day 
LPS administration, a significant reduction was still present. This could be due to the 
high dose of LPS used in this CD paradigm in comparison to other repeated LPS 
studies. 
Though neuroinflammation was not assessed here, repeated administration of 
LPS can also alter the inflammatory profile within the brain. Repeated injections (3 over 
24 h) of high dose LPS (3 mg/kg) has been shown to enhance IL-6 and TNF-α 
expression and reduce IL-1β expression in comparison to a single dose in mice 
(Erickson and Banks, 2011). Two consecutive injections of 0.83 mg/kg LPS in mice 
causes a significantly greater increase in brain kynurenine and quinolinic acid when 
compared to a single dose of LPS, as well as an increased kynurenine/tryptophan ratio 
(Larsson et al., 2016). Similar findings were observed in rats following LPS 
administration (0.5 mg/kg) every other day for 2 weeks, increasing kynurenine and 
reducing the kynurenine/tryptophan ratio (Guo et al., 2016). These findings indicate 
that repeated LPS administration may enhance kynurenine pathway induction, inducing 
excitotoxicity and depleting tryptophan levels. 
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By using a novel paradigm of progressive increasing dose (ID) of LPS in the 3-
day experiment, the tolerance to repeated administration of LPS was overcome 
somewhat. Mice undergoing ID LPS exhibited a similar level of reduced locomotion 
compared to acute LPS treated mice. In addition, the weight loss is greater than acute 
LPS treated mice. These findings indicate repeated injections in the 3-day ID LPS mice 
caused further weight loss and sickness behaviour in the OFT similar to acute LPS, as 
LPS tolerance had not developed. However, in the 5-day experiment, the reduced 
locomotion following ID LPS was attenuated compared to acute LPS, similar to CD 
LPS. In addition, the body weight of mice following 5-day ID LPS was greater than 
acute LPS treated mice, indicating mice had begun eating normally and gaining weight, 
even during LPS treatments. This indicates the development of behavioural tolerance. 
These findings suggest that whilst increasing the LPS dose over three days delays the 
development of LPS tolerance, over 5 days the development of tolerance cannot be 
avoided by increasing the dose protocol. 
 
3.4.6.2 Depressive-like behaviour following repeated LPS 
3-day ID LPS was the only treatment group to exhibit a depressive-like 
behaviour in the FST. Depressive-like behaviour in the FST, TST and/or the SPT has 
been reported in mice following varying repeated LPS protocols. In Swiss mice, 8 
injections (every other day) of 0.1 mg/kg LPS resulted in a depressive-like behaviour in 
the TST, with no effect of OFT line crossing (Xie et al., 2012). In rats, 7 injections 
(every other day) of 0.5 mg/kg LPS resulted in depressive-like behaviours in the FST 
and SPT (Guo et al., 2016). In ICR mice, 10 consecutive injections of 0.83 mg/kg LPS 
induced a depressive-like behaviour in the FST (Guo et al., 2014). In these studies, the 
development of LPS tolerance is neither discussed nor assessed. LPS tolerance is 
consistently reported following repeated LPS, and therefore it would be assumed that 
LPS tolerance was developed in these models (Franklin et al., 2003; Engeland et al., 
2001). If so, the level of LPS-induced inflammation would not be constant, but diminish 
over time. However, depressive-like behaviours are still reported, though the time-point 
at which behaviours were assessed after LPS injection was not clear. A study that 
used a protocol of 4 daily consecutive LPS injections (1 mg/kg) in rats showed an 
induction of depressive-like behaviour in a 15 minute FST, though body weight began 
to rise after the initial weight loss following the first LPS administration, indicating the 
development of tolerance (Bay-Richter et al., 2011). However, locomotion assessed +2 
h after the first, second and third injections did not appear to show a diminished effect. 
A recent chronic intermittent LPS study that administered 0.25 mg/kg LPS to C57Bl/6 
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mice twice a week for up to 12 weeks (Krishna et al., 2016). After 6 and 12 weeks, 
increased FST immobility was reported. Decreased locomotion was observed at 6 
weeks and increased locomotion was observed at 12 weeks. The treatment also 
caused persistent microglia activation. This chronic intermittent model demonstrates a 
sustained effect of repeated LPS and the induction of depressive-like behaviour, with 
greater face validity than acute LPS studies (Krishna et al., 2016).  
Together, these studies show that repeated administration of the same dose of 
LPS can induce depressive-like behaviours, in contrast to the findings presented here 
with 3-day and 5-day CD LPS. However, the variation in dosing and timing make direct 
comparisons difficult. The only study to use changing doses of LPS is a 4-month study 
that showed a 5-day rising and falling of LPS doses, once a month, induced SPT 
anhedonia in female mice in the final weeks (Kubera et al., 2013). This study 
incorporates extended periods of rest between each 5-day LPS treatment, which may 
avoid the development of LPS tolerance, as well as using a rising and falling LPS dose. 
However, sustained anhedonic behaviour was observed only in the final month, and 
only in female mice, even after the protocol was adapted in male mice to 5 injections 
over 10 days instead of 5 days. Whilst this model has more face validity, in that it 
assesses chronic inflammation, the article does not report if the behaviour was 
sustained beyond the final 2 weeks of the 4-month protocol, and fails to report any FST 
or TST data, though one would expect such experiments to have been carried out in 
such a longitudinal study. 
Injections can act as a stressor (Ryabinin et al., 1999), and repeated injections 
may influence depressive-like behaviour in the FST. When comparing the 3-day and 5-
day LPS experiments, the FST immobility is similar, though the immobility of saline 
controls is ~80 seconds and ~135 seconds in the 3-day and 5-day experiments, 
respectively. In addition, the saline-treated controls in the acute LPS experiments show 
FST immobility at ~80 seconds. Physical restraint for injection has been shown to act 
as a stressor in rodents, increasing corticosterone and CRF levels (Harbuz et al., 1994) 
(Balcombe et al., 2004). Repeated restraint stress can be used to model depressive-
like behaviours in mice, though these stressors are typically around 2 h restraints in a 
restraint device (Alcocer-Gómez et al., 2015). The repeated stress of injection in the 5-
day experiment may increase FST immobility and therefore mask the depressive 
effects of LPS treatment.  
 
Here, a novel 3-day protocol of increasing LPS dose partially addresses some of 
the drawbacks of the acute LPS model of depressive-like behaviour. Whilst 3 days of 
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inflammation is not chronic, it is sustained and enables the biochemical and 
behavioural assessment of sustained inflammation. Furthermore, the increasing dose 
circumvents the development of behavioural tolerance observed in earlier studies in 
response to LPS (Engeland et al., 2001; Franklin et al., 2003). This protocol may 
provide an alternative method for studying the sustained inflammation present in 
depression. In order to develop the model, further time points would need to be 
assessed to show the time course of behavioural changes, and the ability of chronic 
antidepressant treatment should be tested to provide predictive validity. In addition, 
other behaviours could be assessed, such at the TST, SPT, FUST, as well as pro-
inflammatory markers within the brain. 
An ideal model would be one that involves chronic low-grade inflammation. Such 
models could be developed based upon a study that used very low LPS doses (1 
µg/kg) over 10 consecutive days (Tarr et al., 2012). A progressively increasing 
sickness behaviour in the OFT was observed, though no depressive-like behaviour 
was assessed. The same dose administered 4 times over a month can also 
progressively induce anxiety-like behaviour in the light-dark box, indicating 
sensitisation to LPS (Banasikowski et al., 2015). Whilst these studies are not assessing 
depressive-like behaviour, the development of a similar chronic model may provide 
greater insight into inflammation-associated depression. Another approach is the use 
of poly(I:C), a synthetic double-stranded RNA agonist for TLR3. Poly(I:C) has been 
show to induce an acute immune response that is not diminished upon secondary 
stimulation (Cunningham et al., 2007). Furthermore, acute poly(I:C) has been shown to 
induce sickness and depressive-like behaviours in a similar fashion to acute LPS 
(Gibney et al., 2013). Therefore, poly(I:C) could be a viable tool for inducing sustained 
inflammation to study inflammation-induced depressive-like behaviour in mice. Though 
the separation of sickness and depressive-like behaviour is still necessary in the use of 




Chapter 4: NLRP3 inflammasome 




4.1.1 Microglia  
Within the CNS, the innate immune system is mediated by microglia, which 
respond to a wide range of stimuli. BV2 cells are an immortalised murine microglia cell 
line that have been previously utilised to assess NLRP3 inflammasome activity and IL-
1β production (Shi et al., 2012). Whilst BV2 microglia are a useful tool for studying 
microglia, primary murine microglia provide greater validity (Henn et al., 2009). There 
are a number of methods for the isolation of primary microglia. The most common 
method of isolation from mixed glia cultures incorporates an extended period of 
shaking to detach and harvest microglia. However, the physical stress exerted on 
mixed glia cultures induces amoeboid microglia morphology and has been shown to 
induce the release ATP in astrocytes (Praetorius and Leipziger, 2009; Coco et al., 
2003; Kettenmann et al., 2011). The retraction of microglia processes can occur via 
adenosine 2A receptor stimulation following extracellular ATP degradation, promoting 
the amoeboid morphology (Orr et al., 2009). Alternatively, primary microglia can be 
isolated with the use of mild trypsin, which causes the astrocytic layer to detach, 
leaving microglia attached in the well (Saura et al., 2003). This process avoids the 
mechanical stress and any potential release of ATP and microglia activation 
(Praetorius and Leipziger, 2009). 
 
4.1.2 NLRP3 inflammasome in microglia and disease 
NLRP3 signalling in microglia has been widely studied due to the growing 
understanding of neuroinflammation and its role in numerous neurological diseases. 
Microglia express the components for NLRP3 inflammasome signalling and respond to 
many stimuli, similar to macrophages (Shi et al., 2012). Some reports demonstrate 
astrocytes do not to express a functional NLRP3 inflammasome, indicating microglia 
are responsible for IL-1β production within the CNS (Gustin et al., 2015). However, this 
is controversial as Aβ has been shown by others to induce IL-1β release in astrocytes 
(Couturier et al., 2016). In addition, some studies have indicated NLRP3 
inflammasome activity in neurons (de Rivero Vaccari et al., 2008; Compan et al., 
2012). Inflammasome activity and microglia activation is a feature seen in various 
neurological diseases and infections (Walsh et al., 2014a). Bacterial infections, such as 
S. aureus, induce NLRP3 inflammasome activation and IL-1β release in microglia with 
partial dependency on local ATP stimulation of P2X7 receptors (Hanamsagar et al., 
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2011). NLRP3 expression and activity is induced following a cerebral ischemia 
reperfusion model of stroke, and NLRP3-/- protects against neurovascular damage 
(Yang et al., 2014). Furthermore, the NLRP3-induced neuronal damage was mediated 
by microglia activation. Neurodegenerative prion proteins activate microglia and induce 
inflammasome signalling, whilst the blockade of K+ efflux and ROS signalling can 
attenuate NLRP3 inflammasome activation (Shi et al., 2012). It has also been shown 
that NLRP3 activation is important in Alzheimer’s disease. Aβ can lead to microglia 
recruitment and NLRP3 inflammasome signalling (Khoury et al., 2007; Halle et al., 
2008). In addition, mouse models of Alzheimer’s disease show increased microglia 
activation and NLRP3-/- microglia exhibited a more anti-inflammatory phenotype, with 
increased IL-4 and reduced NOS2 expression (Heneka et al., 2014). Subsequently, 
NLRP3-knockout led to an increase in Aβ clearance and improved performance in 
cognitive tasks, demonstrating the potential negative effects of excessive NLRP3 
inflammasome signalling in microglia.  
Depression, which is associated with inflammation, has also been hypothesised 
to involve inflammasome signalling (Iwata et al., 2013). Microglia activation is a feature 
of the acute LPS model of depression in mice, as demonstrated by the increased 
expression of microglia marker ionised calcium-binding adapter molecule 1 (Iba-1) in 
brain regions such as the hippocampus and prefrontal cortex (Biesmans et al., 2013; 
Wang et al., 2014; van Buel et al., 2015). Microglia activation plays a critical role in 
responding to systemic inflammation following acute LPS and propagating that 
inflammatory response within the brain and influencing behaviour. Minocycline, a brain 
permeable anti-inflammatory drug, has been shown to inhibit LPS-induced microglia 
activation by reducing NF-κB signalling, the expression of pro-inflammatory cytokines 
and inhibiting morphological changes associated with activation (Kobayashi et al., 
2013; Fan et al., 2007). Pre-treatment with minocycline has also been shown to 
attenuate LPS-induced sickness and depressive-like behaviours (Henry et al., 2008; 
O'Connor et al., 2009a; Fan et al., 2007). Reducing LPS-TLR4 signalling can also 
inhibit LPS-induced microglia activation and sickness behaviours. By blocking the LPS 
receptor TLR4 or the downstream messenger MyD88, the expression of TNF-α and 
p38 MAPK can be completely inhibited, as well as maintaining a resting microglia 
morphology and preventing the reduced locomotion sickness behaviour (Hines et al., 
2013). These findings affirm the role microglia play in peripherally induced 
neuroinflammation and the resulting changes in behaviour. 
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4.1.3 The hypoxic brain 
The level of oxygen (O2) availability within the body is highly variable, 
depending on the metabolic activity of the tissue. Atmospheric partial pressure of O2 
(PO2) at sea level is 160 mmHg, constituting 21 % of the atmosphere. Once inspired, 
the increase in CO2 and water vapour within the lungs reduces the PO2, and the 
availability of O2 within body tissue is considerably lower that the atmospheric level, as 
the level of available O2 falls further once it passes into the bloodstream and into tissue 
(Figure 4.1) (Masamoto and Tanishita, 2009). Furthermore, the brain is highly 
metabolic, accounting for 20 % of metabolism within the body, and subsequently the 
availability of O2 from cerebral vessels is lower than other tissues. Early invasive 
recordings using O2-sensitive probes reported the partial pressure of O2 to be lower 
than atmospheric PO2 (Ivanovic, 2009). Such recordings have been done in humans 
during surgery, with brain tissue PO2 reportedly averaging 27.6 mmHg, equivalent to 
3.6 % (Hemphill et al., 2005). O2 sensitive probes have also been used to measure O2 
availability in rodents. Cerebral arterial PO2 is measured to be 90-110 mmHg and 
venous PO2 is measured to be 30-40 mmHg (Nwaigwe et al., 2000; Erecińska and 
Silver, 2001). Brain tissue is reported to be even lower. For example, hypothalamic 
measurements were 11-16 mmHg, hippocampal measurements were 20.3 mmHg and 
thalamic measurements were 26 mmHg, with overall ranges comparable to 0.5 – 7 % 
O2 (Cater et al., 1961; Nwaigwe et al., 2000; Ivanovic, 2009). Although measurements 
were variable and averages were potentially overestimated due to the presence of 
blood vessels, the overall conclusion of these findings is that the brain exists in a 
relatively low O2 environment (Ndubuizu and LaManna, 2007). However, recent 
advances in technology allow the measurement of PO2 in vivo, accurately and non-
invasively. The method by which this is done is two-photon imaging using 
phosphorescent probes that quench in an O2-dependent manner, enabling capillary 
and tissue PO2 to be measured (Sakadzić et al., 2010; Lecoq et al., 2009). This 
technique has recently been further developed to be used in awake mice, and reports a 
capillary PO2 of 36 mmHg and an interstitial PO2 in olfactory bulb and somatosensory 
cortex of 23 mmHg, equivalent to 3 % O2 (Lyons et al., 2016). Such findings confirm 
the relative hypoxic environment in which the brain exists. However, nearly all in vitro 
research that studies the function of CNS cells, such as neurons, microglia and 
astrocytes, is in cells cultured in atmospheric (~20 %) O2 conditions. This environment 
should be considered hyperoxic relative to the in vivo microenvironment, and 
conversely, hypoxia could be considered as in situ normoxia (Ivanovic, 2009). 
Furthermore, PO2 is lower in the liquid phase of cell media than atmospheric PO2, with 
37 mmHg PO2 (5 %) conditions reportedly resulting in 20 mmHg PO2 (~2.6 %) in 
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cultures of 50,000 astrocytes (Bambrick et al., 2011). This finding suggests a ~5 % O2 
incubation of microglia cultures may provide conditions more similar to the 23 mmHg 
PO2 reported in the mouse cortex (Lyons et al., 2016). Changes to the availability of O2 
may have effects on the functioning of a cell. When investigating microglia immune 
function in vitro, whether in relation to depression, Alzheimer’s disease, infection or any 
other neurological disease, the effect of a hyperoxic environment needs to be 
considered. 
 
Figure 4.1. O2 concentration in tissue in vivo. 
The partial pressure of O2 falls as it moves from the atmosphere and into tissue. 
Atmospheric PO2 at sea level is 160 mmHg, or 21 %. The PO2 falls within the lungs 
due to an increase in CO2 and H2O, and falls further to between 60 – 100 mmHg in 
arterial blood. PO2 has been recorded as 23 mmHg in the cortex (Lyons et al., 2016). 
At O2 concentrations below 5 %, HIF-1α protein is stabilised and an enhance cell 
survival and inflammation (Jiang et al., 1996; Mazure et al., 2010). Severe hypoxic 
conditions can induce cell death (Shimizu et al., 1996). Wickens original artwork. 
 
4.1.4 Oxygen, metabolism and ROS generation 
O2 is required by all cells in the human body to undergo aerobic cellular 
respiration for the production ATP. Via the process of glycolysis, the Krebs cycles and 
the electron transport chain, glucose and O2 produce water, CO2 and generates ATP. 
ATP in turn provides the energy required for most cellular processes. Therefore, O2 
availability to cells in culture is critical. However, during the electron transport chain 
process within the mitochondria, O2 can accept free electrons resulting in the formation 
of superoxide radicals (O2−). These radicals have the potential to cause significant 
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damage within the cell due to their oxidative ability, and so they are tightly regulated 
enzymes such as superoxide dismutase (SOD), which converts O2− to hydrogen 
peroxide (H2O2). H2O2 can then be processed into H2O and O2 via catalase, or into 
another ROS, hydroxyl radicals (OH), as a result of partial reduction (Turrens, 2003). 
The over-production of ROS is considered ‘oxidative stress’, and whilst ROS can have 
detrimental effects within a cell, they also act as important signalling molecules, in 
particular within the innate immune system. For example, increased ROS levels is 
involved in NLRP3 inflammasome activation, which can be abrogated by inhibiting 
ROS signalling (Cruz et al., 2007).  
 
4.1.5 Hypoxia and inflammation 
The association between O2 availability and mitochondrial ROS generation is 
generally considered linear. Increasing O2 causes an increase in mitochondrial O2− 
and H2O2 (Boveris and Chance, 1973; Turrens et al., 1982; Murphy, 2009), whilst 
mitochondrial ROS production can fall during hypoxia, as O2 is the substrate for ROS 
generation (Hoffman et al., 2007; Kussmaul and Hirst, 2006). However, there is 
considerable data that demonstrate that in severe hypoxia (≤1 % O2) mitochondrial 
ROS signalling increases (Guzy et al., 2005; Desireddi et al., 2010; Hernansanz-
Agustín and Izquierdo-Álvarez, 2014). Mitochondrial ROS generation is an important 
signalling messengers for a number of cellular responses in hypoxia, including the 
activation of transcription factors and signalling molecules (Sena and Chandel, 2012; 
Waypa et al., 2016). An initial burst of ROS production in acute hypoxia has been 
reported which subsequently diminishes (Hernansanz-Agustín and Izquierdo-Álvarez, 
2014). Whilst the mechanisms by which hypoxia can induce ROS signalling is unclear, 
low O2 (~1 %) has been shown to increase the expression of TLR4, proinflammatory 
cytokines and chemokines in immune cells and microglia (Ock et al., 2007; Blengio et 
al., 2013; Kim et al., 2010). 
Acute hypoxia can affect most cells types by altering ion movement and 
metabolism, though long-term effects of hypoxia are thought to be mediated primarily 
through the activity of hypoxia-inducible factor 1 (HIF-1) (Mukandala et al., 2016). HIF-
1 is a transcription factor that can induce the expression of proteins involved in cell 
migration, metabolism, growth and apoptosis, transport and angiogenesis (Schofield 
and Ratcliffe, 2004). HIF-1α is one of the most characterised proteins involved in cell 
signalling under low O2 conditions and is a transcription factor formed of two subunits, 
HIF-1α and HIF-1β. HIF-1β is constitutively expression, whilst HIF-1α is sensitive to O2 
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concentration and is rapidly degraded in high O2 conditions (Huang et al., 1996). HIF-
1α activity is controlled post-translationally via prolyl hydroxylases (PHD), which is 
dependent upon O2 for HIF-1α hydroxylation under normoxic conditions, leading to its 
ubiquitination via a von Hippel-Lindau (pVHL)-E3 ligase complex and its subsequent 
degradation (Figure 4.2) (Masson et al., 2001; Jaakkola et al., 2001; Tanimoto, 2000). 
Under low oxygen levels, PHD activity is reduced and stabilised HIF-1α translocates to 
the nucleus and form a dimer with HIF-1β to induce transcription at genes contained a 
hypoxia-response element (HRE). ROS signalling in hypoxia is thought to contribute to 
the PHD inhibition and HIF-1α stabilisation (Guzy et al., 2005; Chandel et al., 2000). 
NF-κB and MAPK induction, as demonstrated by IL-1 and LPS stimulation, can also 
induce HIF-1α stabilization (Frede et al., 2006; Bonello et al., 2007). HIF-1α 
stabilisation has also been reported to be mediated by mitochondrial ROS, whereby 
HIF-1α induces REDD1 expression, which suppresses mitochondrial ROS generation 
and inhibits HIF-1α stabilisation in a negative feedback loop (Horak et al., 2010). 
 
 
Figure 4.2. HIF-1α degradation and stabilisation. 
HIF-1α is constitutively expressed. In high-oxygen conditions, hydroxylation of HIF-1α 
via prolyl hydroxylases (PHD) leads to ubiquitination via the von Hippel-Lindau (pVHL) 
ubiquitination complex and, ultimately, its degradation. In low oxygen conditions, PHD 
activity is reduced, leading to the stabilisation of HIF-1α and its translocation to the 
nucleus, where it forms a dimer with HIF-1β to induce transcription at hypoxia-
response elements (HREs). ROS, NF-κB and MAPK activity can also lead to HIF-1α 
stabilisation. Wickens original artwork. 
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Hypoxia can have detrimental effects within the CNS, involving 
neuroinflammation, neurotransmission and excitotoxicity. Acute hypoxia induces 
inflammatory signalling processes in microglia. Severe hypoxia (≤0.2 % O2) has been 
shown to induce microglia activation and inflammatory signalling, including p38 MAPK 
and NF-κB activation, nitric oxide (NO) production and TNF-α secretion (Guo and Bhat, 
2006; Park et al., 2002; Lu et al., 2006). The activation of NF-κB in hypoxia was 
observed in microglia and not astrocytes, inducting the inflammatory response in 
hypoxia is primarily microglia-mediated (Guo and Bhat, 2006). The induction of iNOS 
(inducible nitric oxide synthase) and NO in microglia is reportedly dependent of PI3K 
signalling and the activation of HIF-1α (Lu et al., 2006). Minocycline, an anti-
inflammatory drug that has been shown to inhibit microglia activation, can inhibit the 
hypoxia-induced p38 MAPK activation and the production of NO and inflammatory 
cytokines (Suk, 2004). 
Overall, these data indicate that severe hypoxia can induce ROS signalling, 
HIF-1α expression and proinflammatory signalling. However, most studies that assess 
the effect of hypoxia on inflammation use very low concentrations of O2, usually in an 
attempt to mimic ischemia. Hypoxia is not usually used to replicate the in vivo 
microenvironment within the brain. HIF-1α stabilisation is induced at around 5 % O2 
and increases as O2 concentration decreases, showing maximal expression at 0.5 % 
O2 (Jiang et al., 1996). Above 5 % O2, HIF-1α is degraded, with astrocytes cultured at 5 
% O2 demonstrating no HIF-1α protein (Liu et al., 2006). A more physiologically 
relevant cell culture environment would be closer to this level, similar to the in situ 
microenvironment and therefore able to detect more subtle changes in O2, and not just 
massive reductions from a hyperoxic state (21 %) to severe ischemia (1 % O2). 
However, microglia function and inflammatory signalling has yet to be fully examined 
within this range of O2 concentration. 
 
4.1.6 Aims of Chapter 4 
The aims of this thesis chapter were to first characterise NLRP3 inflammasome 
expression and activity in BV2 microglia and primary microglia isolated by mild 
trypsinisation, and to study the influence of mild hypoxia. Whilst NLRP3 inflammasome 
signalling has been demonstrated in microglia before, it has not been characterised in 
primary microglia isolated by mild trypsinisation. Subsequently, 5 % O2 incubation was 
utilised to assess the effect of moderate hypoxia on NLRP3 inflammasome priming and 
activity, in an attempt to better replicate the natural conditions of microglia within the 
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brain. O2 availability within the brain is considered to range between 0.5 and 7 %, 
depending on the region and its metabolic activity (Ivanovic, 2009). Nevertheless, cell 
culture is routinely performed using ~20 % O2, which would be a hyperoxic 
environment. O2 concentration can influence O2-dependent cell signalling, including 
ROS generation and the stabilisation of HIF-1α (Mukandala et al., 2016). Generally, 
experiments that examine hypoxic conditions utilise O2 concentrations below 1 % to 
model ischemia and reperfusion. Such conditions have been shown to induce ROS 
generation and cytokine production (Suk, 2004). The use of a ‘moderate’ hypoxic 
environment to replicate the in vivo microenvironment has not previously been studied, 
and inflammasome signalling in mild hypoxia has not previously been assessed in 
microglia. Incubation periods in low O2 of 4 h, 24 h and 3 weeks were employed to 
study cytosolic protein expression, cytokine secretion and P2X7 receptor activity. 
Necrotic cell death was also studied to investigate ATP-induced pyroptosis. In addition, 
the influence of ketamine on NLRP3 inflammasome activity was assessed, as 
ketamine has been shown to attenuate LPS-induced neuroinflammation and 




4.2.1 NLRP3 inflammasome function in BV2 microglia and the 
effects of acute hypoxia on LPS-induced priming 
4.2.1.1 Stimulation of BV2 microglia with lipopolysaccharide (LPS) 
To study microglia function and NLRP3 inflammasome activity, microglia 
require priming in order to upregulate proteins required for inflammasome activation. 
Here, we stimulated our microglia with LPS, which is regularly used to stimulate innate 
immune responses from immune cells. The cells used here are a commonly used 
immortalized murine microglia cell line (BV2) with a previously established LPS 
response (Henn et al., 2009). In order to determine an effective concentration of LPS to 
use for cell stimulation, BV2 microglia were stimulated with 0.01 – 1 µg/ml LPS for 4 h. 
A range of LPS concentrations were tested to ensure the selected LPS concentration 
used for future experiments induced the expression of NLRP3 (Figure 4.3A) and proIL-
1β (Figure 4.3B) with the potential for increased expression. Quantitative measurement 
of protein was possible via infrared fluorescent western blot analysis. LPS stimulation 
had a significant effect on NLRP3 (one way ANOVA, F(3,8) = 7.045, p = 0.0124) and 
proIL-1β (one way ANOVA, F(3,8) = 8.515, p = 0.0072) expression. All doses of LPS 
induced a significant increase in the protein expression of both NLRP3 (estimated 
molecular weight: 118 kDa) and proIL-1β (estimated molecular weight: 31 kDa) when 
compared to control levels (p < 0.05 for 0.01 & 0.1 µg/ml, p < 0.01 for 1 µg/ml). The 
middle dose of 0.1 µg/ml LPS was selected to be used for future experiments as it 
induced a significant increase in proIL-1β and NLRP3 expression but still had the 
capacity for further increased expression of proIL-1β, allowing the study of both 
increases and decreases in protein expression. 
 
4.2.1.2 Spatial expression of NLRP3 and proIL-1β in BV2 microglia 
Following activation by PAMPs, such as LPS, microglia alter their protein 
expression. CD11b is an membrane-bound antigen expressed by microglia which is 
upregulated following activation and is commonly used to confirm microglia phenotype 
(Roy et al., 2006). Increased CD11b is reported in neuroinflammation and is thought to 
be involved with changes in morphology and motility (Rock et al., 2004). Fluorescent 
imaging of BV2 microglia via immunocytochemistry confirmed the expression of 
CD11b. Following LPS stimulation (0.1 µg/ml; 4 h), CD11b expression is upregulated 
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(Figure 4.4A). BV2 microglia exhibited a basal level of NLRP3 expression, which was 
increased following 4 h stimulation with LPS (Figure 4.4B). ProIL-1β was not detectable 
in the absence of LPS, and expression was induced following LPS stimulation (Figure 
4.4C). A Z-stacked image of a CD11b-stained BV2 microglia shows extended 
processes that are an indicator of resting ramified microglia (Figure 4.4E; (Stence et 
al., 2001). 
 
Figure 4.3. Western blot analysis of protein expression in BV2 microglial cells 
following LPS stimulation.  
NLRP3 (A; green) and proIL-1β (B; green) expression was assessed relative to β-actin 
by quantitative western blotting (C) following stimulated with 0.1-1 µg/ml LPS (4 h). 
Histograms represent fluorescence intensity relative to β-actin (red). Data shown are 
mean ± SEM (n=3) and analysed by one-way ANOVA with Dunnett posthoc analysis. 
*p < 0.05, **p < 0.01, both compared to control.   
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Figure 4.4. Confocal micrographs of BV2 microglial cells.  
The expression of microglial marker CD11b (A), NLRP3 (B) and proIL-1β (C) were 
assessed following LPS stimulation (0.1 µg/ml, 4 h). Primary antibodies were omitted 
for negative controls (D). Cells were counterstained with nuclear marker DAPI (blue). 
Z-stacked image of an unstimulated BV2 microglia (E). 
 
4.2.1.3 Time dependent protein expression in BV2 microglia 
The time course of LPS-induced expression of NLRP3 (Figure 4.5A), proIL-1β 
(Figure 4.5B) and P2X7 (Figure 4.5C) in BV2 microglia was quantified using multiple 
time points (0, 1, 2 and 4 h). LPS stimulation has a significant effect of NLRP3 (one 
way ANOVA, F(3,8) = 14.43, p = 0.0014) and proIL-1β (one way ANOVA, F(3,8) = 4.281, 
p = 0.0444) expression, but not on P2X7 expression (t test, p = 0.9527). BV2 microglia 
exhibit a basal level of NLRP3 expression, and upon LPS stimulation, the level of 
NLRP3 increases in an LPS time-dependent manner, with a significant increase at 2 h 
(p < 0.01) and 4 h (p < 0.01). Whilst there is no basal expression of proIL-1β, 
expression can be seen after 1 h LPS stimulation, and a significant increase can be 
observed after 4 h (p < 0.05). The stimulation of the ATP-gated receptor P2X7 has 
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been shown to mediate ATP-induced inflammasome activation in macrophages 
(Kahlenberg and Dubyak, 2004). Confirming previous studies (Gendron and 
Chalimoniuk, 2003), BV2 cells express the P2X7 receptor (estimated molecular weight: 
75 kDa), necessary for ATP-induced inflammasome activation. LPS stimulation did not 
alter P2X7 expression levels. 
 
4.2.1.4 P2X7 receptor activity in BV2 microglia 
Extracellular ATP-induced uptake of ethidium is an indicator of P2X7 receptor 
function, with ATP-P2X7 activation (EC50: 214 µM for YOPRO dye uptake) resulting in 
the formation of pores and allowing the entry of large molecules (Chessell et al., 1998). 
Functional P2X7 receptor activity in BV2 cells, necessary for ATP-induced 
inflammasome activation, was assessed. When stimulated with high doses of ATP (≥1 
mM) in calcium and magnesium containing buffer, ethidium uptake and fluorescence in 
BV2 cells rapidly increases, indicating functional P2X7 receptor activity (Figure 4.6A). 
Fluorescence values were normalised to a maximal signal (following cell lysis with 
triton X-100). At 20 min post-administration of ATP, a significant effect of ATP on 
ethidium uptake was observed (Figure 4.6B; one way ANOVA, F(5,12) = 72.76, p < 
0.001). BV2 microglia exhibit a significant increase in ethidium uptake with 1, 3 and 5 
mM ATP (p < 0.01, p < 0.001 and p < 0.001, respectively). A-740003 is a selective 
P2X7 receptor antagonist that can block mouse- and human-P2X7 agonist-evoked dye 
uptake (Donnelly-Roberts et al., 2009) and IL-1β release in human THP-1 cells 
(Honore et al., 2006). A significant effect of treatment on ethidium uptake was 
observed (Figure 4.6C; one way ANOVA, F(5,12) = 38.18, p < 0.001). When BV2 
microglia were incubated with A-740003 ethidium fluorescence was significantly 
reduced at 10 µM (56 ± 9 %; n = 3; p < 0.001) and 30 µM (32 ± 2 %; n = 3; p < 0.001). 
In addition, whilst a significant effect of treatment was observed, LPS stimulation for 4 
h prior to experimentation did not alter ATP-induced ethidium uptake (Figure 4.6D; one 
way ANOVA, F(3,12) = 74.13, p < 0.001), nor did LPS stimulation influence the activity of 
the P2X7 receptor antagonist, A-740003 (Figure 4.6E; one way ANOVA, F(3,8) = 19.22, 
p < 0.001). 
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Figure 4.5. Western blot analysis of protein expression in BV2 microglial cells 
following LPS stimulation.  
NLRP3 (A; green), proIL-1β (B; green) and P2X7 (C; red) expression following 0-4 h 
LPS stimulation (0.1 µg/ml). Histograms represent fluorescence intensity relative to β-
actin. Data shown are mean ± SEM (n=3-4) and analysed by one-way ANOVA with 
Dunnett posthoc analysis (A & B) or Student’s t-test (C). *p < 0.05, **p < 0.01, both 
compared to control.  
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Figure 4.6. P2X7 receptor-mediated uptake of ethidium in BV2 microglia. 
Raw ethidium fluorescence following stimulation with ATP (0.1 – 5 mM; A) and 
analysed following 20 min ATP stimulation (B). P2X7 receptor inhibition with selective 
antagonist A-740003, added 5 min before ATP (10 and 30 µM; C). The effect of LPS 
stimulation (0.1 µg/ml; 4 h) on P2X7 activity (D) and on A-740003 inhibition of the P2X7 
receptor (E). Values are 20 min post-ATP addition and represent % of a maximal 
fluorescence signal after lysing cells with 0.2 % Triton X-100 (B-E). Data represent 
mean ± SEM (n=3) and analysed by two-way ANOVA with Tukey’s post hoc test. *p < 
0.05, **p < 0.01, ***p < 0.001, all compared to control; #p < 0.05, ##p < 0.01, ###p < 
0.001 compared to +ATP. 
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4.2.1.5 The effect of acute 5 % O2 hypoxia on BV2 microglia priming 
O2 partial pressure measurements taken within the brain indicate that the 
microenvironment in which microglia exist is hypoxic when compared to the 
approximately 20 % O2 conditions commonly used in cell culture (Lyons et al., 2016). 
To study microglia in conditions that better mimic the in vivo microenvironment 
(Ivanovic, 2009), cells were exposed to 5 % O2 for 5 h and stimulated with LPS (0.1 
µg/ml; 4 h) before proIL-1β (Figure 4.7A) and NLRP3 (Figure 4.7B) expression was 
assessed. A two-way ANOVA revealed a significant effect LPS (F(1,8) = 426.5, p < 
0.001) and hypoxia (F(1,8) = 62.98, p < 0.001) on proIL-1β expression, and a significant 
interaction between LPS and hypoxia (F(1,8) = 62.12, p < 0.001). A two-way ANOVA 
also revealed a significant effect LPS (F(1,8) = 157.4, p < 0.001) on NLRP3 expression 
and a significant interaction between LPS and hypoxia (F(1,8) = 7.096, p = 0.0286), but 
no significant effect of hypoxia alone (F(1,8) = 5.135, p = 0.0532). Stimulation with LPS 
resulted in a significant increase in proIL-1β expression (p < 0.001) and NLRP3 
expression (p < 0.001) in comparison to control. However, when incubated in hypoxic 
(5 % O2) conditions 1 h prior to and during LPS stimulation, the cytosolic levels of 
proIL-1β (45 ± 3 %; n = 3; p < 0.001) and NLRP3 (74 ± 5 %; n = 3; p < 0.05) were 
significantly lower compared to 20 % O2. This finding suggests that acute exposure to 
low O2 attenuates TLR4-mediated priming of microglia cells. 
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Figure 4.7. ProIL-1β and NLRP3 protein expression in BV2 microglia under 
normoxia and acute low oxygen conditions.  
Cytosolic proIL-1β (A) and NLRP3 (B) expression with and without LPS stimulation (4 
h; 0.1 µg/ml) in 5 or 20 % O2 (5 h) in BV2 microglia. Histograms represent density 
relative to β-actin. Data represent mean ± SEM (n=3) and analysed by two-way 
ANOVA with Tukey posthoc analysis. ***p < 0.001 compared to no LPS; #p < 0.05. 
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4.2.1.6 BV2 microglia priming response to TNF-α and IL-1β stimulation 
In order to understand if this phenomenon of attenuated NLRP3 and proIL-1β 
expression under acute hypoxia was specific to TLR4 signalling, BV2 microglia were 
incubated with proinflammatory murine cytokines IL-1β and TNF-α, which both also 
induce NF-κB signalling via their respective receptors and in turn induce the expression 
of inflammatory proteins (Verstrepen et al., 2008). NLRP3 (Figure 4.8B) and proIL-1β 
(Figure 4.8C) expression was assessed after 4 h stimulation with LPS (0.1 µg/ml), IL-
1β (1- 10 ng/ml) and/or TNF-α (1- 10 ng/ml). A two-way ANOVA revealed a significant 
effect of LPS treatment (F(5,24) = 94.46, p < 0.001) and hypoxia (F(1,24) = 13.11, p = 
0.0014) on NLRP3 expression, and a significant effect of hypoxia on the LPS response 
(F(5,24) = 5.168, p = 0.0023). A two-way ANOVA revealed a significant effect of LPS 
treatment (F(5,24) = 19.23, p < 0.001) on proIL-1β expression, with a significant effect of 
hypoxia on the LPS response (F(5,24) = 3.14, p = 0.0255), but no significant effect of 
hypoxia alone (F(1,24) = 3.14, p = 0.0891). Whilst LPS still induced a significant increase 
in proIL-1β and NLRP3 expression (p < 0.001 for both), both IL-1β and TNF-α failed to 
induced expression, contrasting previous findings that shown microglia activation with 
IL-1β and TNF-α (Sheng et al., 2011). 
 
4.2.1.7 Inflammasome activity in BV2 microglia 
The danger associated molecular pattern, extracellular ATP, is a potent 
activator of the NLRP3 inflammasome and regularly used to study inflammasome 
activity (Mariathasan et al., 2006). IL-1β release following ATP stimulation (5 mM; 30 
min) was assessed in LPS-primed (0.1 µg/ml; 4 h) BV2 microglia and J774.2 
macrophages as a positive control (Figure 4.9). A two-way ANOVA revealed a 
significant effect ATP (F(1,12) = 5.008, p = 0.045) and cell type (F(1,12) = 4.946, p = 
0.0461) on IL-1β secretion. Whilst the expression of ATP-receptor P2X7, NLRP3 and 
the IL-1β precursor protein has been demonstrated, ATP failed to induce IL-1β 
secretion in LPS-primed BV2 microglia detected by ELISA. Conversely, LPS-primed 
J774.2 macrophages secreted a significant level of IL-1β (p < 0.05) when stimulated 
with ATP under the same conditions. These data suggest that unlike previous 
literature, these BV2 microglia do not have a functional NLRP3 inflammasome 




Figure 4.8. ProIL-1β and NLRP3 protein expression in BV2 microglia following 
stimulation with proinflammatory cytokines.  
Cytosolic expression of NLRP3 and proIL-1β expression assessed by western blotting 
(A) following stimulation with LPS (4 h; 0.1 µg/ml), IL-1β (4 h; 1 and 10 ng/ml) or TNF-α 
(4 h; 1 and 10 ng/ml) in 5 or 20 % O2 (5 h) in BV2 microglia. Histograms represent 
density relative to β-actin for proIL-1β (B) and NLRP3 (C). Data represent mean ± SEM 
(n=3) and analysed by two-way ANOVA with Tukey post hoc analysis. ***p < 0.001 
compared to control; ##p < 0.01, ###p < 0.001. 
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Figure 4.9. ATP-induced IL-1β release from BV2 microglia and J774.2 
macrophages.  
ELISA detection of IL-1β release following ATP stimulation (5 mM; 30 min) in LPS 
primed (0.1 µg/ml; 4 h) BV2 microglia and J774.2 macrophages. Data shown are mean 
± SEM (n=3) and analysed by two-way ANOVA with Tukey’s posthoc analysis. *p < 
0.05 compared to control. #p < 0.05. 
 
4.2.1.8 BV2 microglia cell death 
Lactate dehydrogenase (LDH) is an important cytosolic enzyme that is released 
during cell death as a cell dies as the membrane degrades (Korzeniewski and 
Callewaert, 1983). The release of LDH was assessed in LPS (0.1 µg/ml; 4 h) and ATP 
(5 mM; 30 min) stimulated BV2 microglia (Figure 4.10B) to investigate if the cells 
exhibit a normal cell death response to stimulation when compared to macrophages 
(Figure 4.10A). LPS / ATP stimulation had a significant effect of LDH release in J774.2 
macrophages (one way ANOVA, F(3,8) = 9.933, p = 0.0045), but not in BV2 microglia 
(one way ANOVA, F(3,8) = 2.474, p = 0.1359). When stimulated with both LPS and ATP, 
J774.2 macrophages released LDH (p < 0.01), an indicator of cell death. However in 
BV2 cells, LDH secretion was not significantly affected by LPS and/or ATP stimulation, 
with a baseline level of LDH release noticeably higher that of J774.2 macrophages. 





Figure 4.10. Cell death in J774.2 macrophages and BV2 microglia.  
The release of lactate dehydrogenase (LDH), an indicator of necrotic cell death, in 
J774.2 macrophages (A) and BV2 microglia (B) following LPS (0.1 µg/ml; 4 h) and ATP 
(5 mM; 30 min) stimulation. Data represent mean ± SEM (n=3) and analysed by one-
way ANOVA with Dunnett posthoc analysis. **p < 0.01 compared to control. 
 
4.2.1.9 ASC expression in BV2 microglia 
ASC is a critical component of the NLRP3 inflammasome that bridges NLRP3 
to procaspase-1, allowing inflammasome assembly and procaspase-1 autocleavage. 
The production of caspase-1 in turn cleaves proIL-1β resulting in the mature bio-active 
form, IL-1β (Schroder and Tschopp, 2010). Following the absence of ATP-mediated IL-
1β secretion ASC expression was assessed via western blotting. It was found that 
whilst J774.2 macrophages expressed ASC protein, BV2 microglia did not (Figure 
4.11A), which elucidates the absence of secreted IL-1β and cell death following ATP 
stimulation. Whilst ASC protein could not be detected, PCR revealed the presence of 
ASC mRNA (Figure 4.11B), suggesting ASC protein expression may be inhibited at a 
translational level or that the level of ASC protein is below the detectable range. 
Due to the unusual phenotype of the BV2 cells, with the absence of ASC 
protein expression, the lack of IL-1β secretion, the failed priming with inflammatory 
cytokines and the cell death response to stimulation, all future experiments were 
carried out with primary microglia isolated from C57BL/6J mice in order to confidently 




Figure 4.11. ASC protein and mRNA expression in BV2 microglia and J774.2 
macrophages.  
Western blot analysis of ASC expression (red) in BV2 microglia and J774.2 
macrophages (A) with and without LPS stimulation (0.1 µg/ml; 4 h). Histogram 
represents fluorescence intensity relative to β-actin (green). PCR analysis of ASC 
mRNA in BV2 microglia and J774.2 or RAW264.7 macrophages (B). Two separate 
sets of ASC primers were used (#1 & #2), and a β-actin primer (#3) as a control. Data 




4.2.2 Characterisation of NLRP3 inflammasome function in neonatal 
primary microglia isolated by mild trypsinisation  
4.2.2.1 Isolation of primary microglia 
The majority of primary microglia cultures are obtained by an extended period 
of shaking of mixed glia cultures, ranging from 15 min to 5 h (Parvathenani et al., 2003; 
Liu et al., 2001). The shaking process causes microglia to enter an amoeboid form 
whereby cells retract their projections to allow free movement and detach from the 
surface of the well to be harvested and re-plated (Giulian and Baker, 1986). The 
primary disadvantage of shaking is the mechanical stress that is placed upon the cells. 
The retraction of projections is an indicator of microglia activation (Kettenmann et al., 
2011) and potentially extracellular ATP (Orr et al., 2009), though this phenotype allows 
the isolation of detached microglia in the supernatant. This process may alter microglia 
behaviour and affect microglia stimulation during experimentation the following day. In 
an attempt to avoid potential mechanical stress and activation of microglia, we used a 
method of mild trypsin to isolate primary microglia (Figure 4.12A) (Saura et al., 2003). 
After 3 weeks in culture, a layer of astrocytes form in the mixed glial cultures, which 
overlay microglia (Figure 4.12C) (Sheng et al., 2011). By using a low concentration of 
trypsin for a brief period (10 – 20 min), the astrocytic layer becomes detached and can 
be removed, leaving microglia still adhered to the surface of the well (Figure 4.12D). 
The conditioned media from the mixed glia culture is then added back to the well. 
Confocal imaging showed that before isolation, there are many GFAP-positive cells, 
indicating the presence of astrocytes (Figure 4.12E). Following isolation, only GFAP-
negative / CD11b-positive cells remain, demonstrating a pure culture of primary 
microglia (Figure 4.12G). The primary microglia exhibit numerous projections, 
demonstrating a resting ramified morphology. LPS stimulation (0.1 µg/ml; 4 h) of 
primary microglia induced a visible increase in NLRP3 expression from the low basal 
level of expression detected by immunocytochemistry (Figure 4.13A). A visible 
upregulation of cytosolic proIL-1β can also be seen following LPS stimulation, with no 
basal expression (Figure 4.13B). In addition, the microglia morphology following LPS 
stimulation appeared more rounded with retracted processes. 
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Figure 4.12. Isolation of primary microglia from mixed glia cultures taken from 
neonatal C57BL/6J mice.  
Mixed glial cells are cultured for 3 weeks until microglia are isolated prior to 
experimentation (A). Light microscope images show mixed glia culture from 1 day in 
vitro (DIV) through to 19 DIV (C) and isolated microglia cells via mild trypsinisation at 
22 DIV (D). Confocal images of mixed glia cultures and isolated microglia with nuclei 
counterstained in DAPI (blue). Mixed glial cultures contain GFAP-positive (green) 
astrocytes (E). Following mild trypsinisation, GFAP-positive cells are removed where 
DAPI staining indicates the presence of cells (F) leaving only CD11b-positive (green) 
microglia (G). Images are representative of n=3. 
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Figure 4.13. Immunocytochemical imaging of NLRP3, proIL-1β and CD11b 
expression in microglia isolated from neonatal C57BL/6J mice.  
NLRP3 (red; A), proIL-1β (red; B) and CD11b (green) expression following LPS 
stimulation (4 h; 0.1 µg/ml). The nuclei were counterstained in DAPI (blue). Scale bar is 




4.2.2.2 Protein expression in primary microglia 
NLRP3 (Figure 4.14A), proIL-1β (Figure 4.14B), P2X7 (Figure 4.14C) and ASC 
(Figure 4.14D) expression in trypsin isolated primary microglia was determined. LPS 
stimulation (0.1 µg/ml; 4 h) had a significant effect on NLRP3 (one way ANOVA, F(3,8) = 
6.019, p = 0.019) and proIL-1β (one way ANOVA, F(3,12) = 3.543, p = 0.0481) 
expression. Similarly to BV2 microglia, primary neonatal microglia show a basal level of 
NLRP3 protein expression. Following 4 h LPS stimulation, a significant upregulation in 
NLRP3 is observed (p < 0.01), as well as a significant induction of proIL-1β expression 
(p < 0.05). In addition, primary neonatal microglia express the adaptor protein ASC, 
essential for NLRP3 inflammasome assembly, as well as P2X7. A two way ANOVA 
revealed no effect of LPS stimulation on P2X7 expression (F(1,12) = 0.6439, p = 0.4379) 
or ASC expression (F(1,12) = 0.4754, p = 0.9473), demonstrating a similar expression 
pattern to J774.2 macrophages. 
 
4.2.2.3 P2X7 receptor function and inflammasome activity in primary 
microglia 
The P2X7 receptor mediates ATP-induced NLRP3 inflammasome activation 
(Kahlenberg and Dubyak, 2004). By measuring ATP-induced ethidium uptake, P2X7 
receptor function can be assessed (Figure 4.15A). A significant effect of treatment on 
ethidium uptake was observed (one way ANOVA, F(3,12) = 30.54, p < 0.001). Following 
stimulation with ATP, primary microglia significantly increase the level of ethidium 
uptake (p < 0.001). This increase in ethidium fluorescence is significantly attenuated 
following incubation with the P2X7 receptor specific antagonist A-740003 at 10 µM (79 
± 8 %; n = 4; p < 0.05) and 30 µM (74 ± 3 %; n = 4; p < 0.05), indicating functional 
P2X7 receptor activity. With ASC expression and functional P2X7 receptor activity 
confirmed, inflammasome activity and IL-1β secretion was tested. When primed with 
LPS (0.1 µg/ml; 4 h) and stimulated with ATP (5 mM; 30 min), primary microglia 
release IL-1β into the supernatant, unlike BV2 microglia (Figure 4.15B). A two-way 
ANOVA revealed a significant effect ATP (F(1,24) = 24.31, p < 0.001) and LPS (F(3,24) = 
13.19, p < 0.001) on IL-1β release, with a significant interaction between LPS and ATP 
(F(3,24) = 11.64, p < 0.001). IL-1β release was significantly greater than LPS alone (p < 
0.001) and ATP alone (p < 0.001). Caspase-1 is the functional enzyme of the NLRP3 
inflammasome. To show that the release of IL-1β in primary microglia is a result of 
NLRP3 inflammasome activity, cells were incubated with the caspase-1 inhibitor Ac-
YVAD-cmk (Figure 4.15C). A significant effect of treatment on IL-1β release was 
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observed (one way ANOVA, F(3,8) = 6.993, p = 0.0126). Ac-YVAD-cmk induced a dose-
dependent inhibition of IL-1β secretion, with significant reductions observed at 10 µM 
(39 ± 13 % of control; n = 3; p < 0.05) and 40 µM (17 ± 5 % of control; n = 3; p < 0.01), 
indicating a caspase-1-dependent inflammasome. 
 
4.2.2.4 Primary microglia cell death 
To assess necrotic/pyroptotic cell death induced by LPS (0.1 µg/ml; 4 h) and 
ATP (5 mM; 30 min), LDH release was measured (Figure 4.16). We previously showed 
that BV2 microglia did not show a significant change in LDH release following 
stimulation whilst J774.2 macrophages did (Figure 4.10). In primary microglia, a 
significant effect of LPS / ATP stimulation on LDH release was observed (one way 
ANOVA, F(3,8) = 7.506, p = 0.0103). Similar to J774.2 macrophages, when stimulated 
with both LPS and ATP, primary microglia released significant levels of LDH (p < 0.01), 
indicating a pyroptotic response similar to macrophages and contrasting the response 




Figure 4.14. Western blot analysis of cytosolic protein expression in primary 
neonatal microglia isolated from C57BL/6J mice.  
NLRP3 (green; A) and proIL-1β (green; B) expression following LPS stimulation (0 – 4 
h; 0.1 µg/ml) in primary microglia. P2X7 (red; C) and ASC (red; D) expression in 
primary microglia and J774.2 macrophages following LPS stimulation (4 h; 0.1 µg/ml). 
Histograms represent fluorescence intensity relative to β-actin. Data shown are mean ± 
SEM (n=3) and analysed by one-way ANOVA with Dunnett posthoc analysis. *p < 0.05, 
**p < 0.01, both compared to control. 
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Figure 4.15. P2X7 receptor function and ATP-induced release of IL-1β in neonatal 
primary microglia isolated from C57BL/6J mice.  
Histogram illustrating ethidium fluorescence following 10 min with or without ATP (5 
mM) addition in primary microglia. P2X7 receptor inhibition (10 & 30 µM A-740003 
added 5 min before ATP addition) (A). ELISA detection of IL-1β release following LPS 
priming (0 – 4 h; 0.1 µg/ml) and ATP stimulation (5 mM; 30 min) (B). Caspase-1 
inhibition (2 – 40 µM YVAD; 4 h incubation) of IL-1β release from LPS primed (4 h; 0.1 
µg/ml) primary microglia detected by ELISA (C). Data represent mean ± SEM (n=3) 
and analysed by one-way ANOVA with Tukey’s posthoc test (A), two-way ANOVA with 
Tukey’s post hoc test (B) or one-way ANOVA with Dunnett’s posthoc test (C). *p < 
0.05, **p < 0.01, ***p < 0.001, all compared to control; #p < 0.05,  ###p < 0.001 




Figure 4.16. Cell death in neonatal primary microglia isolated from C57BL/6J 
mice.  
LDH release following LPS priming (4 h; 0.1 µg/ml) and ATP stimulation (30 min; 5 
mM). Data represent mean ± SEM (n=3) and analysed by one-way ANOVA with 
Dunnett posthoc analysis. **p < 0.01 compared to control. 
 
4.2.2.5 The effect of ketamine of primary microglia function 
Ketamine has become a revolutionary new tool in the treatment of treatment-
resistant depression, with clinical studies reporting fast-acting improvements in mood 
following a single dose (Murrough et al., 2013; Berman et al., 2000). In pre-clinical 
studies, ketamine has been shown to attenuate inflammation-induced depressive-like 
behaviours in preclinical experiments (Autry et al., 2011; Walker et al., 2013). The 
antidepressant activity of ketamine in the forced swim test was shown earlier in 
C57BL/6J mice (Figure 3.1D), but failed to reverse the depressive effects of LPS in the 
female urine sniffing test (Figure 3.6). Ketamine is a NMDA receptor antagonist and its 
primary action is stimulating NMDA receptors on neurons, enhancing synaptic protein 
synthesis and synaptogenesis (Duman et al., 2012). Ketamine has been shown to 
have anti-inflammatory effects in microglia, including the inhibition of IL-1β release, 
though the majority of work looking at the effects of ketamine is done in neurons 
(Chang et al., 2009; Shibakawa et al., 2005). We tested the effects of ketamine on 
NLRP3 inflammasome expression and function in primary neonatal microglia. Before 
testing inflammasome function, ketamine-induced cell death was assessed with and 
without ATP stimulation (5 mM; 30 min) via LDH release (Figure 4.17A). A two-way 
ANOVA revealed a significant effect of ATP on LDH release (F(1,20) = 23.68, p < 0.001), 
but no significant effect of ketamine (F(4,20) = 0.2277, p = 0.9196), and no interaction 
between ATP and ketamine (F(4,20) = 0.056, p = 0.9938). When stimulated with ATP, 
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LDH release was increased, though ketamine treatment (1-1000 µM) did not alter LDH 
release in the presence or absence of ATP. This indicates that ketamine does not 
induce cell death in microglia in a 4 h incubation period. In turn, LPS-induced (0.1 
µg/ml; 4 h) expression of proIL-1β (Figure 4.17B) and NLRP3 (Figure 4.17C) was 
assessed following incubation with ketamine. No significant of ketamine on LPS-
induced proIL-1β observed (one way ANOVA, F(4,10) = 2.614, p = 0.0993) or NLRP3 
observed (one way ANOVA, F(4,10) = 0.2984, p = 0.8724) expression was observed. 
Subsequently, the influence of ketamine on ATP-induced IL-1β release was assessed, 
both when added during the 4 h LPS priming (Figure 4.17D), nor the 30-minute ATP 
stimulation (Figure 4.17E). No significant of ketamine on ATP-induced IL-1β release 
was observed when treated during LPS-priming (one way ANOVA, F(4,10) = 2.258, p = 
0.135) or ATP-stimulation (one way ANOVA, F(4,10) = 1.677, p = 0.231). These data 
suggest that ketamine does not directly influence NLRP3 inflammasome expression or 
ATP-induced inflammasome activity in primary microglia cells. An earlier study showed 
ketamine inhibited LPS-induced IL-1β secretion, though this was a 12 h LPS 
stimulation without ATP (Chang et al., 2009). Therefore, our findings indicate the ability 
of ketamine to attenuate neuroinflammation in vivo is independent of P2X7 receptor-
mediated NLRP3 inflammasome pathways.  
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Figure 4.17. The effects of ketamine on cell death and NLRP3 inflammasome 
expression and activation in neonatal primary microglia isolated from C57BL/6J 
mice.  
LDH release following incubation with ketamine (1 – 1000 µM; 4 h) and ATP 
stimulation (5 mM; 30 min) in primary microglia (A). Expression of proIL-1β (green; B) 
and NLRP3 (green; C) in LPS-primed (4 h; 0.1 µg/ml) primary microglia incubated with 
ketamine. Histograms represent fluorescence intensity relative to β-actin. ATP-induced 
IL-1β release in LPS-primed primary microglia incubated with ketamine during either 
the 4 h LPS-priming step (D) or the 30-minute ATP stimulation (E). Data represent 
mean ± SEM (n=3) and analysed by two-way ANOVA (A) or one-way ANOVA (B-E) 
with Dunnett’s post hoc tests. ***p < 0.001. 
  





































































































































4.2.3 The effect of 5 % O2 on inflammasome function in primary 
microglia 
Brain in microglia will exist in constant state of low O2 relative to atmospheric O2 
availability (Ivanovic, 2009). In this section, it was asked whether long-term culture 
under low O2 would alter the microglia phenotype. As such, primary mixed glia cultures 
were cultured under low O2 (5 %) conditions, from immediately after dissection and 
plating, to sample collection at the end of experiments 3 weeks later. These conditions 
will be described as chronic hypoxia. Subsequently, mixed glia cultures were incubated 
in normoxic conditions (20 % O2 for 3 weeks) before a 24 h incubation in 5 % O2 
hypoxia following microglia isolation. These conditions will be described as acute 
hypoxia. These conditions were tested to produce an O2 environment that would 
theoretically closer represent the natural environment within the brain, reported to be 
between 0.5 – 7 %, and provide a more realistic insight into microglia function, though 
not hypoxic enough to induced ischemia (Ivanovic, 2009; Lyons et al., 2016; Ndubuizu 
and LaManna, 2007; Lecoq et al., 2011). 
 
4.2.3.1 NLRP3 inflammasome expression and activity in chronic 5 % O2 
hypoxia 
P2X7 receptor-mediated IL-1β release was assessed in LPS (0.1 µg/ml; 4 h) 
and ATP (5 mM; 30 min) stimulated primary microglia cultured in either atmospheric O2 
conditions (20 %) or chronic 5 % O2 (Figure 4.18). A two way ANOVA revealed a 
significant effect of LPS / ATP treatment (F(3,52) = 38.39, p < 0.001) and hypoxia (F(1,52) 
= 9.025, p = 0.0041) on IL-1β release, with a significant interaction between treatment 
and hypoxia (F(3,52) = 14.02, p < 0.001). Whilst LPS / ATP stimulation caused a 
significant release in IL-1β in 20 % O2 (p < 0.001), IL-1β release was significantly 
reduced in microglia cultured in chronic 5 % O2 (26 ± 4 % of control; n = 10; p < 0.001). 
Following 4 h LPS stimulation, quantification of proIL-1β (Figure 4.19A), NLRP3 (Figure 
4.19B), P2X7 (Figure 4.19C) and ASC (Figure 4.19D) was assessed by western blot. 
For proIL-1β, a two way ANOVA revealed a significant effect of LPS on expression 
(F(1,8) = 7.49, p = 0.0256), but no effect of hypoxia (F(1,8) = 0.8922, p = 0.3725) and no 
interaction between hypoxia and LPS (F(1,8) = 0.8699, p = 0.3783). For NLRP3, a two 
way ANOVA revealed a significant effect of LPS treatment (F(1,8) = 33.18, p < 0.001) 
and hypoxia (F(1,8) = 9.555, p = 0.0149) on expression, and a interaction between 
hypoxia and LPS (F(1,8) = 9.506, p = 0.015). For P2X7, a two way ANOVA revealed no 
effect of LPS F(1,8) = 0.2569, p = 0.6259) or hypoxia F(1,8) = 1.666, p = 0.2328). For 
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ASC, a two way ANOVA revealed no effect of LPS F(1,8) = 0.4882, p = 0.5045) or 
hypoxia F(1,8) = 0.7008, p = 0.4268). The level of cytosolic NLRP3 was significantly 
greater in microglia cultured at chronic 5 % O2 than 20 % O2 (p < 0.05), whilst proIL-1β, 
P2X7 and ASC levels were not significantly affected.  
 
Figure 4.18. The effect of chronic 5 % O2 availability on IL-1β release in neonatal 
primary microglia isolated from C57BL/6J mice.  
ELISA detection of IL-1β release following LPS priming (4 h; 0.1 µg/ml) and ATP 
stimulation (30 min; 5 mM) under chronic (3 weeks) 20 % or 5 % O2. Data represent 
mean ± SEM (n=10) and analysed by two-way ANOVA with Tukey’s post hoc test. ***p 





Figure 4.19. Western blot analysis of protein expression primary neonatal 
microglia isolated from C57BL/6J mice cultured in 20 % or chronic 5 % O2.  
ProIL-1β (green; A), NLRP3 (green; B), P2X7 (red; C) and ASC (red; D) expression in 
the presence and absence of LPS (0.1 µg/ml; 4 h) in primary microglia cultured in 
chronic (3 weeks) 20 % or 5 % O2. Histograms represent fluorescence intensity relative 
to β-actin. Data shown are mean ± SEM (n=3) and analysed by two-way ANOVA with 




However, when the level of loading control protein β-actin alone was quantified 
(Figure 4.20A), it showed that there was a significant reduction in β-actin levels in all 
samples (control and LPS) from chronic 5 % O2 (23 ± 4 % of control; n = 24; t test, p < 
0.001). β-actin is commonly used at a loading control as the cytosolic levels of the 
protein is generally unaffected by treatment and is therefore used as a means to 
assess protein concentration in a sample. This finding suggests that the samples of 
microglia cultured in 20 % O2 contain less protein, a consequence of a reduced number 
of cells. In order to investigate this theory, a DNA content-based assay was used to 
look at the number of viable cells in the cultures. The assay was carried out on mixed 
glia cultures at 7, 14, 22 DIV, as well as on isolated microglia cultures on 22 DIV 
(Figure 4.20B). A significant effect of hypoxia was observed (one way ANOVA, F(4,10) = 
20.65, p < 0.001). Significant reductions in cell number were observed in chronic 5 % 
O2 mixed glia cultures at 7 DIV (55 ± 11 %; n = 3; p < 0.001), 14 DIV (68 ± 4 %; n = 3; 
p < 0.01), 22 DIV (68 ± 2 %; n = 3; p < 0.01), and in isolated microglia (28 ± 6 %; n = 3; 
p < 0.001). This finding would explain why a reduction in IL-1β release is observed in 
chronic 5 % O2 following stimulation: a reduced cell number.  
Figure 4.20. Cell density of primary neonatal microglia isolated from C57BL/6J 
mice cultured in 20 % or chronic 5 % O2.  
Western blot detection of β-actin expression in samples (±LPS) from primary microglia 
cultured in chronic (3 weeks) 20 % or 5 % O2 (A). Cell density assessment with a 
DNA-based fluorescent probe of primary mixed glia and microglia cultures in chronic 
20 % or 5 % O2 after 7, 14 and 22 days in vitro (DIV) as well as after microglia isolation 
(B). Data shown are mean ± SEM (n=24) and analysed by Student’s t-test (A) or data 
shown are mean ± SEM (n=3) and analysed by one-way ANOVA with Dunnett’s 
posthoc analysis (B). **p < 0.01, ***p < 0.001, all compared to control.  
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4.2.3.2 Microglia cell density in 24 h 5 % O2 hypoxia  
To avoid the confounding factor of a reduced cell number when cultured under 
low O2 conditions, microglia were cultured and isolated under normoxic conditions, and 
subsequently moved into 5 % O2 before experimentation 24 h later. This allowed all 
microglia to proliferate at a similar rate before any change in conditions. In order to first 
evaluate that the microglia cell number was not affected by 24 h 5 % O2 hypoxia, the 
DNA content-based assay was used to assess cell number (Figure 4.21). No 
significant difference in cell density was observed between 20 % O2 and 24 h 5 % O2 (t 
test, p = 0.4786). Using this protocol, the difference in proliferation when cultured under 
chronic 5 % O2 was eliminated. 
 
Figure 4.21. Cell density of primary neonatal microglia isolated from C57BL/6J 
mice in 20 % or acute 5 % O2 (24 h).  
Cell density assessment with a DNA-based fluorescent probe of primary microglia in 20 
% or acute 5 % O2 (24 hr). Data shown are mean ± SEM (n=3) and analysed Student’s 
t-test. 
 
4.2.3.3 NLRP3 inflammasome expression and activity in primary microglia 
death in 24 h 5 % O2 hypoxia 
Following LPS priming (0.1 µg/ml; 4 h) of primary microglia exposed to 24 h 
hypoxia, the protein expression levels of NLRP3 (Figure 4.22A), proIL-1β (Figure 
4.22B) and P2X7 (Figure 4.22C) were assessed. For NLRP3 expression, a two way 
ANOVA revealed a significant effect of LPS (F(1,12) = 5.861, p = 0.0323) but no effect of 
hypoxia (F(1,12) = 0.4022, p = 0.5379). For proIL-1β expression, a two way ANOVA 
revealed a significant effect of LPS (F(1,12) = 9.029, p = 0.011) but no effect of hypoxia 
(F(1,12) = 0.053, p = 0.8224). For P2X7 expression, a two way ANOVA revealed no 
significant effect of LPS (F(1,8) = 0.1295, p = 0.7283) or hypoxia (F(1,8) = 0.0037, p = 
0.9632). Expression levels in 5 % O2 were not significantly affected when compared to 
microglia cultured and stimulated in 20 % O2, indicating a priming response similar to 
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normoxic conditions. Following LPS (0.1 µg/ml; 4 h) and ATP (5 mM; 30 min) 
stimulation, IL-1β release was assessed in 20 % O2 and acute (24 h) O2 (Figure 
4.23A). A two-way ANOVA revealed a significant effect of ATP (F(1,8) = 44.79, p < 
0.001) and hypoxia (F(1,8) = 7.514, p = 0.0254) on IL-1β release, and a significant 
interaction between ATP and hypoxia (F(1,8) = 7.353, p = 0.0266). IL-1β secretion was 
significantly increased in ATP-treated microglia in 20 % O2 (p < 0.001) and significantly 
reduced in acute 5 % O2 (42 ± 4 % of control; n = 3; p < 0.05), even though cell density 
is unaffected in 24 h hypoxia (Figure 4.21). To test whether the loss of astrocytes is a 
factor in the altered inflammasome function of microglia, mixed glia cultures were 
examined (Figure 4.23B). A two-way ANOVA revealed a significant effect of ATP (F(1,8) 
= 702.6, p < 0.001) and hypoxia (F(1,8) = 105.5, p < 0.001) on IL-1β release, and a 
significant interaction between ATP and hypoxia (F(1,8) = 111.5, p < 0.001). A similar 
pattern of IL-1β release to isolated microglia cultures was observed, with significant 
increase following ATP in 20 % O2 (p < 0.001), which was significantly reduced in 24 h 
5 % O2 conditions (45 ± 2 % of control; n = 3; p < 0.001). This finding suggests that 
reducing the O2 availability to 5 % inflammasome activity is attenuated shows and that 
whilst astrocytes have important homeostatic roles within the brain, it is not a factor 
responsible for this reduction. Our data did show that IL-1β release is higher when 
mixed glia cultures were stimulated compared to microglia alone, however the process 
of removing astrocytes also removes a portion of microglia as collateral which would 
result in an overall lower level of IL-1β release. The release of inflammatory cytokines 
TNF-α (Figure 4.23C) and IL-6 (Figure 4.23D) was also assessed. A two way ANOVA 
revealed a significant effect of stimulation on TNF-α release (F(1,8) = 738.8, p < 0.001), 
but no effect of hypoxia (F(1,8) = 0.264, p = 0.6213) and no interaction between 
stimulation and hypoxia (F(1,8) = 0.2168, p = 0.6539). Similarly, a two way ANOVA 
revealed a significant effect of stimulation on IL-6 release (F(1,8) = 121.0, p < 0.001), but 
no effect of hypoxia (F(1,8) = 1.325, p = 0.283) and no interaction between stimulation 
and hypoxia (F(1,8) = 1.264, p = 0.2934). A significant increase in TNF-α and IL-6 
release was observed following LPS and ATP stimulation (p < 0.001 for all), but no 
difference between microglia incubation in 20 % O2 or acute 5 % O2. These data 
demonstrate that the reduction seen in ATP mediated IL-1β release in 5 % O2 is 
specific to IL-1β and does not affect all other inflammatory cytokines. 
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Figure 4.22. Western blot analysis of protein expression in primary neonatal 
microglia isolated from C57BL/6J mice in 20 % or acute 5 % O2 (24 h).  
NLRP3 (green; A), proIL-1β (green; B) and P2X7 (red; C) protein expression in primary 
microglia with and without LPS (0.1 µg/ml; 4 hr) in 20 % or acute 5 % O2 (24 h). 
Histograms represent fluorescence intensity relative to β-actin. Data shown are mean ± 





Figure 4.23. The effect of 5 % O2 on cytokine release in neonatal primary 
microglia and mixed glia cultures isolated from C57BL/6J mice.  
ELISA detection IL-1β release from primary microglia (A) and mixed glia (B) following 
stimulation with LPS (0.1 µg/ml; 4 h) and ATP (5 mM; 30 min) in 20 % or 5 % O2 (both 
chronic and 24 h). TNF-α (C) and IL-6 (D) release following LPS and ATP stimulation in 
20 % or acute 5 % O2 (24 h). Data represent mean ± SEM (n = 3) and analysed by two-
way ANOVA with Tukey’s post hoc test. ***p < 0.001 compared to 20 % O2 no ATP; #p 
< 0.05, ###p < 0.001, compared to 20 % O2 no ATP (A & B).  ***p < 0.001 compared to 




4.2.3.4 Microglia cell death in 24 h 5 % O2 hypoxia 
LDH release following LPS (0.1 µg/ml; 4 h) and ATP (5 mM; 30 min) stimulation 
was assessed as a measure of cell death to investigate the effect of O2 conditions on 
pyroptosis associated with inflammasome activation (Figure 4.24). A two way ANOVA 
revealed a significant effect of treatment on LDH release (F(1,12) = 15.09, p = 0.0022), 
but no significant effect of hypoxia (F(1,12) = 1.692, p = 0.2178) and no interaction (F(1,12) 
= 1.931, p = 0.1899). It was found that, similar to earlier data, microglia cultured in 20 
% O2 significantly increased LDH release when stimulated (533 ± 147 % of control; n = 
4; p < 0.01). When stimulated in 5 % O2, there was not a significant increase in LDH 
release. However, there was also no significant difference between stimulated 
microglia in 20 % and 5 % O2. This finding suggests that a higher O2 availability may 
enhance P2X7 receptor-mediated cell death and pyroptosis. 
 
 
Figure 4.24. Cell death of primary neonatal microglia isolated from C57BL/6J 
mice in 20 % or acute 5 % O2 (24 h).  
LDH release following LPS (0.1 µg/ml; 4 h) and ATP (5 mM; 30 min) stimulation in 
primary microglia in 20 % or acute 5 % O2. Data shown are mean ± SEM (n=3) and 
analysed by two-way ANOVA with Tukey’s post hoc analysis (B). **p < 0.01 compared 
to control. 
 
4.2.3.5 ROS production in LPS-stimulated primary microglia in 24 h 5 % 
O2 hypoxia 
To try and understand some of the underlying mechanisms underlying the 
attenuated NLRP3 inflammasome activity observed in primary microglia under 5 % O2 
conditions, ATP-induced production of reactive oxygen species (ROS) was 
investigated. ROS levels have been shown to be directly linked to O2 availability and 
can activate the NLRP3 inflammasome following priming (Zhou et al., 2011; Heid et al., 
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2013). After LPS stimulation (0.1 µg/ml; 4 h), cells loaded with DCFDA and stimulated 
with ATP. DCFDA fluorescence (Figure 25.B) was then measured alongside ethidium 
fluorescence (Figure 25.A) in the same samples. A two way ANOVA revealed a 
significant effect of ATP on ethidium uptake (F(3,16) = 36.03, p < 0.001), but no 
significant effect of hypoxia (F(1,16) = 0.676, p = 4231) and no significant interaction 
(F(3,16) = 0.1134, p = 0.951). Significant increases in uptake ethidium were seen with 3 
and 5 mM ATP in 20 % O2 (p < 0.01 and p < 0.001, respectively) and in 5 % O2 (p < 
0.05 and p < 0.001, respectively), indicating the activation of the P2X7 receptor is 
insensitive to low O2. Whilst a robust signal was detected following the addition of 100 
µM hydrogen peroxide (H2O2), a two way ANOVA revealed no significant effect of ATP 
(F(3,16) = 1.215, p = 0.3362) or hypoxia (F(1,16) = 0.5331, p = 0.4759) on DCFDA signal. 
This result indicates no significant increase in the production of reactive O2 species 
following ATP stimulation detectable by DCFDA. 
 
Figure 4.25. P2X7 receptor activation and ROS production following ATP 
stimulation in LPS-primed primary neonatal microglia isolated from C57BL/6J 
mice cultured in 20 % or 5 % O2  (24 h).  
Ethidium uptake at 10 min after ATP or control buffer addition (A) and ROS generation 
as detected by DCFDA fluorescence (B) in LPS-primed (0.1 µg/ml; 4 h) primary 
microglia stimulation with ATP (1 – 5 mM ATP) in 20 % or acute 5 % O2 (24 h). 100 µM 
H2O2 used as a positive control. Data shown are mean ± SEM (n=3) and analysed by 
two-way ANOVA with Tukey posthoc analysis.  
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4.3 Summary of findings 
• BV2 microglia exhibit normal LPS-induced (0.1 µg/ml; 4 h) protein expression 
and ATP-induced (5 mM; 30 min) P2X7 receptor function, but do not express 
ASC and do not have a functional NLRP3 inflammasome. 
• Under 5 h hypoxia (5 % O2), LPS-induced (0.1 µg/ml; 4 h) inflammasome 
protein expression in BV2 microglia is attenuated. 
• Primary microglia, isolated via mild trypsinisation, exhibit a ramified 
morphology, and express a functional NLRP3 inflammasome following LPS (0.1 
µg/ml; 4 h) and ATP stimulation (5 mM; 30 min). 
• Following chronic hypoxia (3 weeks; 5 % O2), primary microglia cell number is 
reduced. 
• Following acute hypoxia (24 h; 5 % O2), primary microglia show attenuated 
ATP-induced (5 mM; 30 min) IL-1β release and cell death compared to 
normoxia, but no change in ATP-induced TNF-α or IL-6 release. 
• No change in ROS generation was observed in primary microglia following 





4.4.1 The characterisation of NLRP3 inflammasome expression and 
activity in BV2 microglia and primary neonatal microglia 
4.4.1.1 BV2 microglia 
BV2 microglia are a raf/myc-immortalised murine neonatal microglia cell line 
that are regularly used to study microglia function and neuroinflammation (Blasi et al., 
1990). Though BV2 microglia are not commercial available, and therefore not 
controlled, access to BV2 microglia is usually obtained as gifts from other research 
labs. As an immortalised cell line, there are a number of differences between BV2 
microglia and primary microglia in terms of function and protein expression. This cell 
line has previously been used to study NLRP3 inflammasome function (Shi et al., 
2012). Consistent with other studies, BV2 microglia exhibited CD11b expression, a 
commonly used marker for identifying microglia, that increased following LPS 
stimulation (Roy et al., 2006). The upregulation of inflammatory proteins has been 
previously demonstrated in BV2 microglia, whereby LPS stimulation induces NF-κB 
activity and protein expression (Lee and Kim, 2012; Liang et al., 2015). P2X7 
expression was not altered following LPS stimulation, as P2X7 expression has not 
been shown to be mediated by NF-κB (Zhou et al., 2009). P2X7 expression has been 
reported before in microglia (Bartlett et al., 2013). A 16 h LPS stimulation of the N9 
microglia cell line caused a significant reduction in P2X7 expression (Bianco et al., 
2006). Similarly, long incubation with LPS (3 days) has also been shown to increase 
P2X7 mRNA expression in macrophages (Humphreys et al., 1998). ATP stimulation 
induced the uptake of ethidium in a dose-dependent fashion and could be abrogated 
by P2X7 receptor inhibition, demonstrating functional P2X7 receptor activity and is 
supported by similar findings in microglia and macrophages (Schilling et al., 1999; 
Pelegrin and Surprenant, 2006; Bartlett et al., 2013). P2X7 receptor function has been 
shown to mediate microglia activation and pore formation (Monif et al., 2009), as well 
as proliferation in early development (Rigato et al., 2012). Taken together, these data 
confirm the expected pattern of proIL-1β and NLRP3 expression in microglia (Gustin et 
al., 2015), alongside functional expression of P2X7 receptors. However, ASC protein 
expression and ATP mediated IL-1β secretion were not detected following LPS / ATP 
stimulation. ASC expression has previously been observed in BV2 microglia (Shi et al., 
2012). IL-1β release has also been reported following ATP, prion and viral stimulation 
(Liang et al., 2015; Shi et al., 2012; Kaushik et al., 2012). In contrast, some studies 
have reported impaired IL-1β production following 24-48 h LPS stimulation (Horvath et 
 159 
al., 2008). Our findings demonstrate the presence of ASC mRNA, and yet no ASC 
protein, indicating impaired translation and would explain the inability of BV2 microglia 
to produce mature IL-1β. Consistent with this data, ASC-/- primary microglia failed to 
secrete IL-1β following stimulation with S. aureus, whilst wildtype primary microglia 
exhibited a strong IL-1β response (Hanamsagar et al., 2011). Differences in the protein 
expression profile of BV2 microglia may contribute the differences in ASC expression 
and inflammasome activity, as BV2 microglia only express 17 % of proteins expressed 
in primary microglia following LPS stimulation (Henn et al., 2009). The lack of ASC 
protein and IL-1β production makes these BV2 microglia a poor platform for studying 
ATP-induced NLRP3 inflammasome activity.  
Pyroptosis is an inflammatory form of cell death mediated by the activity of 
caspase-1 and subsequent cell rupture (Miao et al., 2011). The processing of 
gasdermin-D (GSDMD) to form membrane pores has been shown to be important in 
macrophage pyroptosis (Sborgi et al., 2016). Though GSDMD has not been studied in 
activated microglia, an earlier study reported it not to be expressed in the healthy brain 
(Tamura et al., 2007). BV2 microglia exhibited impaired cell death following stimulation, 
as assessed by LDH release. Conversely, LDH release from J774.2 macrophages was 
as expected. A similar pattern of LDH release has been reported in LPS-primed 
BMDMs, with ATP inducing a significant increase (Yu et al., 2014). An increase in cell 
death following ATP stimulation has previously been observed in the EOC13 microglia 
cell line in a P2X7 receptor-dependent manner (Bartlett et al., 2013) These findings 
indicate BV2 microglia display impaired pyroptosis in comparison to macrophages and 
microglia cell lines, as well as primary microglia (Brough et al., 2002). As pyroptosis is 
considered to be dependent upon caspase-1 activity, the lack of ASC protein and the 
subsequent lack of a functional NLRP3 inflammasome would impair the ability of ATP 
to induce rapid caspase-1 activity and would therefore impair pyroptosis in these cells. 
Other inflammasomes also depend of ASC for its functional activity, and ASC has been 
shown to be necessary for pyroptosis following the activation of the AIM2 and NLRP3 
inflammasome (Sagulenko et al., 2013). ASC-knockout was shown to protect 
macrophages from cell death induced by nigericin and double-stranded DNA. With the 
use of fluorescent imaging to detect ASC, macrophage stimulation can be shown to 
induce the formation of a large aggregate of ASC that enables an amplified 
inflammasome signal (Fernandes-Alnemri et al., 2007). This oligomerisation of ASC 
provides multiple sites for the interaction with procaspase-1 and its autocleavage (Dick 
et al., 2016). Without ASC expression, normal pyroptosis in BV2 microglia cannot be 
studied. 
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BV2 stimulation with murine IL-1β and TNF-α failed to induce the expression of 
proIL-1β and NLRP3. Both IL-1β and TNF-α have long been known to bind to their 
respective receptors and induce NF-κB signalling, resulting in the upregulation of 
proinflammatory proteins (Li & Verma, 2002). The failure of cytokine-induced priming 
further demonstrates the atypical phenotype of the BV2 microglia used here. The lack 
of cytokine-induced priming, absent ATP-induced cell death, ASC protein deficiency 
and subsequent failed release of IL-1β suggests that for the study of NLRP3 
inflammasome activity and neuroinflammation in general, BV2 microglia should be 
avoided. This sentiment is supported by others, who have demonstrated significant 
differences in inflammatory signalling in BV2 microglia compared to primary microglia 
(Horvath et al., 2008). 
 
4.4.1.2 Primary neonatal microglia 
As previously mentioned, there are many differences between primary microglia 
and an immortalised cell line, such as the BV2 microglia. These differences include 
altered protein expression, increased proliferation and adherence, reduced expression 
of NO and reduced cytokine expression in BV2 microglia when compared to primary 
microglia (Horvath et al., 2008). Therefore, BV2 microglia provide only a partial model 
of primary microglia. In order to study LPS priming and NLRP3 inflammasome 
signalling, the impaired IL-1β production and altered LPS-induced protein synthesis 
exhibited by BV2 microglia is a confounding factor (Horvath et al., 2008). Primary 
microglia can be harvested from the mouse brain through a number of techniques, 
including separation by density gradient, shaking mixed glia cultures to separate 
microglia, separation by immunolabeling, or the removal of astrocytes using a low 
concentration of trypsin (Frank et al., 2006; Giulian and Baker, 1986; Marek et al., 
2008; Saura et al., 2003). Overall, the use of primary microglia cultures provides a 
more accurate model to study microglia function compared to cell lines. 
Microglia isolation from mixed glial cultures via mild trypsinisation is an effective 
way to study primary microglia, that allows proliferation in the presence of astrocytes 
and isolation without the mechanical stress of vigorous shaking (Saura et al., 2003). 
Here, the isolation of CD11b-positive / GFAP-negative cells indicated the presence of 
microglia that exhibited a ramified and branched morphology. This method of isolation 
has been utilised for a number studies, including LPS-TLR4 signalling and cytokine 
expression, though NLRP3 inflammasome has not directly been investigated (Yao et 
al., 2013). The primary microglia isolated here exhibited similar LPS-induced protein 
expression as BV2 microglia. Importantly, primary microglia did express ASC, 
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necessary for inflammasome formation. Similar to macrophages, the level of ASC 
protein was unaffected by LPS stimulation, a finding supported by previous studies in 
macrophages (Yamamoto et al., 2004). ATP-induced uptake of ethidium has been 
shown before in microglia cell lines, as well as P2X7 receptor inhibition (Monif et al., 
2009; Sanz et al., 2009; Bartlett et al., 2013). However, this has not previously been 
shown in primary microglia. Here, functional P2X7 receptor activity was observed in 
primary microglia following ATP stimulation, as well as caspase-1-dependent ATP-
induced IL-1β release, consistent with previous findings in macrophages (Cruz et al., 
2007). These data demonstrate the ability of these microglia cells to respond to LPS 
and ATP simulation and exhibit functional NLRP3 inflammasome activity. The 
expression and activity of the NLRP3 inflammasome in primary microglia has been 
reported numerous times that have used alternative isolation protocols. These studies 
include prion protein stimulation, bacterial and viral stimulation, ischemia, and LPS / 
ATP stimulation (Shi et al., 2012; Hanamsagar et al., 2011; Walsh et al., 2014b; Yang 
et al., 2014; Gustin et al., 2015).  
Primary microglia exhibited increased LDH release following LPS / ATP 
stimulation similar to macrophages, demonstrating the induction of pyroptosis and cell 
death. As opposed to BV2 microglia, the primary microglia express ASC and therefore 
exhibit functional NLRP3 inflammasome activity in response to ATP, inducing caspase-
1 activity necessary for pyroptosis (Miao et al., 2011). ATP-induced cell death in 
primary microglia, as assessed by LDH release, has been demonstrated before 
(Brough et al., 2002) The data in this thesis demonstrate, for the first time in detail, the 
characterisation of functional P2X7 receptor activity and NLRP3 inflammasome 
expression in primary microglia isolated by the technique of mild trypsinisation, as well 
as a normal ATP-induced pyroptotic response. 
 
4.4.2 Ketamine failed to attenuate NLRP3 inflammasome priming or 
activation in primary microglia 
Ketamine in an NMDA receptor antagonist that has been shown to suppress 
the depressive behaviours in mice following acute inflammatory insult (Walker et al., 
2013). The authors demonstrate the ability of ketamine to abrogate LPS-induced 
depressive-like behaviour is probably by inhibiting the excitotoxic activity of quinolinic 
acid, which is upregulated following LPS administration. Microglia convert tryptophan to 
quinolinic acid, which is enhanced following stimulation (Heyes et al., 1996). In 
addition, NMDA administration has been shown to induce microglia activation in vivo 
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(Acarin et al., 1996). These data demonstrate an association between excessive 
glutamatergic signalling and microglia activation. In vitro, ketamine has previously been 
shown to inhibit LPS-induced secretion of TNF-α and IL-1β following extended periods 
of LPS stimulation (12-24 h) in primary microglia (Shibakawa et al., 2005; Chang et al., 
2009). The mechanisms reportedly involved included the inhibition of LPS-induced 
ERK1/2 and PGE2 signalling. Similarly, the NMDA receptor antagonist MK-801 also 
causes a dose-dependent reduction TNF-α release and COX-2 expression in BV2 
microglia, measured 24 h after a 1 h LPS treatment (Thomas and Kuhn, 2005). In vivo, 
ketamine suppressed LPS-induced cytokine expression within the intestine via NF-κB 
inhibition (Sun et al., 2004). In this thesis, it was hypothesised that inhibiting the activity 
of the NMDA receptor in the microglia culture following LPS stimulation would 
attenuate microglia activation and ATP-induced NLRP3 inflammasome activity. 
Ketamine alone did not induce cell death, nor did it affect ATP-induced cell death, 
consistent with previous data in macrophages (Zhang et al., 2013). However, 
incubation with ketamine did not alter LPS-induced expression of inflammasome 
components. Furthermore, incubation with ketamine failed to alter NLRP3 
inflammasome activation and IL-1β release. These findings indicate ketamine does not 
influence NLRP3 inflammasome expression or ATP-induced activity in microglia cells 
and contrast the earlier studies reporting anti-inflammatory properties of ketamine. 
However, these studies stimulated microglia for 12 or 24 h, which may result in a 
slower process of IL-1β release, as LPS can stimulate the release of ATP as a DAMP, 
which in turn causes inflammasome activation via P2X7 receptor activity (Sperlágh et 
al., 1998). The application of high concentration ATP after LPS priming accelerates IL-
1β processing by enhancing the activation of the NLRP3 inflammasome immediately. 
This may, therefore, mask any effects ketamine may have of IL-1β production. IL-1β 
mRNA and protein expression following 4 h LPS stimulation in mixed glial cultures has 
also been shown to be reduced when incubated with ketamine (1 mM), incongruent 
with the protein expression observed in this study (Tanaka et al., 2013). This difference 
may be due to the presence of astrocytes present in the mixed glial culture. Other 
antidepressants have been shown to directly affect P2X7 receptor function. Whilst 
ketamine targets glutamate signalling, SSRI antidepressants target serotonergic 
signalling. The SSRI paroxetine has previously been shown to inhibit ATP-induced 
ethidium uptake in HEK-293 cells expressing human P2X7 and attenuate ATP-induced 
IL-1β release in primary monocytes (Dao-Ung et al., 2015). However, the ability to 
reduce ethidium uptake was only apparent for human P2X7 and not rodent P2X7. 
Furthermore, fluoxetine failed to suppress ethidium uptake or IL-1β release. 
Paroxetine, amongst other antidepressants, have also been shown to impair P2X4 
mediated calcium signalling (Nagata et al., 2009). Overall, these findings demonstrate 
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the ability of some SSRI antidepressants to alter P2X7 receptor and IL-1β signalling, 
though the data here indicates ketamine does not immediately influence NLRP3 
inflammasome expression or activity in primary microglia. 
 
4.4.3 The use of primary microglia and BV2 microglia in studying 
neuroinflammation 
The data presented in this thesis provide support for the use of primary microglia 
isolated via mild trypsinisation for studying NLRP3 inflammasome signalling. This 
method of isolation, along with the use of protocols such as CD11b-labeled magnetic 
beads, avoids the mechanical stress of shaking and overt microglia activation (Saura et 
al., 2003; Marek et al., 2008). A robust NLRP3 inflammasome signalling response can 
be generated, as well as P2X7 receptor signalling and ATP-induced pyroptosis. 
However, BV2 microglia present an inconsistent phenotype across the literature and 
only a partial model for studying microglia function (Horvath et al., 2008). Here, it was 
shown that BV2 microglia did not express ASC and therefore did not have a functional 
NLRP3 inflammasome. These conclusions are supported by previous work that show 
BV2 express only 17 % of the proteins that are observed in primary microglia following 
LPS stimulation (Henn et al., 2009). BV2 microglia have also been shown to exhibit 
impaired cytokine production, as well as increased proliferation, increased adherence 
and decreased NO and cytokine production (Horvath et al., 2008). However, ASC 
protein has previously been described before, as well as ATP-induced IL-1β 
expression (Shi et al., 2012). This indicates a variation in the phenotype of BV2 
microglia across labs. Such variation may be due to the lack of control over the cell 
line, as it is not commercially available but shared between labs. Therefore, the age 
and any further mutations of the cell line are not monitored. In order to avoid any overt 
confounding factor of BV2 microglia, the cells should be characterised before use. The 
use of primary microglia provides a more translatable model of microglia function with 
functional NLRP3 inflammasome activity. Finally, mixed glia cultures may be a useful 
tool for studying NLRP3 inflammasome signalling, as astrocytes provide homeostatic 
support to microglia within the CNS and are not thought to express a functional NLRP3 
inflammasome, though this is controversial (Gustin et al., 2015; Couturier et al., 2016). 
If true, IL-1β production could be assessed in microglia using a mixed glia culture that 
better replicates the environment within the brain. 
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4.4.4 The effect of O2 availability on NLRP3 inflammasome 
signalling in microglia 
The availability of O2 within the brain is considered to range between 0.5 – 7 %, 
which is significantly lower than atmospheric levels of O2 (Ivanovic, 2009). In an 
attempt to model the microenvironment in which microglia exists, a 5 % O2 
environment was utilised for short and extended periods of incubation. Stabilisation of 
HIF-1α protein has been shown to begin around 5 % O2, and astrocytes have been 
show to not express HIF-1α protein at 5 % O2 (Jiang et al., 1996; Liu et al., 2006). By 
incubating cells at this O2 concentration, the role of O2 availability on NLRP3 
inflammasome signalling could be studied in primary microglia and BV2 microglia. 
However, the majority of hypoxia studies within existing literature use O2 
concentrations below 5 % to model ischemia, making direct comparisons difficult.  
 
4.4.4.1 Brief 5 % O2 hypoxia (5 h) in BV2 microglia 
Whilst the BV2 microglia exhibit impaired inflammasome activity and IL-1β 
release, LPS priming was shown to be upregulated NLRP3 and proIL-1β (Figure 4.3). 
The process of LPS priming could subsequently be studied in mild hypoxia. Though 
basal expression levels were unaffected following a 5 h 5 % O2 hypoxic incubation 
period, the LPS-induced expression of both NLRP3 and proIL-1β was attenuated. 
Whilst inflammation in hypoxia is regularly studied, most studies have utilised a hypoxic 
atmosphere of ≤ 1 % O2 as a model of ischemia, and therefore do not represent the 
environment within the healthy brain. It has been shown that an 8 h hypoxia (<0.2 %) 
incubation in BV2 microglia attenuated in LPS-induced NF-κB activation, supporting 
the findings present here (Ock et al., 2007). In addition, a 24 h exposure to 1 % O2 
showed attenuated induction of MyD88 expression and NF-κB activation in hypoxia 
following LPS stimulation, though this finding was demonstrated in corneal epithelial 
cells (Pan & Wu, 2012). This article also showed significant reductions in basal TLR4 
expression following hypoxia. Conversely, it has been reported that hypoxia can 
enhance TLR4 and NF-κB signalling. In macrophages, brief hypoxia (2 – 4 h) induced 
an increase in basal TLR4 expression via HIF-1α activity and enhanced LPS-induced 
IL-6 and COX-2 expression (Kim et al., 2010). In BV2 microglia and in primary 
microglia, an 8 h hypoxia exposure induced an upregulation of TLR4 expression and 
enhanced LPS-induced TNF-α release and increased NF-κB activity (Ock et al., 2007; 
Guo and Bhat, 2006). 8 h hypoxia also induced p38 MAPK activation in BV2 microglia 
and primary microglia (Park et al., 2002). These findings demonstrate changes in cell 
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type, hypoxia duration and hypoxia severity may lead to difference inflammatory 
responses following stimulation. Many of these pro-inflammatory effects are a result of 
HIF-1α activity, though HIF-1α stabilisation has been shown to have a threshold of 5 % 
O2 and increase as O2 concentration falls (Jiang et al., 1996). Astrocytes cultured in to 
5 % O2 have been shown not to express HIF-1α (Liu et al., 2006). Therefore, the 
difference between ≤ 1 % and 5 % O2 incubation may have significant effects on a cells 
response to LPS. A study utilising a milder hypoxic model of 3 % O2 for 24 h in primary 
microglia demonstrated an increase in IL-1β and TNF-α expression without stimulation 
(Yao et al., 2013). This is also incongruent with the findings presented here that show 
no induction of proIL-1β following hypoxia alone, though in this thesis a shorter 
exposure window of 5 h was used along with a higher O2 concentration of 5 %. 
Together, these findings indicate 5 h moderate hypoxia does not alter basal expression 
of NLRP3 and proIL-1β in BV2 microglia but attenuates expression inducted by LPS, 
potentially by reducing MyD88 and NF-κB expression and activity (Pan & Wu, 2012). 
 
4.4.4.2 Chronic 5 % O2 hypoxia (3 weeks) in primary microglia 
Though 5 h 5 % O2 hypoxia was shown to attenuate LPS priming in BV2 
microglia, this was a model of acute hypoxia and did not address the sustained hypoxic 
environment in which microglia exist. Furthermore, primary microglia were used for 
subsequent experiments as opposed to BV2 microglia in order to study a more 
accurate model of inflammasome signalling in microglia. From dissection, mixed glia 
cultures take up to 3 weeks to reach confluency. In an attempt to maintain the low O2 
environment in the brain, cells were cultured and microglia were isolated entirely under 
5 % O2 conditions to maintain constant hypoxia. Under these chronic hypoxia 
conditions, ATP-induced IL-1β release in LPS-primed cells was significantly 
attenuated, indicating a diminished ATP-induced inflammatory response. However, the 
cell number of primary microglia cultured in chronic 5 % O2 was significantly decreased 
(Figure 4.19). This was demonstrated by assessment of β-actin levels and by a DNA-
content assay that showed the final primary microglia culture in hypoxia had a cell 
density approximately one third of that apparent in primary microglia cultured at 20 % 
O2. These findings indicate that culturing mixed glia in chronic 5 % O2 impaired 
proliferation and survival. 
Much of the work studying cell proliferation under hypoxic conditions is directed 
towards understanding tumour growth. Severe hypoxia has been shown to impair cell 
survival and enhance apoptosis and necrosis (Shimizu et al., 1996; Papandreou et al., 
2005). This process involves the breakdown of the mitochondrial membrane and 
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increased caspase-9 activity (Weinmann et al., 2004). Low levels of O2 can impair 
mitochondrial respiration, necessary for the production of ATP, as well as enhance 
ROS generation (Semenza, 2007). However, less severe hypoxia (~1 – 3 % O2) is 
considered to enhance cell survival (Mazure and Pouysségur, 2010). This control of 
cell survival and proliferation in different O2 conditions is mediated via the action of 
HIF-1α, which can help a cell adapt to reduced O2 environments by reducing 
mitochondrial O2 consumption (Carmeliet et al., 1998; Papandreou et al., 2006). 
Suppression of HIF-1α can result in increased hypoxia-induced cell death (Kilic et al., 
2007). These findings contrast the data presented here, as chronic mild hypoxia 
reduced cell number. However, many of the studies assessing hypoxia are 24 or 48 h 
incubations at lower O2 concentration, whilst here, cells were in a mild hypoxic 
environment for 3 weeks. In addition, culturing primary astrocytes under chronic mild 
hypoxia of 5 % O2 does not induce HIF-1α, suggesting HIF-1α signalling is not 
mediating the change in cell density observed (Liu et al., 2006). In this study, culturing 
primary astrocytes under chronic mild hypoxia of 5 % O2 avoided the reduced 
proliferation of SOD2-/- astrocytes seen in 20 % O2 (Liu et al., 2006). As SOD2-/- 
astrocytes cannot neutralise superoxide radicals, this demonstrates that at 20 %, there 
is excessive superoxide, which inhibits cell survival in SOD2-/- astrocytes. Reducing the 
O2 to 5 % reduced superoxide levels and enabled cell survival of SOD2-/- astrocytes. In 
addition, low-dose H2O2 has been shown to enhance cell proliferation in various cells, 
as low levels of ROS can act as endogenous signalling molecules in healthy cellular 
function (Liu et al., 2003; Liu et al., 2002; Na et al., 2008; Stone and Collins, 2002). 
Therefore, it may be that in 20 % O2 there is an increase in ROS levels due to the 
greater O2 availability, enhancing cell proliferation but not inducing oxidative stress. 
Culturing cells at 5 % O2 avoids excessive ROS generation (enabling SOD2-/- 
astrocytes to survive) and may attenuate ROS-enhanced proliferation, without the 
hypoxia being severe enough to induce oxidative stress itself. However, to make a 
direct comparison between the effects of O2 on NLRP3 inflammasome signalling, the 
same cell density is required. Therefore, a 24 h hypoxia incubation period was utilised 
following long-term culture in 20 % O2. 
 
4.4.4.3 Acute 5 % O2 hypoxia (24 h) in primary microglia 
To avoid the confounding factor of altered cell proliferation under 5 % O2 
hypoxia, mixed glia were cultured in 20 % O2 and transferred to 5 % O2 incubation 
immediately after isolation of primary microglia for 24 h prior to sample collection. By 
doing so, it can be assured a similar cell density is being examined, confirmed 
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following DNA-content assessment. In accordance, it has been previously 
demonstrated that low O2 (3 %) exposure in BV2 microglia does not significantly affect 
cell viability (Yao et al., 2013). Following 24 h 5 % O2 incubation, basal and LPS-
induced expression of NLRP3, proIL-1β, P2X7 and ASC were unchanged, 
demonstrating 5 % O2 hypoxia does not affect LPS-priming in primary microglia. 
Hypoxia (1 % O2) has been shown to significantly increase NF-κB-mediated 
transcription activation in HeLa cells after 48 h, though NF-κB translocation into the 
nucleus was detected after 4 h. This process was via the phosphorylation of IKK (IκB 
kinase), which leads to the phosphorylation of IκB and activation of NF-κB (Cummins et 
al., 2006). Furthermore, 24 h 2 % O2 in macrophages has been shown to increase 
LPS-induced expression of NLRP3 and proIL-1β in macrophages, though a far lower 
concentration of LPS (5 ng/ml) was used (Folco et al., 2014). Conversely, in corneal 
endothelial cells, hypoxia (1 % O2 24 h) has been shown to attenuate LPS-induced 
MyD88 expression and IL-6 secretion (Pan & Wu, 2012). As detailed earlier, hypoxia 
has been reported to both increase and decrease TLR4 expression, and also induce 
IL-1β and TNF-α secretion in BV2 microglia (Kim et al., 2010; Pan & Wu, 2012; Ock et 
al., 2007). Therefore, hypoxia has the capability to alter protein expression, though the 
data presented here demonstrates that 24 h 5 % O2 does not change basal expression 
or LPS-induced expression in primary microglia. For this reason, 5 % hypoxia may be 
an appropriate and physiologically valid environment to examine microglia function, as 
LPS-induced inflammatory priming is not enhanced at this point, but further reductions 
in O2 can induce inflammatory signalling. In addition, previous studies have shown that 
5 % O2 does not induce HIF-1α stabilisation (Liu et al., 2006; Jiang et al., 1996).  
Though the LPS-induced expression of NLRP3 and proIL-1β were unaffected 
by 24 h 5 % O2 hypoxia, ATP-induced IL-1β release was significantly attenuated. This 
reduction was specific for IL-1β, as ATP-induced TNF-α and IL-6 levels were 
unchanged, indicating 24 h hypoxia specifically suppressed IL-1β processing. In 
addition, P2X7 receptor-activity as assessed by ethidium uptake was not impaired at 5 
% O2, demonstrating an effect of low O2 downstream from P2X7. Many studies have 
shown an altered pattern of cytokine secretion under hypoxic conditions. In the same 
conditions as described here (24 h; 5 % O2), LPS-induced IL-6 production was 
attenuated in placental cells, as well as LPS-induced ROS (Shirasuna et al., 2015). 
Whilst this demonstrates an anti-inflammatory effect of 5 % O2 hypoxia, the data here 
shows that in primary microglia IL-1β and not IL-6 was attenuated by 5 % O2. In LPS-
primed macrophages, stimulation with an NLRP3 inflammasome activator (cholesterol 
crystals), IL-6 and TNF-α production was unaffected by incubation in 2% O2, as 
reported here with ATP stimulation (Folco et al., 2014). However, IL-1β production was 
enhanced in hypoxia, demonstrating 2% hypoxia enhances NLRP3 inflammasome 
 168 
activation. This is supported by enhanced LPS-induced IL-1β production following 24 h 
3% O2 hypoxia (Yao et al., 2013). These findings demonstrate NLRP3 inflammasome 
activity in particular is sensitive to O2 concentration. Whilst lower levels of O2 enhance 
IL-1β production, the data presented here indicates 5 % O2 attenuates NLRP3 
inflammasome activity. 
Astrocytes play an important role in homeostasis within the CNS (Gee and 
Keller, 2005). ATP-induced IL-1β release in mixed glia cultures was tested to assess if 
astrocytic support abrogated the impaired IL-1β release seen in primary microglia in 5 
% hypoxia, however a mixed glia culture did not provide protection from the hypoxia-
induced attenuation of IL-1β release. Astrocytes have been shown to not exhibit 
NLRP3 inflammasome activity and would therefore not contribute to ATP-induced IL-1β 
production (Gustin et al., 2015). However, there are contrasting studies that report 
astrocytic production of IL-1β (Couturier et al., 2016). In comparison to primary 
microglia, all ATP-induced IL-1β production was higher in mixed glia samples, though 
this was probably due to loss of microglia during the isolation process. This finding 
indicates the effect of hypoxia on NLRP3 inflammasome function is directly through 
microglia function, and not through the absence of astrocytic support. 
Cell death was significantly increased following ATP stimulation. In 5 % O2 
hypoxia, this increase was not statistically significant. This indicates a potential 
reduction in ATP-induced pyroptosis under low O2 conditions. This could be due to a 
reduction in ROS generation and, subsequently, a reduction in inflammasome 
signalling and cell death following ATP (Cruz et al., 2007; Heid et al., 2013). In 
addition, reduced pyroptosis and pore formation via GSDMD, which mediates LDH 
release in BMDMs, is important in the release of IL-1β as GSDMD-/- macrophages 
exhibit impaired nigericin-induced release (Shi et al., 2015). Therefore, the reduction in 
pyroptosis and pore formation may be the reason for reduced IL-1β release, as 
opposed to attenuated IL-1β processing. However, there was no statistical significance 
between 20 % O2 and 5 % O2 following ATP stimulation. 8 h hypoxia has been shown 
to enhance LDH release in unstimulated primary microglia (Guo & Bhat, 2006). 
However this was carried out using ≤0.2 % O2, which has been shown to induce cell 
death (Shimizu et al., 1996; Papandreou et al., 2005). In SOD2-/- astrocytes, 5 % O2 
reduced cell death by lowering ROS generation (Liu et al., 2006). Together, these 
findings indicate that whilst severe hypoxia alone can induce cell death, 5 % O2 may 
attenuate ATP-induced cell death. This conclusion would fit with the reduction in ATP-
induced NLRP3 inflammasome activity observed in 5 % O2, as the induction of 
caspase-1 activity is considered to drive pyroptosis (Miao et al., 2011; Kim et al., 
2015). 
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A reasonable explanation for the attenuated NLRP3 inflammasome activation at 
5 % O2 is a reduction in the level of ROS, a mediator of inflammasome activity. At the 
same time, 5 % O2 is not hypoxic enough to induce HIF-1α signalling, oxidative stress 
and increased ROS generation. Severe hypoxia can induce ROS generation in many 
cells, including microglia cells, and mediate cell activation and cytokine release (Guo 
and Bhat, 2006; Park et al., 2002; Lu et al., 2006). The increase in ROS in severe 
hypoxia can lead to HIF-1α stabilisation (Chandel et al., 2000). In addition, the 
generation of ROS relative to O2 availability has been shown to be linear, until severe 
hypoxia induces an increase (Yao et al., 2013; Hernansanz-Agustín and Izquierdo-
Álvarez, 2014). In a study utilising 5 % O2 for glial cells, it was shown that SOD2-/- 
astrocytes required 5 % O2 to survive due to an inability to regulate the generation of 
superoxide radicals at 20 % O2 (Liu et al., 2006). Therefore, whilst LPS-induced 
expression of pro-inflammatory proteins is unaffected at 5 % O2, a small reduction in 
ROS signalling may mediate the attenuated ATP-induced IL-1β production. To study 
this, DCFDA was used to measure intracellular ROS generation. However, in primary 
microglia cultures, no difference in ROS were detected between 20 % and 5 % O2, 
indicating ROS levels are unaffected. ATP stimulation also failed to induce a significant 
induction of ROS. This is inconsistent with previous reports that demonstrate ATP-
induced ROS detection with DCFDA, as ATP has been shown to induce increased 
levels of ROS in the BV2 microglia, EOC13 microglia, primary microglia and 
macrophages via P2X7 receptor activation at concentrations between 1 and 3 mM ATP 
(Bartlett et al., 2013; Spencer et al., 2016; Parvathenani et al., 2003; Cruz et al., 2007). 
In the same samples in which ROS was measured, ATP-induced ethidium uptake was 
detected, indicating the presence of functional P2X7 receptor signalling in a dose-
dependent manner in primary microglia, though no significant changes in DCFDA 
signal. This may be due to a weak signal, as primary microglia isolation results in a 
relatively low density, and measurement had to be done in a clear-bottom 12-well plate 
due to the mild trypsinisation protocol. The use of DCFDA has several limitations, such 
as its non-specificity, its susceptibility to self-amplification (as partial oxidisation of DCF 
can react with O2 to generate O- and, in turn, H2O2), and the assumption that all 
conditions exhibit the same efficiency in DCF radical generation and redox cycling 
(Kalyanaraman et al., 2012). Therefore, whilst the ethidium-DNA fluorescence is strong 
enough to produce a detectable signal, the DCFDA fluorescence may have not been. 
In addition, the primary microglia used here were LPS-primed. Priming BV2 microglia 
has been shown to enhance the ATP-induced ROS production, and therefore a signal 
would be expected (Spencer et al., 2016). In order to elucidate the effect of ROS on 
NLRP3 inflammasome activation in 5 % and 20 % O2 microglia cultures, a ROS 
inhibitor could be utilised or an alternative method of ROS detection such as electron 
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spin resonance, which can enable sensitive detection of short-lived ROS (Kohno, 
2010). In addition, other primary microglia preparations could be used to a higher cell 
density and seeding in a 96-well plate. 
 
4.4.5 Conclusions 
The data presented in this chapter demonstrate a NLRP3 inflammasome signalling 
in primary microglia isolated by mild trypsinisation but not in the BV2 microglia cell line, 
which exhibited a number of atypical characteristics. In primary microglia, NLRP3 
inflammasome signalling and pyroptosis was shown to be attenuated in 5 % O2, 
demonstrating a sensitivity to O2 availability. However, the underlying mechanisms 
were not elucidated. This use of ‘mild hypoxia’ may provide a better model for studying 
neuroinflammation ex vivo. 
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Chapter 5: Investigating the involvement 
of NLRP3 in microglia function and 
inflammation-induced depressive 




5.1.1 Generation of NLRP3-/- mice 
To investigate the role of NLRP3 in microglia function and LPS-induced 
depressive-like behaviour, NLRP3-/- mice (B6.129S6-Nlrp3Tm1Bhk/J; Jackson Labs, UK) 
were obtained for behavioural assessment and microglia isolation. The NLRP3-/- mice 
were first generated by using a neomycin resistance cassette to replace the entire 
NLRP3 coding sequence in 129S6-derived embryonic stem (ES) cells, and the 
resulting chimeric males were bred with 129S6/SvEvTac females and subsequently 
bred to C57BL/6J mice for at least 11 generations (Kovarova et al., 2012). 
Homozygous NLRP3-knockout mice are fertile and viable, with no identified specific 
behavioural phenotype. The mice were originally generated to demonstrate the 
selectivity of NLRP1 in IL-1β production in macrophages stimulated with lethal toxin of 
Bacullus anthracis (Kovarova et al., 2012). It was shown that NLRP3-/- macrophages 
exhibit normal LDH release following LPS and lethal toxin, and that lethal toxin-induced 
IL-1β release was NLRP1-dependent and not NLRP3-dependent. In addition, it was 
shown that IL-1β production in response to the microbial components muramyl 
dipeptide or peptidoglycan following LPS priming was NLRP3-dependent. 
 
5.1.2 NLRP3 signalling in microglia and disease 
Microglia mediate the CNS response to danger and pathogenic signals such as 
LPS and ATP, which require a functional NLRP3 inflammasome in order to produce the 
proinflammatory cytokine IL-1β (Gustin et al., 2015). As detailed in Chapter 4 (Section 
4.2.2.4), in addition to the production of pro-inflammatory cytokines, ATP-induced 
inflammasome activation can lead to a form of inflammation-induced cell death in 
microglia, called pyroptosis (Bergsbaken et al., 2009). NLRP3 inflammasome signalling 
in microglia has been implicated in the pathophysiology of numerous neurological 
disorders (Walsh et al., 2014a). Enhanced expression of inflammasome components 
have been detected in the microglia of HIV-infected people, and HIV infection of 
microglia cultures enhances ASC translocation, caspase-1 activity and IL-1β release 
(Walsh et al., 2014b). In modeling brain abscesses, Staphylococcus aureus induces 
NLRP3-mediated IL-1β production in microglia via ATP-dependent means 
(Hanamsagar et al., 2011). In a G93A-SOD1 transgenic mouse model of amyotrophic 
lateral sclerosis (ALS), microglia exhibit increased caspase-1 activity and IL-1β 
production (Meissner et al., 2010). α-synuclein, a hallmark protein of Parkinson’s 
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disease, can also induce IL-1β release in microglia cells in a caspase-1-dependent 
process via endocytosis and lysosomal damage (Zhou et al., 2016). Microglia exposure 
to prion peptides (PrP106-126) induces NLRP3 inflammasome activation via K+ and 
ROS signalling (Shi et al., 2012). Capsase-1 expression was enhanced in the brains of 
AD patients, and NLRP3-/- mice exhibit protection from cognitive impairments in a 
genetic mouse model of AD (APP/PS1). In addition, NLRP3-knockout reduced the level 
of amyloid-β deposition and enhances amyloid-β phagocytosis in microglia isolated 
from AD mice (Heneka et al., 2014). 
 
5.1.3 P2X7 receptor and NLRP3 inflammasome signalling in mouse 
models of depressive-like behaviour 
There have been several recent studies investigating the role of NLRP3 in 
neuroinflammation and depressive-like behaviour in rodents. It has be suggested that 
inflammasome signalling has a role in the pathology of psychiatric disorders, including 
depression (Iwata et al., 2013). This is a result of the growing evidence implicating 
inflammation, and in particular IL-1β signalling, in inflammation-induced and stress-
induced models of depression. Inhibiting the activity of IL-1β, through antagonism (IL-
1Ra) or genetic knockouts (IL-1R-/- and capsase-1-/-), can attenuate or even abolish 
inflammation-mediated sickness and depressive-like behaviours as well as the 
depressive-like and antineurogenic effects of chronic stress (Koo and Duman, 2008; 
Lawson et al., 2013a; Zhu et al., 2010). The central administration of IL-1β alone can 
induce sickness behaviour similar to LPS, though LPS stimulation is not completely 
dependent upon IL-1β as other inflammatory cytokines such as TNF-α are thought to 
compensate (Bluthé et al., 2000). Pharmacological inhibition of caspase-1 has also 
been shown to abrogate acute LPS-induced depressive-like behaviour in mice (Zhang 
et al., 2014). Furthermore, the same group showed that pre-treatment with an 
alternative caspase-1 inhibitor inhibited the depressive-like effects of chronic mild 
stress (Zhang et al., 2015). Restraint stress-induced depressive behaviours have also 
been shown to require a functional NLRP3 inflammasome, with NLRP3-knockout mice 
protected from the depressive effects of stress (Alcocer-Gómez et al., 2015). One 
study has also shown that peripheral blood mononuclear cells isolated from individuals 
with depression exhibit elevated levels of ASC mRNA, indicating enhanced 
inflammasome expression (Momeni et al., 2016).  
P2X7 receptor signalling is an important mediator of NLRP3 inflammasome 
activity. A recent study reported chrysophanol, a Chinese natural medicine, to reduce 
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P2X7 expression and attenuate LPS-induced depressive-like behaviour, though the 
detailed mechanisms of action were not elaborated upon (Zhang et al., 2016). Mice 
lacking P2X7 (deletion of the carboxyl-terminal domain) exhibit an antidepressant 
phenotype in the TST and FST compared to wildtype mice (Basso et al., 2009). P2X7-
knockout mice also show resilience in a repeated FST model of stress, whereas 
wildtype mice show an increase in immobility following repeated FST exposure 
(Boucher et al., 2011). These studies indicate the potential of targeting the P2X7 
receptor in depression. The SSRI paroxetine has been reported to suppress P2X7 
receptor-induced inflammasome activity in human monocytes, demonstrating a link 
between SSRI antidepressant function and attenuated inflammasome activity (Dao-
Ung et al., 2015). Acute restraint stress in rats has been shown to induce an increase 
in extracellular ATP and glutamate in the hippocampus, and the administration of a 
selective P2X7 receptor inhibitor (A-804598) blocked the stress-induced expression of 
pro-inflammatory cytokines and NLRP3 inflammasome activation (Iwata et al., 2016). 
In addition, chronic treatment with the P2X7 receptor antagonist reversed chronic 
unpredictable stress-induced depressive-like behaviours. IL-1β inhibition via targeted 
antibody treatment was also able to reverse the depressive-like behavioural effects of 
chronic stress (Iwata et al., 2016). These findings demonstrate the importance of 
stress-induced ATP-P2X7-NLRP3-IL1β signalling in the development of depressive-like 
behaviour and the ability of psychological stimuli to induce pro-inflammatory signalling 
within the brain. 
 
5.1.4 Aims of Chapter 5 
In this thesis chapter, NLRP3-/- mice were used in the 3-day ID repeated LPS 
model detailed earlier (Section 3.4.6) to assess the role of NLRP3 in inflammation-
induced sickness and depressive-like behaviours. In addition, microglia priming and 
activation, as well as ATP-P2X7 signalling and cell death were investigated in NLRP3-/- 





5.2.1 Inflammatory signalling in NLRP3-/- primary microglia 
5.2.1.1 Validation of NLRP3-/- mice  
Four breeding pairs of wildtype C57BL/6J mice (NLRP3+/+) and four pairs of 
NLRP3-/- mice (on a C57BL/6J genetic background) were obtained from Charles River 
(UK). Genotyping of the first generation (F1) NLRP3-/- and NLRP3+/+ mice was carried 
out (Section 2.2). NLRP3-/- mice samples did not contain the NLRP3 gene but did 
contain the internal control, whilst NLRP3+/+ mice samples contained both genes 
(Figure 5.1).  
 
5.2.1.2 NLRP3-/- neonatal microglia cultures 
Neonatal mixed glia were cultured from NLRP3+/+ and NLRP3-/- mice and 
primary microglia were isolated as described previously, resulting in a CD11b-positive 
and GFAP-negative culture (Section 2.3.2). Primary microglia were isolated by mild 
trypsinisation after 21 DIV and tested after 22 DIV. To ensure a similar number of 
microglia were obtained from NLRP3+/+ and NLRP3-/- cultures, cell density was 
assessed via CyQuant analysis of DNA content (Figure 5.2). No significant difference 
in cell density was observed between NLRP3-/- and NLRP3+/+ microglia cultures (t test, 
p = 0.4022), indicating the lack of NLRP3 has not affected the ability of neonatal 




Figure 5.1. Genotyping of NLRP3
-/-
 mice.  
DNA isolated from ear clippings of NLRP3+/+ and NLRP3-/- F1 mice breeding pairs were 
genotyped using primers designed to target NLRP3 (A) and GRCm38, a validated 
internal control (B). 
 
Figure 5.2. The viability of NLRP3
-/-
 primary microglia cultures.  
Assessment of NLRP3+/+ and NLRP3-/- neonatal primary microglia cultures (22 DIV) 
with a DNA-based fluorescent probe. Data shown are mean ± SEM (n=3) and analysed 
by Student’s t-test.  
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To confirm the absence of NLRP3 protein in primary microglia cultures, NLRP3 
protein expression was assessed via quantitative western blotting (Figure 5.3A). 
Primary microglia were incubated with or without LPS (0.1 µg/ml; 4 h). A two-way 
ANOVA revealed a significant effect of LPS treatment (F(1,8) = 20.66, p = 0.0019) and 
genotype (F(1,8) = 42.17, p < 0.001), with a significant interaction between the two (F(1,8) 
= 20.28, p = 0.002). NLRP3+/+ microglia expressed NLRP3 at a significantly higher level 
following LPS stimulation compared to unstimulated baseline expression (p < 0.001). 
NLRP3 expression could not be detected in NLRP3-/- microglia at baseline nor after 
LPS stimulation. There was a significant difference between NLRP3 expression in LPS 
stimulated NLRP3+/+ and NLRP3-/- microglia (p < 0.001).  
Isolated microglia were stimulated with LPS (0.1 µg/ml; 4 h) and ATP (5 mM; 30 
min) to assess NLRP3 inflammasome function and IL-1β release (Figure 5.3B). A two-
way ANOVA revealed a significant effect of treatment (F(3,16) = 8.896, p = 0.0011) and 
genotype (F(1,16) = 5.594, p = 0.031), with a significant interaction between the two 
(F(3,16) = 5.594, p = 0.0081). Stimulation of NLRP3+/+ microglia with both LPS and ATP 
induced a significant release in IL-1β (p < 0.01). The small level of IL-1β observed in 
the NLRP3-/- microglia is most likely a result of cell death following LPS and ATP 
stimulation (as demonstrated later by LDH release, Section 5.2.1.4), and in turn the 
release of cytosolic proIL-1β. Furthermore, there was a significant difference between 
IL-1β release in stimulated NLRP3+/+ and NLRP3-/- microglia (p < 0.01). In addition, the 
level of IL-6 and TNF-α released in the same samples was assessed (Figure 5.3C-D). 
A two-way ANOVA revealed a significant effect of treatment (F(1,8) = 35.82, p < 0.001) 
on IL-6, but no effect of genotype (F(1,8) = 2.502, p = 0.1524). Similarly, a two-way 
ANOVA revealed a significant effect of treatment (F(1,8) = 40.47, p < 0.001) on TNF-α, 
but no effect of genotype (F(1,8) = 1.897, p = 0.2058). There were no significant 
differences in IL-6 or TNF-α release in NLRP3+/+ and NLRP3-/- microglia following 
stimulation. 
Together, these data show that NLRP3-/- microglia do not express NLRP3, nor 
do they exhibit IL-1β release following LPS priming and ATP stimulation in vitro. 





Figure 5.3. Characterisation of neonatal primary microglia isolated from NLRP3-/- 
mice.  
Cytosolic expression of NLRP3 protein was assessed via quantitative western blotting 
with and without LPS stimulation (0.1 µg/ml; 4 hr) (A). The release of IL-1β (B), IL-6 (C) 
and TNF-α (D) following LPS (0.1 µg/ml; 4 hr) and ATP (5 mM; 30 min) in NLRP3+/+ 
and NLRP3-/- microglia cultures (22 DIV). Data represent mean ± SEM (n=3) and 
analysed by two-way ANOVA with Tukey’s post hoc test. *p < 0.05, **p < 0.01 ***p < 
0.001 compared to control; #p < 0.05 ###p < 0.001. 
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5.2.1.3 Protein expression and P2X7 receptor activity in NLRP3-/- 
neonatal microglia 
Quantitative western blotting was used to assess the expression of proIL-1β 
(Figure 5.4A), ASC (Figure 5.4B) and P2X7 (Figure 5.4C) following LPS stimulation 
(0.1 µg/ml; 4 h) in NLRP3-/- microglia. A two-way ANOVA revealed a significant effect 
of LPS treatment (F(1,8) = 10.63, p = 0.0115) on proIL-1β expression, but no effect of 
genotype (F(1,8) = 2.332, p = 0.1653). A two-way ANOVA revealed no significant effect 
of LPS treatment (F(1,8) = 0.1433, p = 0.7148) or genotype (F(1,8) = 0.0816, p = 0.7824) 
on ASC expression. However, for P2X7 expression, a two-way ANOVA revealed no 
significant effect of LPS treatment (F(1,8) = 1.763, p = 0.2209), but a significant effect of 
genotype (F(1,8) = 60.62, p < 0.001). P2X7 expression was significantly reduced in 
NLRP3-/- microglia compared to NLRP3+/+ microglia at baseline (58 ± 3 %; n = 3; p < 
0.01) and following LPS stimulation (53 ± 4 %; n = 3; p < 0.01). This finding suggests 
that the basal expression of P2X7, which is not affected by 4 h LPS stimulation, is 
lower in NLRP3-/- microglia than in NLRP3+/+ microglia and may result in a reduced 
P2X7 receptor-dependent inflammatory signalling.  
Subsequently, ATP-induced (5 mM) P2X7 receptor signalling was assessed by 
ethidium bromide uptake (Figure 5.4D). A two-way ANOVA revealed a significant effect 
of ATP stimulation (F(1,8) = 27.73, p < 0.001) on ethidium fluorescence at T+10 min, but 
no effect of genotype (F(1,8) = 0.04506, p = 0.8372). ATP stimulation induced a 
significant increase in ethidium uptake and fluorescence in NLRP3+/+ and NLRP3-/- 
microglia (p < 0.05 for both). This finding suggests that while the expression level of 
P2X7 in NLRP3-/- microglia is lower than NLRP3+/+ microglia, P2X7 receptor function in 
response to high-concentration ATP is not significantly affected. 
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Figure 5.4. Western blot analysis of protein expression and P2X7 receptor 
function in primary neonatal microglia isolated from NLRP3
-/-
 mice.  
ProIL-1β (A), ASC (B) and P2X7 (C) expression with and without LPS stimulation (0.1 
µg/ml; 4 hr) in NLRP3+/+ and NLRP3-/- microglia cultures (22 DIV). ATP-induced (5 mM; 
30 min) uptake of ethidium bromide detected by fluorescence at T+10 min in NLRP3+/+ 
and NLRP3-/- microglia cultures (D). Data shown are mean ± SEM (n=3-4) and 
analysed by two-way ANOVA with Tukey posthoc analysis. *p < 0.05 compared to 




5.2.1.4 NLRP3-/- neonatal microglia cell death 
 
Cell death of both NLRP3+/+ and NLRP3-/- microglia following LPS (0.1 µg/ml; 4 
h) and ATP (5 mM; 30 min) stimulation was assessed by the release of LDH (Figure 
5.5). A two-way ANOVA revealed a significant effect of treatment (F(1,12) = 43.81, p < 
0.001) and genotype (F(1,12) = 12.98, p = 0.0036) on LDH release, but no significant 
interaction between the two (F(1,12) = 0.4398, p = 0.5198). LPS/ATP stimulation 
significantly increased LDH release in both NLRP3+/+ (172 ± 12 %; n = 4; p < 0.01) and 
NLRP3-/- microglia (182 ± 9 %; n = 4; p < 0.01). However, the increase observed in 
NLRP3-/- microglia was significantly attenuated in comparison to NLRP3+/+ microglia 
(76 ± 4 %; p < 0.05). This finding demonstrates reduced cell death in NLRP3-/- 




Figure 5.5. Cell death in neonatal primary microglia isolated from NLRP3
-/-
 mice.  
The release of lactate dehydrogenase (LDH), an indicator of cell death, in NLRP3+/+ 
and NLRP3-/- microglia cultures (22 DIV) following LPS (0.1 µg/ml; 4 hr) and ATP (5 
mM; 30 min) stimulation. Data represent mean ± SEM (n=3) and analysed by two-way 
ANOVA with Bonferroni’s post hoc analysis. **p < 0.01 compared to control; #p < 0.05.  
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5.2.2 The role of NLRP3 in repeated LPS-induced sickness and 
depressive-like behaviour 
5.2.2.1 Sickness behaviour 
 The role of NLRP3 in LPS-induced sickness and depressive-like behaviours 
was assessed using NLRP3-/- mice and the 3-day ID LPS injection protocol established 
previously (Section 3.2.5.1). Three treatment groups were included: saline (SAL / SAL / 
SAL), acute LPS (SAL / SAL / 0.83 mg/kg LPS) and 3-day ID LPS (0.21 / 0.42 / 0.83 
mg/kg LPS). A two-way repeated measures ANOVA of body weight over the course of 
the experiment revealed a significant interaction between treatment group and time 
(F(20,552) = 130.0, p < 0.001; Figure 5.6A). A two-way ANOVA of body weight at +24 h 
(Figure 5.6B) revealed a significant effect of treatment (F(2,138) = 658.4, p < 0.001) and 
genotype (F(1,138) = 8.716, p = 0.0037), though no significant interaction between 
treatment and genotype (F(2,138) = 2.872, p = 0.06). All LPS treatments resulted in a 
significant reduction in body weight at +24 h after final injection, regardless of genotype 
(p < 0.001 for all). Following acute LPS, body weight at +24 h was reduced in 
comparison in NLRP3+/+ (90 ± 0.2 %; n = 24) and NLRP3-/- mice (91 ± 0.2 %; n = 23), 
respectively, in comparison to saline-treated controls. Following 3-day ID LPS, body 
weight at +24 h was in NLRP3+/+ (87 ± 0.4 %; n = 25) and NLRP3-/- mice (89 ± 0.6 %; n 
= 24), respectively, in comparison to saline-treated controls. Furthermore, the body 
weight reduction of 3-day ID LPS-treated mice was significantly greater than acute 
LPS-treated mice for both NLRP3+/+ and NLRP3-/- mice (p < 0.001 for both). However, 
following 3-day ID LPS, the reduction in body weight of NLRP3-/- mice was significantly 
attenuated compared to NLRP3+/+ mice (p < 0.05). A two-way ANOVA of body weight 
at +48 h (Figure 5.6C) revealed a significant effect of treatment (F(2,138) = 224.5, p < 
0.001), but not of genotype (F(1,138) = 2.518, p = 0.01149). No significant interaction 
between treatment and genotype was observed (F(2,138) = 0.6639, p = 0.5165). At +48 h 
after the final injection, all LPS treatment groups still showed a significant reduction in 
body weight (p < 0.001). Following acute LPS, body weight at +48 h was reduced in 
NLRP3+/+ (93 ± 0.4 %; n = 24) and NLRP3-/- mice (94 ± 0.7 %; n = 23), respectively, in 
comparison to saline-treated controls. Following 3-day ID LPS, body weight at +48 h 
was reduced in NLRP3+/+ (92 ± 0.4 %; n = 25) and NLRP3-/- mice (93 ± 0.5 %; n = 24), 
respectively, in comparison to saline-treated controls. There was no significant 
difference between NLRP3+/+ mice and NLRP3-/- mice. These findings suggest the 
absence of NLRP3 provides some protection against the 3-day ID LPS-induced 
reduction in body weight in mice. 
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The distance travelled in the OFT following treatment was assessed at either +6 
h or +24 h after the final injection. At +6 h (Figure 5.7A), a two-way ANOVA revealed a 
significant effect of treatment (F(2,71) = 70.14, p < 0.001) and genotype (F(1,71) = 33.93, p 
< 0.001) on distance travelled in the OFT. A significant interaction between treatment 
and genotype was also observed (F(2,71) = 5.536, p = 0.0058). All LPS treatments 
caused a significant reduction in distance travelled in the OFT at +6 h (p < 0.001 for 
all). Following acute LPS, distance travelled in the OFT at +6 h was reduced in 
NLRP3+/+ (46 ± 4 %; n = 13) and NLRP3-/- mice (73 ± 4 %; n = 12), respectively, 
compared to saline-treated controls. Following 3-day ID LPS, distance travelled in the 
OFT at +6 h was reduced in NLRP3+/+ (54 ± 3 %; n = 13) and NLRP3-/- mice (71 ± 4 %; 
n = 13), respectively, compared to saline-treated controls. However, the reduction in 
locomotion was significantly greater for NLRP3+/+ mice following both acute LPS (p < 
0.001) and ID LPS (p < 0.01) in comparison to NLRP3-/- mice. There were no 
significant differences in distance travelled in the OFT between acute LPS and 3-day 
ID LPS. At +24 h (Figure 5.7B), a two-way ANOVA revealed a significant effect of 
treatment (F(2,61) = 11.49, p < 0.001) and genotype (F(1,61) = 6.047, p = 0.0168) on 
distance travelled in the OFT. A significant interaction between treatment and genotype 
was also observed (F(2,61) = 8.113, p < 0.001). In NLRP3+/+ mice, distance travelled in 
the OFT at +24 h was reduced following acute LPS (76 ± 2 %; n = 11) and 3-day ID 
LPS (67 ± 3 %; n = 12) in comparison to saline-treated controls (p < 0.001 for both). 
However, neither acute LPS nor 3-day ID LPS caused a significant reduction in NLRP3-
/- mice at +24 h. Furthermore, following 3-day ID LPS, OFT locomotion was significantly 
reduced in NLRP3+/+ mice compared to NLRP3-/- mice (p < 0.01). These data show 
that, firstly, LPS-induced sickness behaviour in the OFT is attenuated in NLRP3-/- mice 
when compared to NLRP3+/+ wildtype mice and, secondly, NLRP3+/+ wildtype mice still 
show sickness behaviour in the OFT +24 h after treatment, whilst NLRP3-/- mice do not. 
This suggests that the lack of NLRP3 provides protection against both acute and 3-day 
ID LPS-induced sickness behaviours. 
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Figure 5.6. The effect of 3-day ID LPS administration on body weight and 
behaviour in NLRP3-/- mice.  
NLRP3+/+ and NLRP3-/- mice were treated with saline or LPS for 3 consecutive days. 
The three groups were: increasing dose (ID) LPS (0.21 / 0.42 / 0.83 mg/kg); acute LPS 
(0.83 mg/kg); saline controls (A). Body weight throughout the 3-day experiment was 
tracked (B). Body weight +24 h (C) and +48 h (D) after final injection. Values shown 
are mean ± SEM of n=23-25 per group. ***p < 0.001 compared to saline injected 




Time spent in the centre of the OFT at +6 h (Figure 5.7C) and +24 h (Figure 
5.7D) was also measured. At +6 h, a two-way ANOVA revealed there was no 
significant effect of treatment (F(2,71) = 2.511, p = 0.0884) on the time spent in the 
centre of the OFT, although there was a significant effect of genotype (F(1,71) = 6.737, p 
= 0.001). Similarly, at +24 h, a two-way ANOVA revealed there was no significant 
effect of treatment (F(2,61) = 1.73, p = 0.1859) on the time spent in the centre of the 
OFT, though there was a significant effect of genotype (F(1,61) = 6.627, p = 0.0125). 
Multiple comparisons revealed no significant differences between groups. These 
findings indicate no significant effect of acute LPS or 3-day ID LPS treatment on 
anxiety-like behaviour at +6 h or +24 h in the OFT, although the low level of light used 
was not optimised to induce anxiety-like behaviours. 
 
5.2.2.2 Depressive-like behaviour 
 At +24 h after the final injection, FST immobility was assessed (Figure 5.8). A 
two-way ANOVA revealed a significant effect of treatment on FST immobility (F(2,71) = 
11.01, p < 0.001), though no significant effect of genotype (F(2,71) = 1.822, p = 0.1813) 
or interaction (F(2,61) = 0.2544, p = 0.7761) was observed. Post hoc analysis revealed a 
significant increase in FST immobility following 3-day ID LPS in both NLRP3+/+ mice 
(141 ± 7 %; n = 13; p < 0.01) and NLRP3-/- mice (130 ± 8 %; n = 13; p < 0.05). This 
finding indicates that 3-day ID LPS induced a depressive-like behaviour in the FST at 
+24 h after treatment in both sets of mice and the absence of NLRP3 did not 




Figure 5.7. The effect of 3-day ID LPS administration on open field test behaviour 
in NLRP3-/- mice.  
NLRP3+/+ and NLRP3-/- mice were treated with saline or LPS for 3 consecutive days. 
The three groups were: increasing dose (ID) LPS (0.21 / 0.42 / 0.83 mg/kg); acute LPS 
(0.83 mg/kg); saline controls. Distance travelled in the OFT at +6 h (A) and +24 h (B) 
after final injection. Time spent in centre (%) of the open field (C, D). Values shown are 
mean ± SEM of n=11-13 per group. ***p < 0.001 compared to saline injected controls; 





Figure 5.8. The effect of 3-day ID LPS administration on depressive-like 
behaviour in the forced swim test in NLRP3-/- mice.  
NLRP3+/+ and NLRP3-/- mice were treated with saline or LPS for 3 consecutive days. 
The three groups were: increasing dose (ID) LPS (0.21 / 0.42 / 0.83 mg/kg); acute LPS 
(0.83 mg/kg); saline controls. Time spent immobile in the FST +24 h after final 
injection. Values shown are mean ± SEM of n=12-13 per group. *p < 0.05, **p < 0.01 




5.3 Summary of findings 
• NLRP3-/- microglia expressed proIL-1β and ASC, but had reduced P2X7 
expression in comparison to NLRP3+/+ microglia. 
• NLRP3-/- microglia did not release IL-1β following LPS (0.1 µg/ml; 4 h) and ATP 
(5 mM; 30 min) stimulation. 
• NLRP3-/- microglia exhibited reduced ATP-induced cell death compared to 
NLRP3+/+ microglia. 
• NLRP3-/- mice exhibited reduced sickness behaviour (attenuated reductions in 
body weight and locomotion) following acute LPS and 3-day ID LPS treatments 
in comparison to NLRP3+/+ mice. 
• The absence of NLRP3 in mice had no effect on the depressive-like behaviour 




Using NLRP3-/- mice, the role of the NLRP3 inflammasome in the function of 
microglia and in mediating LPS-induced depressive like behaviour was investigated. It 
was shown that NLRP3-/- primary microglia (22 DIV), when challenged with LPS (0.1 
µg/ml; 4 h), failed to express NLRP3 and did not release IL-1β following ATP 
stimulation (5 mM; 30 min). Other pro-inflammatory cytokines (TNF-α and IL-6) were 
produced and ASC protein expression was detected. Interestingly, the expression of 
P2X7 was reduced and P2X7 receptor-mediated pyroptosis was impaired in 
comparison to NLRP3+/+ primary microglia. In vivo experiments with NLRP3-/- mice 
revealed that sickness behaviour following the 3-day increasing dose LPS paradigm 
was attenuated but there was no effect on depressive-like behaviours in the FST 
compared to NLRP3+/+ mice.  
 
5.4.1 Proinflammatory signalling and pyroptosis in NLRP3-/- 
microglia 
In this thesis, the absence of NLRP3 did not impair the culture of primary 
neonatal microglia isolated from NLRP3-/- mice. NLRP3 knockdown in human 
lymphocytes has been shown to stimulate growth (Salaro et al., 2016), though cell 
growth has not been reported in other studies using NLRP3-/- macrophage cultures 
(Harder et al., 2009; Sagulenko et al., 2013) and microglia cultures (Gustin et al., 
2015). Consistent with previous findings, NLRP3-/- microglia exhibited impaired IL-1β 
secretion following ATP-stimulation (Gustin et al., 2015). The small extracellular IL-1β 
signal seen here in NLRP3-/- microglia is most likely due to the release of proIL-1β 
following ATP-induced cell death, demonstrated by LDH release. NLRP3-/- microglia 
exhibited normal proIL-1β and ASC expression and normal ATP-induced expression of 
IL-6 and TNF-α. Though this is the first demonstration of ATP-induced IL-6 and TNF-α 
production in NLRP3-/- primary microglia, TNF-α induction by S. aureus has also been 
shown to be unaffected by the absence of NLRP3 (Hanamsagar et al., 2011). A similar 
finding is observed in primary macrophages, whereby TNF-α production in response to 
bacterial infection is unchanged in NLRP3-/- macrophages (Harder et al., 2009). These 
reports support the findings presented here, that the production of TNF-α and IL-6 is 
independent of NLRP3. In contrast, the partial reduction in IL-1β release in primary 
microglia following NLRP3 siRNA knockdown paralleled a reduction in TNF-α and IL-6 
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release, though this was in response to oxygen-glucose deprivation which could alter 
microglia function in general (Yang et al., 2014). 
NLRP3 and P2X7 are strongly linked due to their function in inflammation; 
P2X7 receptor stimulation is a robust activator of the NLRP3 inflammasome and cell 
death in response to endogenous ATP (Mariathasan et al., 2006). P2X7 protein 
expression has not previously been assessed in NLRP3-/- microglia and it was found 
that P2X7 expression was significantly reduced in comparison to wildtype NLRP3+/+ 
microglia. This finding suggests that the absence of NLRP3 results in a reduced P2X7 
expression in microglia. Previously, siRNA knockdown of NLRP3 in THP-1 cells has 
been shown to enhance P2X7 protein expression, whilst NLRP3 overexpression 
reduced P2X7 protein expression (Salaro et al., 2016). In NLRP3-/- mice, P2X7 mRNA 
levels were also increased in macrophages and bone marrow. However, P2X7 protein 
levels were decreased in embryo fibroblasts but not in lymphocytes (Salaro et al., 
2016). These findings demonstrate an influence of cell type on P2X7 expression. 
Salarao et al. (2016) suggest the upregulation of P2X7 expression in NLRP3-/- mice 
may be specific to cells of hematopoietic origin. Microglia are thought to originate from 
hematopoietic stem cells in the yolk sac, so it is unclear why microglia would 
apparently behave differently to other hematopoietic derived cells. The reduction in 
P2X7 expression in microglia did not translate into a reduction in ATP-induced uptake 
of ethidium, as the uptake of ethidium induced by high-dose ATP was not affected by 
the absence of NLRP3. This finding is supported by ethidium uptake measurements 
taken from primary macrophages following 5 mM ATP, which show no difference 
between NLRP3-/- cells and wildtype controls (Muñoz-Planillo et al., 2013). A lower 
dose of ATP may be more sensitive to the reduction in P2X7 expression, as 5 mM may 
induce a maximal response (Section 4.2.2.4).  
Cell death induced by LPS and ATP stimulation was significantly attenuated in 
NLRP3-/- microglia. This finding is supported by LPS-primed NLRP3-/- BMDMs that 
exhibit an inhibited LDH release following ATP stimulation (5 mM) in comparison to 
wildtype BMDMs (Yu et al., 2014). Furthermore, it has been previously reported that 
siRNA knockdown of NLRP3 in THP-1 cells increased cell survival and NLRP3 
overexpression impaired cell survival (Salaro et al., 2016). Stimulation of NLRP3 
inflammasome activity induces caspase-1 activity and IL-1β production. Caspase-1 
then cleaves GSDMD, which can rapidly form membrane pores and enable cell lysis 
(Sborgi et al., 2016). By suppressing NLRP3 signalling, ATP-induced caspase-1 
activity and pyroptosis can be attenuated. Caspase-1-/- macrophages also exhibit 
delayed cell death following stimulation with NLRP3 inflammasome agonist nigericin 
(Sagulenko et al., 2013). Additionally, nigericin-induced cell death was completely 
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inhibited in NLRP3-/- macrophages. The study showed that caspase-1 activation 
induced immediate cell death, whilst the delayed cell death was an apoptotic caspase-
8-dependent process. However, the data presented in this thesis show a partial 
inhibition and not a complete inhibition of ATP-induced necrotic cell death. This finding 
may be due to differences between the response of macrophages and microglia to 
brief ATP stimulation. The NLRP3-/- microglia did exhibit reduced P2X7 expression, 
which would suggest reduced ATP-P2X7 signalling may have contributed to the 
reduced ATP-induced cell death. However P2X7 receptor-mediated ethidium uptake 
was unaffected in NLRP3-/- microglia following 5 mM ATP, indicating no difference in 
ATP-induced P2X7 receptor signalling. In summary, the absence of NLRP3 does not 
influence the production of other proinflammatory cytokines or LPS-induced priming in 
microglia, but does attenuate ATP-induced pyroptosis, in support of existing literature.  
 
5.4.2 Attenuated acute and repeated LPS-induced sickness in 
NLRP3-/- mice 
As previously observed in wildtype C57BL/6J mice (Section 3.2.5.1), 3-day ID LPS 
induced sickness behaviours as seen in body weight reductions and reduced 
locomotion. Hypolocomotion observed at +6 h was attenuated in NLRP3-/- mice 
following acute and 3-day ID LPS. There was no indication of LPS tolerance following 
3-day ID LPS, as there was no difference in hypolocomotion between acute LPS and 
3-day LPS. At +24 h, the body weight reduction and hypolocomotion following 3-day ID 
LPS, but not acute LPS, was attenuated in NLRP3-/- mice. These findings indicate an 
impaired sickness response in NLRP3-/- mice, which was more apparent in the 
sustained inflammation model. 
In a repeated stress model of depression, NLRP3-/- mice have also shown 
normal food consumption whilst wildtype C57BL/6J mice exhibit a reduced food intake, 
supporting our findings (Alcocer-Gómez et al., 2015). Caspase-1 knockout in C57BL/6 
mice does not protect against acute LPS-induced weight loss, both systemically and 
centrally administered (Lawson et al., 2013a). Consistent with the acute LPS findings 
presented here, blocking NLRP3 inflammasome signalling does not attenuate acute 
LPS-induced weight loss. These data suggest the absence of NLRP3 provides 
significant protection against sustained stress or inflammation, such as the chronic 
stress model or the 3-day ID LPS model described here. Body weight or food 
consumption was not reported in previous studies that assessed NLRP3 function via 
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pharmacological caspase-1 inhibition in the acute LPS model and CMS model of 
depressive-like behaviour in mice (Zhang et al., 2014; Zhang et al., 2015). 
Whilst LPS-induced sickness in the OFT was not completely abolished in 
NLRP3-/- mice compared to NLRP3+/+ mice, it did provide partial protection against 
acute and sustained inflammation induced by LPS. The hypolocomotion seen in 
NLRP3+/+ mice at +24 h following acute LPS (consistent with earlier findings in Section 
3.2.2.2) and 3-day ID LPS indicate the presence of sickness and is a confounding 
factor in the increased FST immobility. This confounding behaviour is not present in 
NLRP3-/- mice, indicating an absence of sickness. Locomotion at +24 h after systemic 
acute LPS has been shown to not be affected by capase-1-knockout, though basal 
locomotion in those mice were significantly lower than wildtype and may therefore 
affect LPS-induced changes (Lawson et al., 2013a). Again, sickness behaviour was not 
assessed during the pharmacological inhibition of caspase-1 in the acute LPS model of 
depression (Zhang et al., 2014; Zhang et al., 2015). In a repeated stress model, the 
reduction in social interaction that was observed in wildtype C57BL/6J mice was 
abolished in NLRP3-/- mice, though this was not an assessment of sickness as it was 
not assessing an inflammation-based model of depression (Alcocer-Gómez et al., 
2015). The data presented here is the first to assess sickness following acute or 
repeated LPS in NLRP3-/- mice and demonstrates a small protective effect of NLRP3-
knockout in the development of sickness following LPS treatment, particularly in a 
model of sustained inflammation, as assessed by both reduced body weight and 
hypolocomotion. 
 
5.4.3 NLRP3-knockout failed to attenuate repeated LPS-induced 
depressive-like behaviour 
In NLRP3+/+ mice, acute LPS failed to significantly increase FST immobility, 
whilst the 3-day ID LPS protocol induced a depressive-like behaviour (Section 3.2.5.1, 
Section 5.2.2.2). However, a similar phenotype was observed in NLRP3-/- mice. This 
indicates that the absence of NLRP3 attenuated sickness but not depressive-like 
behaviour induced by sustained inflammation. This contrasts with studies of acute 
LPS-induced depressive-like behaviours, which are reduced following pharmacological 
caspase-1 inhibition and in caspase-1-knockout mice (Zhang et al., 2014; Lawson et 
al., 2013a). In addition, suppressing NLRP3 inflammasome signalling by caspase-1 
inhibition and IL-1r knockout has been shown to attenuate stress-induced depressive-
like behaviours (Koo and Duman, 2008; Zhang et al., 2015). These findings 
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demonstrate NLRP3 exerts an important role in the development of depressive-like 
behaviour in mice following both stress and acute inflammatory insults. However, the 
data presented here suggests blocking NLRP3 inflammasome signalling does not 
attenuate sustained inflammation-induced depressive-like behaviour.  
Taken together, these findings suggest NLRP3 could be important in the 
separation of sickness and depressive-like behaviours, as only sickness behaviour was 
attenuated in NLRP3-/- mice. This may implicate different mechanisms in the origins of 
these behaviours. The apparent contrast to other models of inflammation-induced 
depressive-like behaviour may suggest that NLRP3 is not necessary for the 
development of sustained inflammation-induced depressive-like behaviour, but is 
important in acute inflammation-induced depressive-like behaviour. As NLRP3-
knockout protected against sustained inflammation-induced sickness, it suggests 
inflammation may have been attenuated. However, this attenuated inflammation did 
not translate to attenuated depressive-like behaviour in FST immobility. In an opposite 
fashion, ketamine has been shown to inhibit LPS-induced depressive-like behaviour 
without affecting LPS-induced reductions in locomotion and food consumption (Walker 
et al., 2013). This suggests ketamine is capable of targeting inflammation-induced 
depressive-like behaviour but not general sickness, whilst NLRP3 signalling is critical in 
sickness but not so in sustained inflammation-induced depressive-like behaviour. 
NLRP3, like ketamine, may demonstrate a specific signalling pathway that dissociates 
inflammation-induced sickness from inflammation-induced depressive-like behaviour. 
 
5.4.4 Conclusions 
The data presented in this chapter demonstrate a role of NLRP3 in microglial 
pyroptosis and altered P2X7 expression in NLRP3-/- microglia. NLRP3 was shown to be 
important in the development of sickness in the LPS models of acute and sustained 
inflammation, but was not necessary for the development of depressive-like behaviour 
in the FST, demonstrating a separation between sickness and depressive-like 
behaviour. Further behavioural assessment is needed to validate the 3-day ID LPS 
model of depressive-like behaviour and the role of NLRP3 in anhedonic behaviours.  
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Chapter 6: Discussion 
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6.1 Validity of LPS models of depressive-like behaviour 
Acute LPS enables the dissection of the inflammatory process and the key 
signalling pathways involved, as well as behavioural changes associated with 
inflammation. The acute LPS model of depression has been shown, in this thesis and 
by others, to be unreliable in producing a consistent depressive-like behaviour in mice 
(Painsipp et al., 2011; Corona et al., 2013; Biesmans et al., 2013; André et al., 2014; 
Couch et al., 2016). In addition, the acute LPS model exhibits low face validity, as 
depression in humans is not characterised by a single intense inflammatory event, but 
a mild elevation in inflammation over an extended period of time (Zalli et al., 2016). 
Modeling sustained inflammation is necessary to provide a more translatable model of 
chronic inflammation that better represents inflammation-associated MDD. Repeated 
LPS administration has recently been used to assess sustained inflammation-induced 
depressive-like behaviour in a number of studies (Krishna et al., 2016; Kubera et al., 
2013; Guo et al., 2016; Guo et al., 2014; Xie et al., 2012). The 3-day ID LPS model 
developed here still retains many of the negative characteristics of acute LPS due to 
the relatively short period of time assessed and the relatively high doses of LPS used. 
However, this model is the first to circumvent repeated LPS-induced behavioural 
tolerance and induces a depressive-like behaviour. Whilst the sustained inflammation 
is not the same as MDD, it enables the assessment of a period of sustained 
inflammation, unlike acute LPS. 
The validity of behavioural outputs is another critical aspect of the translatability 
of this model. Though the FST can exhibit good predictive validity (Lucki et al., 2001), 
the test has poor construct validity, as the test is based upon the activity of current 
SSRIs (Hendrie et al., 2013). In addition, the FST assesses a stress-induced behaviour 
(Gong et al., 2015), which may exhibit stress-inflammation interactions in LPS models 
that could influence behaviour. The use of a range of behavioural tasks will give LPS-
based models of inflammation-induced depressive-like behaviour greater validity. The 
SPT and FUST could be tested in the 3-day ID LPS model to assess natural 
behaviours, as well as other measures including social behaviours, such as the social 
approach task (Yang et al., 2011), and cognition, such as negative cognitive bias 
(Hales et al., 2014). Furthermore, the time-course of such behaviours, as well as 
sickness, should be established. NLRP3+/+ and NLRP3-/- mouse brains were collected 
at multiple time points after 3-day ID LPS treatment (+24 h, +1 week and +4 weeks) 
and biochemical analysis would need to take place to examine the expression pattern 
of various cytokines and markers of inflammation, as well as the kynurenine pathway. 
This would enable the assessment of LPS tolerance on a molecular level and how long 
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residual inflammation can last within the brain, as well as the influence of NLRP3-
knockout. 
Repeating the 3-day ID LPS protocol after a period of rest, for example, every 4 
weeks, could further develop this model of sustained inflammation-induced depressive-
like behaviour, similar to a 4-month intermittent LPS model previously demonstrated in 
mice (Kubera et al., 2013). By doing so, inflammation would be induced over a longer 
period of time and may induce longer-lasting behavioural changes. Behaviours may not 
then need to be tested so close to the sickness-depressive border, and could be tested 
with no confounding influence of sickness.  
Alternatively, different inflammatory stimuli could be used to develop novel 
sustained inflammation models of depressive-like behaviour, such as TNF-α, BCG, 
poly(I:C) or IFN-α, which have all demonstrated the ability to induce depressive-like 
behaviour in mice (Kaster et al., 2012; O’Connor et al., 2009b; Gibney et al., 2013; 
Zheng et al., 2014). Whilst all models of depressive-like behaviour have significant 
flaws in validity and translatability, the development of such models is critical in 
understanding the mechanisms that underlie depression and enable drug development 
for treatments tailored to specific pathology. 
 
6.2 Distinguishing sickness and depressive-like 
behaviours 
In LPS-induced models of depression, the separation of sickness and 
depressive-like behaviour is considered very important (Dantzer et al., 2008). The 
presence of overt sickness is a confounding factor on behaviours they rely on 
movement. As detailed earlier (Table 3.1), there is great variability in the time course of 
these two categories of behaviour. Many studies assess locomotion at +24 h and have 
determined there is no sickness, validating depressive-like behaviours at the same 
time-point (O’Connor et al., 2009a), whilst others have detected sickness and therefore 
confound the depressive-like behaviour (Biesmans et al., 2013).  
An important factor in these findings is the sensitivity of the assessment of 
sickness. Simply measuring movement between four quadrants in an OFT test is less 
likely to detect sickness than comprehensively assessing behaviour, such as by 
accurately tracking mice movement during an OFT, assessing social behaviours, food 
intake, water intake and even other measures such as cognition. To confidently dissect 
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the 3-day ID LPS-induced behaviours, depressive-like behaviours would need to be 
assessed at later time points (weeks or months) to eliminate the variable influence of 
sickness. Doing so may provide greater face validity as behavioural changes are likely 
to be a result of residual neuroinflammation as opposed to the transient and intense 
effect of high dose LPS. This is supported by studies that have shown 
neuroinflammation following acute LPS can last up to 10 months (Qin et al., 2007).  
Alternatively, it could be argued that sickness and inflammation-induced 
depressive-like behaviour are the same behavioural output and should not be 
separated. The theory behind the acute LPS model of depressive-like behaviour is that 
depression in humans is associated with inflammation and that inflammation induces 
behavioural changes in depression that are similar to sickness (Raison et al., 2006). 
Therefore, by inducing inflammation and sickness in mice, the sickness behaviours are 
also the behavioural output that should be targeted for drug development. If a 
compound can attenuate inflammation-induced sickness, then it could also attenuate 
inflammation-induced depression, as they are both results of the same process. By this 
standard, reduced exploratory behaviour and social interaction, commonly used to 
assessed and separate sickness, could be described as depressive-like behaviours 
and targeted in a similar way as FST immobility and SPT anhedonia. This approach 
would focus purely on the inflammation-induced behavioural changes, and not try to 
differentiate between behaviours. 
The findings in this thesis demonstrate the difficulty in attempting to separate 
sickness and depressive-like behaviour within the short window of testing post-LPS, in 
both acute and 3-day ID models. By assessing cytokine signalling in the mouse brain 
at various time-points post-treatment, the longevity of neuroinflammation could be 
established. Behavioural assessment could subsequently be performed at later time-
points in which neuroinflammation, but not sickness, is still present. 
 
6.3 Is NLRP3 a target for antidepressant development? 
Previous preclinical studies in acute LPS and chronic stress models of 
depressive-like behaviour indicate NLRP3 signalling would be a good target for 
antidepressant intervention in inflammation-associated depression (Alcocer-Gomez et 
al., 2015; Zhang et al., 2015; Zhang et al., 2014; Iwata et al., 2016). NLRP3-/- mice are 
protected from chronic stress-induced depressive-like behaviours (Alcocer-Gomez et 
al., 2015; Iwata et al., 2016), caspase-1 inhibition can reverse acute LPS- and chronic 
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stress-induced depressive-like behaviours (Zhang et al., 2014; Zhang et al., 2015), and 
P2X7 receptor inhibition can reduce chronic stress-induced inflammasome activation 
and depressive-like behaviours (Iwata et al., 2016). Surprisingly, the data presented in 
this thesis suggest NLRP3 signalling did not mediate the 3-day ID LPS-induced 
depressive-like behaviour in the FST. However, this finding is not conclusive. Other 
depressive-like behaviours, such as the SPT and FUST, would need to be tested as 
well as the time-course of behaviours. Biochemical assessment is also required to 
establish neuroinflammatory differences and potential compensatory mechanisms in 
NLRP3-/- mice. 
Though NLRP3-knockout did not attenuate depressive-like behaviour, it did 
reduce to LPS-induced sickness, suggesting targeting NLRP3 may indeed provide 
protection against the negative effects of sustained inflammation. In addition, ex vivo 
microglia work demonstrated reduced P2X7 expression and signalling in microglia, 
which may have contributed to the attenuated sickness in NLRP3-/- mice and provide a 
target for further investigation. A number of stimuli have been shown to stimulate 
NLRP3 inflammasome activation indirectly via the action of ATP and P2X7, including 
nigericin and uric acid crystals (Riteau et al., 2012; Muñoz-Planillo et al., 2013). 
Therefore, changes in P2X7 expression may influence the cellular response to other 
stimuli. Alternatively, the findings here suggest NLRP3 may be a key protein in 
separating sickness and depressive-like behaviour, as NLRP3-knockout attenuates 
one but not the other. 
In vitro and in vivo findings demonstrate the importance of the NLRP3 
inflammasome and IL-1β signalling within the CNS and microglia, and developing 
drugs to target this pathway may provide significant advances in treating 
neuroinflammatory and neurodegenerative disorders, though the potential for 
psychiatric disorders remains unclear.  
 
6.4 Hypoxia or “in situ normoxia”? 
The conditions in which microglia are cultured and examined in vitro are far 
removed from the natural conditions within the brain. As detailed earlier, the oxygen 
availability in the brain has been shown to be far lower than atmospheric levels 
(Ivanovic, 2009). Recent developments in two-photon microscopy have enabled the 
measurement of PO2 within the brain in vivo in awake mice (Lyons et al., 2016). The 
PO2 in the somatosensory cortex was recorded to be 23 mmHg, equivalent to 3 % O2, 
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demonstrating that under normal conditions, cells within the brain exist in a constant 
‘hypoxic’ environment relative to atmospheric levels. Whilst the O2 availability for cell 
culture incubation is rarely deliberately designed, the vast majority of cell culture 
experiments use “normoxia” set at 20 % O2. However, the studies presented here 
indicate that the biological relevance of this for inflammatory signalling in cultured 
microglia should be considered.  
Culturing primary microglia in moderate hypoxia (5 % O2) can influence cellular 
function, as NLRP3 signalling was specifically attenuated under moderate hypoxia, 
with reduced IL-1β and cell death. Whilst the underlying mechanisms responsible were 
not conclusively examined, it is clear that our understanding of cell signalling is from a 
hyperoxic state. As microglia priming was not affected, the reduced IL-1β release may 
be a result of attenuated NLRP3 activation (possibly via reduced ROS generation), or 
possibly direct attenuation of pyroptosis-mediated pore formation and IL-1β release. A 
more comprehensive assessment of ROS generation is needed using a more sensitive 
method of detection, such as electron spin resonance. Obtaining higher density 
primary microglia cultures may enable greater accuracy in assessing ROS generation. 
The mechanisms of pyroptosis in microglia has not previously been fully characterised 
and GSDMD expression and function needs to be investigated. Doing so may elucidate 
the role of pyroptosis in the reduced IL-1β release seen in low O2. Finally, assessment 
of HIF-1α stabilisation has to be carried out at 5 % O2, as well as a more severe 
hypoxia for comparison, to understand the role of HIF-1α in moderate hypoxia in 
microglia. 
Eukaryotic cells depend on O2 for metabolism and the production of ATP as a 
source of energy for most cellular processes. For this reason, cells are able to sense 
changes in O2 availability in order to respond appropriately (Waypa et al., 2016). 
Understanding the cellular processes that are affected by severe hypoxia is critical in 
understanding pathological conditions involving ischemia, tumour growth and oxidative 
stress, though moderate hypoxia can be used to study healthy cellular function. 
Microglia activation and neuroinflammation has been demonstrated in various 
neurological disorders, including MDD, AD and others. In order to better understand 
normal cell function, greater significance must be placed on replicating the 
microenvironment in which a certain cell type exists in vivo. Only then can a normal 
cellular response be observed. 
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6.5 Final conclusions 
This thesis details, for the first time, a model of repeated LPS-induced 
depressive-like behaviour that circumvents the rapid development of LPS tolerance. By 
doing so, a period of sustained inflammation can be studied. It was also shown that the 
resulting depressive-like behaviour was not affected by NLRP3-knockout, whilst 
sickness is attenuated. Furthermore, NLRP3 signalling was characterised in microglia 
isolated by low concentration trypsin, and NLRP3 inflammasome activity in microglia 
was assessed for the first time in 5 % O2 conditions, in an attempt to replicate the in 
vivo environment within the brain. ATP-induced cell death and IL-1β release was 
shown to be sensitive to O2 availability and may provide a better model for studying 
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